ImmInst Active Topics

The Bortz Biological Age Clock: Better Than PhenoAge?

Sun, 31 May 2026 14:33:54 +0000

Adult vaccines don't extend lifespan. They cut dementia by 20%+.

Wed, 27 May 2026 02:27:56 +0000

A few findings from the writeup that surprised me:

Adult vaccines don't extend lifespan beyond protection from the disease on the label.
They do cut dementia rates by 20%+, in the cleanest natural experiment we have.
The same effect shows up across nearly every adult vaccine, including ones for diseases basically nobody in the developed world catches.
So it's not the vaccine doing its labeled job. It's trained immunity — the immune system doing better housekeeping (clearing senescent cells, amyloid, tau).

Full writeup with references: https://www.unaging.com/healthy-habits/vaccine-bonus-adult-vaccines-cut-dementia/

Novel Glutamatergic Compounds Targeting the Cerebellum

Mon, 25 May 2026 19:26:13 +0000

Cerebellar dysfunction is a hallmark not just of movement disorders (ataxia, tremor, tourette's, etc.) but is also implicated in Autism Spectrum Disorder & Fragile X Syndrome. It's been found that, in people with ASD or FXS, their cerebellum does not automate social and cognitive functions in the same way it does for neurotypical individuals. Behaviors that are more-or-less involuntary or automatic are often experienced as much more difficult and requiring much more effort.

A compound that specifically targets excitatory glutamatergic activity in the cerebellum, without affecting other regions of the brain or CNS, has potential to treat the above-mentioned disorders. However, this is a feature not possessed by any conventional neurological treatments.

The following molecular targets could modulate glutamate activity in the cerebellum in a beneficial way:

mGluR1 (metabotropic glutamate receptor 1) antagonists or NAM's
mGluR4 (metabotropic glutamate receptor 4) agonists or PAM's
α6 GABA subunit agonists or PAM's
EAAT4 and/or EAAT1 potentiators/enhancers
P-type Calcium Channel blockers
Q-type Calcium Channel blockers
AMPA-glutamate receptor antagonist or NAM's

NAM = Negative Allosteric Modulator

PAM = Positive Allosteric Modulator

mGluR1 receptors are highly expressed on Purkinje Cells in the cerebellum and, along with AMPA-glutamate receptors, serve as the main excitatory glutamate receptor in that brain region.

Examples of investigational antagonists/NAM's: JNJ-16259685, YM-298198, YM-202074, YM-230888, FTIDC, Bay 36-762, CPCCOEt, LY-456236, etc.

mGluR4 are presynaptic autoreceptors on cerebellar granule cells which act as a negative feedback loop against glutamate activity.

Examples of investigational agonists/PAM's: Foliglurax, Valiglurax, AP-472, ADX88178, Lu AF21934, Lu AF3261, etc.

α6 is a GABA receptor subunit exclusively found in the cerebellum. Traditional benzodiazepines & Z-drugs do not affect GABA receptors in the cerebellum because they only bind to GABA receptors with α1, α2, α3 or α5 subunits. GABA receptor isoforms with α4 or α6 subunits are deemed benzodiazepine-insensitive for this reason. So, a compound that selectively interacts with α6 GABA receptors would have vastly different effects and therapeutic potential than established GABA acting drugs. It likely would not cause sedation and could potentially treat cerebellum-related disorders better than the current treatment options.

Examples of investigational agonists/PAM's: Compound 6 or PZ-II-029, LAU463, LAU159, DK-I-56-1, DK-I-58-1, DK-I-59-1, etc.

Excitatory Amino Acid Transporters (EAAT) are located on glial (non-neuronal) cells and clear excess glutamate from the synaptic cleft (between postsynaptic & presynaptic neurons). EAAT2 (GLT-1) is widely expressed throughout the brain and is a significant area of research. However, EAAT1 (GLAST-1) & EAAT4 are isoforms more specific to the cerebellum and have not been as extensively studied.

Examples of investigational enhancers/potentiators: Limited

(more to come regarding Calcium Channels & AMPA...)

Hi everyone, I’m Alex

Mon, 25 May 2026 03:18:50 +0000

Hi everyone, I’m Alex and I’m really interested in longevity, brain health, and optimizing overall performance. I’m currently in my 20s and have been researching different ways to support healthy aging and maintain cognitive function long-term. Lately I’ve been reading about compounds like rapamycin, metformin, selegiline, and telmisartan, along with various nootropics and neuroprotective supplements.

I’m here to learn more from people with real experience, stay updated on new research, and have thoughtful discussions about health optimization and life extension. Looking forward to being part of the community and learning from everyone here!

Optimize Brain Health And Longevity: Tommy Wood, MD, PhD

Sun, 24 May 2026 14:25:34 +0000

Blood Test #2 In 2026: Biological Age, CVD Risk, Correlations With Diet

Sun, 17 May 2026 15:24:56 +0000

Putting an end to aging is just around the corner.

Sun, 17 May 2026 03:51:37 +0000

"This theory is currently the most promising theory for ending aging. I have integrated the mainstream aging theories through metabolic flux and temporal sequencing. In subsection 5.7, I have factually falsified the replicative senescence theory, which was previously over-extrapolated to the in vivo context, reducing its absoluteness and status as a primary cause in the field of aging. Here, I welcome individuals to discuss and research the theory with me, and to jointly explore and unravel the mysteries of aging."

Email: DTKK4863@outlook.com

Comprehensive Decoding of Aging Pathways: The Metabolic Homeostasis Cascade Collapse Convergence and Re-Drive Model Hypothesis

Abstract

Static wear-and-tear theories cannot explain the diversity, non-linear acceleration, and cliff-like phenotypes of aging. This paper proposes that the essence of aging is the cascade collapse and self-locking of metabolic flux homeostasis. The core is a central axis model composed of AMPK, mTOR, PGC-1α, and PPARα: the axis slips from rhythmic oscillation to a non-steady state, converging on a decline in mitochondrial functionality (the first internal drive node), subsequently triggering stepwise disorders in glycolipid metabolism, GH/IGF-1 decline, antioxidant network collapse, inflammatory-glucocorticoid hijacking, and senescent cell accumulation, forming a six-factor self-locking cascade. This theory is strictly limited to the human physiological context, provides testable predictions (e.g., adolescent erythrocyte deformability as an early marker of central axis imbalance), and shifts aging intervention from "single-target repair" to "restoring systemic rhythm."

Keywords: Aging; Mitochondria; Metabolic Homeostasis; AMPK; mTOR; PGC-1α; PPARα; Inflammation; Growth Hormone; Paradigm Shift

Author: Yingjie Jin

Email: DTKK4863@outlook.com

Introduction

Current static aging theories define the essence of aging as static wear-and-tear, yet they struggle to explain three core paradoxes: inter-individual heterogeneity, non-linear acceleration, and cliff-like senescence. These three phenomena themselves constitute a falsification of single-causation models.

This paper constructs a dynamic aging theory based on metabolic flux homeostasis, whose architecture possesses a threefold explanatory power. First, through the multi-parameter phase space of metabolic flux homeostasis, it can computationally explain aging diversity—the set-point bias of different individuals on the central axis (AMPK-mTOR-PGC-1α-PPARα) determines the differential emergence of pathological phenotypes. Second, through multi-factorial convergence onto the critical node of declining mitochondrial functionality, it explains the phenotypic convergence of aging. Ultimately, by revealing the mechanism through which the dominant factors of aging switch with the phase transitions of metabolic homeostasis, it elucidates the non-linear dynamic nature of aging acceleration and cliff-like senescence.

However, the core parameters of this dynamic framework (VC antioxidant buffering capacity, GH/IGF-1-NRF1 mitochondrial regulatory axis, local skin IGF signaling network, etc.) have unique metabolic configurations in humans. Traditional research has long extrapolated observational data from rodent models and plant systems (such as bamboo) to humans, ignoring fundamental differences in metabolic architecture between species—humans lack the capacity for endogenous vitamin C synthesis, the regulation mode of the GH/IGF-1 axis is qualitatively different from that in rodents, and the skin exhibits a local IGF signaling dilemma. Such extrapolations carry a significant risk of metabolic context misalignment.

This study establishes a directionally specialized human dynamic aging theory framework, covering multi-level mechanisms including cellular energy metabolism, epigenetic clocks, tissue microenvironment interactions, and systemic homeostasis regulation, forming a comprehensive explanation for the asynchrony, heterogeneity, and intervenability of human aging. This theory is strictly limited to the human physiological context; if applied to rodents, bamboo, or other species, targeted corrections must be made for their metabolic characteristics (such as endogenous VC synthesis, IGF-1 axis patterns, NRF1 tissue expression, etc.) to achieve cross-species compatibility.

Key Argument: Mitochondrial Functional Decline is the Endogenous Driver of Aging

The core argument of this paper is that the decline in mitochondrial functionality, driven by metabolic homeostasis imbalance, is the fundamental, endogenous factor driving the entire aging process.

This argument does not negate the importance of other aging mechanisms but repositions them, describing who is the background driver at this stage, who is the primary driver at this stage, and who is a downstream phenomenon in the aging process, thus forming a temporal sequence. Mitochondrial functionality is the critical node that converges and integrates all upstream factors to re-drive aging. This hypothesis posits that mitochondria are not merely passive "victims" damaged during aging, but active "instigators." The decline in mitochondrial functionality, as the starting point of the aging program, initiates and amplifies a subsequent series of aging-related pathways through its core position as the cell's energy factory and signaling hub. This viewpoint is strongly supported by recent research. For example, a study published in Scientific Reports found that by reprogramming aged individual fibroblasts into induced pluripotent stem cells (iPSCs), age-related mitochondrial respiratory defects could be completely reversed, restoring them to levels comparable to fetal fibroblasts. This result indicates that the aging state of mitochondria is not determined by irreversible mtDNA mutations but is subject to dynamic, reversible epigenetic regulation. Combined with empirical research on epigenetic drift aging, which shows that aging is not caused by gene mutation but by the distortion of information during transmission, it can be jointly deduced that aging is reversible.

Furthermore, based on the empirical study of increased inflammatory factor concentrations in adolescents aged 9-17 [216], the two modes of inflammatory factor increase mentioned in that literature, and the literature on the effects of inflammatory factors on mitochondrial functionality [159][158], and considering that multiple aging pathways commonly point towards pro-inflammatory states, I identify the decline in mitochondrial functionality as the first initiating node of convergence and re-driving of multiple aging factors, while inflammatory factors serve as the linking node running through all aging drivers [50].

1.3 Definition and Scope of Mitochondrial Functional Decline

To precisely articulate our theory, "mitochondrial functional decline" must be strictly defined. In the framework of this paper, mitochondrial functional decline specifically refers to a situation where, under conditions of normal mitochondrial quantity and quality, the efficiency of its physiological function, ATP output, declines. This situation may be caused by multiple factors, such as interference from inflammatory factors, weakened antioxidant function, decreased erythrocyte oxygen release efficiency, shortened duration of AMPK signaling, or excessively weak AMPK signaling—multiple multi-factorial causes triggering mitochondrial functional decline. This functional decline does not lead to cell apoptosis but is sufficient to disrupt the cell's normal physiological rhythm, initiating a series of adaptive or pathological signaling pathways.

For example, literature [173] points out that when erythrocyte deformability decreases, their oxygen affinity increases and oxygen release capacity decreases. Therefore, if human erythrocytes experience decreased deformability due to factors like hyperlipidemia, oxidative stress, and insufficient nitric oxide production, the oxygen released by erythrocytes to normal body cells within the same time window will decrease. Consequently, the cellular oxidative phosphorylation efficiency will decline. This point does not depend on a decrease in mitochondrial quantity and quality.

[Conceptual Distinction]

Epigenetic Inertia: In this hypothesis, this specifically refers to a state where key genes such as PPARα, AMPK, mTOR, and PGC-1α are locked into a stable, low-expression level that is difficult to self-recover after being suppressed. This is a specific dysfunctional pattern in early aging.

Epigenetic Disorder: Refers to the systemic, global dysregulation of genome-wide epigenetic modifications (such as DNA methylation) in the late stages of aging, caused by reasons such as the deficiency of metabolic substrates like α-ketoglutarate (AKG).

2. Core Regulatory Network of Mitochondrial Functional Decline - The Central Axis Model

In literature [216], within a latent class growth analysis model, a total of 6,556 participants were assigned to a group/trajectory class. The optimal model identified three CRP trajectories: 1. Reference group (n=6109; 93%) – persistently low CRP levels. 2. Early-peak group (n=197; 3%) – CRP levels peaked at age 9. 3. Late-peak group (n=250; 4%) – CRP levels peaked at age 17. The mechanism of this inflammation cannot be explained by traditional inflammatory models. Attributing it to developmental, gene-specific drives of different inflammations cannot explain why so many people have the same genetic mutations predisposing them to inflammation. However, the model of erroneous metabolic homeostasis driving inflammatory factor production can explain the source of inflammation in children aged 9-17 and the different patterns of its formation.

2.1 Based on theoretical deduction of existing pathway interaction patterns, I constructed the central axis model, which can integrate past aging theories.

The central axis model is a metabolic network based on the combination of four key metabolic pathways: Peroxisome Proliferator-Activated Receptor Alpha (PPARα), AMP-Activated Protein Kinase (AMPK), Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PGC-1α), and Mammalian Target of Rapamycin (mTOR). This integrates the multiple aging mechanisms from past traditional theories, forming a key central robust mechanism that determines which aging mechanism an organism is more biased towards at the early stages of aging, explaining the diversity of aging and, more profoundly, the underlying principles of this diversity.

Its core can be defined by seven rules.

1. AMPK can inhibit mTOR. Literature [14] points out that mTOR can be inhibited by enhancing AMPK.

2. mTOR can inhibit AMPK. Literature [15] points out that AMPK can be inhibited by enhancing mTOR.

3. Synergy and antagonism between PPARα and PGC-1α. Literature [59] indicates that PGC-1α serves as the basis for PPARα function. Literature [62] points out that if PPARα expression is insufficient, PGC-1α is more inclined to initiate NRF1/NRF2-related antioxidant genes. Therefore, it can be inferred here that PGC-1α is functionally inhibited by PPARα. Conversely, if PGC-1α is highly expressed and PPARα is insufficient, a tendency towards NRF1/NRF2 signaling dominance will occur.

4. AMPK can increase PGC-1α expression, and mTOR can increase PPARα expression. Literature [98] indicates the promotion mechanism of mTOR on PPARα, while literature [14] indicates the promotion mechanism of AMPK on PGC-1α.

5. Oxidized PTEN activates mTOR. Literature [78] indicates that when PTEN is oxidized, the mTOR signaling pathway is activated.

6. The flux of the Pentose Phosphate Pathway (PPP) is a key factor for which AMPK, mTOR, PGC-1α, and PPARα must compete within the same time window. Literature [162] indicates that ribose-5-phosphate (R5P) from the PPP is the sole carbon skeleton source for synthesizing purine/pyrimidine nucleotides, meaning a decrease in its flux will lead to a decrease in the level of the shared resource pool for gene expression. Simultaneously, literature [56] indicates that NADPH, a product of the PPP pathway, provides reducing equivalents for oxidative protein folding; its deficiency increases protein misfolding, increases the proportion of ineffective proteins and inhibits signaling, which can also be viewed as a resource that AMPK, mTOR, PGC-1α, and PPARα must jointly compete for.

7. The interaction mechanism of PPARα/PGC-1α: The transcriptional self-maintenance of PPARα depends on the de novo synthesis of very long-chain fatty acids (VLCFA), a process that consumes NADPH. Conversely, the NRF1/NRF2 antioxidant pathway mediated by PGC-1α also requires NADPH for glutathione regeneration. When PGC-1α is highly expressed, NADPH flux is siphoned off by antioxidant demands, inhibiting VLCFA synthesis, thereby blocking the self-maintaining positive feedback loop of PPARα. This competition for Pentose Phosphate Pathway (PPP) flux constitutes the molecular basis for the 'fatty acid oxidation-antioxidant defense' zero-sum game in the central axis model, determining whether the cell tends towards PPARα-dominated anabolic homeostasis or PGC-1α-dominated catabolic/antioxidant homeostasis. [268]

2.2 The specific operational mechanism of the central axis model.

In the central axis model, the four key gene pathways—PPARα, AMPK, mTOR, PGC-1α—jointly control four mechanisms crucial to organisms: the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, biosynthetic metabolism, and antioxidant networks. These four mechanisms are interconnected. By simplifying the expression and activity state of each core factor (AMPK, mTOR, PGC-1α, PPARα) into three basic levels: too weak, steady state, and too strong, the total number of combinations formed by these four variables is theoretically 3 to the power of 4, i.e., 81 possible "functional state combinations."

Among these 81 combinations, there is one and only one combination representing the perfect internal homeostasis enjoyed in early life: all four cores are in their precise "steady-state" interval. This state is the sole ideal state where mitochondrial function is optimized and energy metabolism is clean and efficient. It is the only stable state where the organism could halt aging before it begins. The remaining 80 combinations all constitute the starting point that triggers the decline in mitochondrial functionality, the primary driver of aging.

2.2.1 Normally functioning central axis model.

Starting with the change in AMP/ATP ratio caused by decreased biosynthetic metabolism controlled by the mTOR pathway, which promotes AMPK, the AMPK pathway is activated due to the AMP/ATP signal. During this process, the high-intensity AMPK signal drives PGC-1α, leading to antioxidant defense and mitochondrial maintenance. However, this path only initiates PGC-1α rather than enhancing its self-maintenance axis strength. When the cell obtains sufficient ATP and completes energy production, mTOR is activated by the energy signal, promoting the TCA cycle by activating PPARα, manufacturing energy, maintaining methylation and demethylation homeostasis, and completing biosynthesis and protein assembly, the key goals for organismal survival. This continues until the mTOR pathway, due to the synthesis process, causes ATP levels to drop, activating the AMPK pathway again, thus starting the next metabolic cycle of the central axis model.

2.2.2 Epigenetic inertia formed by erroneous operation of the central axis's self-maintenance mechanisms.

AMPK, mTOR, PPARα, and PGC-1α all possess self-metabolic maintenance mechanisms, which determine the expression strength of these four pathways.

2.2.2.1 The imbalance mechanism of the first cause: Epigenetic inertia formed by competitive collapse of homeostatic circuits.

This hypothesis posits that the essence of mitochondrial functional decline is the loss of dynamic balance in the core regulatory circuits maintaining its functional homeostasis. These circuits depend on the self-positive feedback maintenance of key molecules and antagonize other circuits. Once external stress persists too long, the positive feedback loops are disrupted, and their expression levels become locked in a pathological range, thus driving mitochondrial function decline through various pathways, forming a convergent model that drives aging.

Definition of Co-activator Factor: Co-activator factor refers to the dynamic resource pool of ribose-5-phosphate and NADPH determined by the flux of the Pentose Phosphate Pathway (PPP).

The Pentose Phosphate Pathway has two main functions: producing NADPH and producing ribose-5-phosphate.

Ribose-5-phosphate sustains cellular gene transcription. If it is deficient, the cell will lack a source of ribonucleotides. NADPH is responsible for the synthesis of cellular deoxyribonucleotides, maintaining intracellular gene repair, and the redox folding of proteins during transcription. The normal expression of the four core genes AMPK, mTOR, PPARα, and PGC-1α requires the joint collaboration of ribose-5-phosphate and NADPH. Therefore, the dynamic resource pool of ribose-5-phosphate and NADPH determined by the upstream Pentose Phosphate Pathway can be identified as the co-activator factor. Although the PPP pathway itself cannot be competed for, the metabolic efficiency and flux of the pathway determine the output quantity of the co-activator factors, maintaining the definition of the co-activator factor.

2.2.2.2 Competition in the energy metabolism hub: Self-maintenance mechanisms and rhythmic inhibition of PPARα and PGC-1α.

PGC-1α achieves its self-maintenance mechanism through the NRF1-lipoic acid-PGC-1α pathway. PPARα achieves its self-maintenance mechanism through co-regulation formed by multiple downstream metabolites of acetyl-CoA during the TCA cycle metabolism. Changes in AMPK and mTOR pathways determine whether PGC-1α dominates or PPARα dominates. Excessive self-maintenance mechanisms will lead to mutual signal antagonism.

Checks and Balances of the Energy Sensing Center: Mutual Inhibition and Self-Maintenance of AMPK and mTOR

A similar "mutual inhibition-self-maintenance" mechanism also exists between the energy sensing centers AMPK and mTOR.

AMPK Self-Maintenance: After AMPK is activated, by inhibiting mTORC1 activity and promoting self-maintenance, this signal would normally reverse through changes in the intracellular AMP/ATP ratio. However, if the pathway where AMPK pathway dominance upregulates NAMPT expression to promote NAD+ regeneration and the NAD+-SIRT1-AMPK pathway malfunctions, then the AMPK pathway will exhibit high or low expression, and the expression intensity will be disordered, failing to maintain rhythmic regulation of PPARα and PGC-1α. This creates an energy environment conducive to its own sustained activation, forming positive feedback.

mTOR Self-Maintenance: After mTORC1 is activated, it promotes the synthesis of macromolecules like proteins and lipids. During this process, a large number of free radicals are generated inside the cell. In the normal process, these free radicals would moderately oxidize and modify PTEN to relieve the inhibition of the mTOR pathway, thereby further enhancing the mTOR pathway. However, NRF2 is induced by oxidative stress to express and reduce oxidized PTEN. When the mTOR pathway is erroneously overexpressed, the oxidative stress it triggers will persistently cause PTEN to be oxidatively modified, while the overexpressed NRF2 also triggers oxidative stress, preventing PTEN redox reduction, forming a self-sustaining high-maintenance state of the mTOR cycle.

The two constitute a precise bistable switch. Under physiological conditions, they dynamically oscillate based on energy status, maintaining overall balance. However, under persistent energy stress or nutrient excess, one side's self-maintenance mechanism may be excessively strengthened, completely suppressing the other. For example, long-term nutrient excess consolidates mTOR's "high expression-high activity" steady state and suppresses AMPK to "low expression-low activity," leading to impaired energy sensing, inhibited autophagy, and directly contributing to a decline in mitochondrial quality.

2.3 Connection points where excessive or deficient expression of the four gene pathways AMPK, mTOR, PPARα, and PGC-1α jointly lead to mitochondrial functional decline.

2.3.1 Mitochondrial functional decline caused by AMPK pathway imbalance

Excessive AMPK Signaling: The AMPK pathway regenerates NAD⁺ through NAMPT. NAD⁺ maintains its own gene expression self-maintenance through the SIRT1-AMPK pathway. When this metabolic level is too high, the AMPK pathway signal will be frequently activated, inhibiting the initiation of mTOR signaling, leading to decreased biosynthetic metabolism. For example, this causes a decrease in nitric oxide (NO) levels, leading to loss of microvascular dilation, and a simultaneous decrease in erythrocyte deformability due to NO deficiency. This triggers microcirculatory disturbance, causing ischemia and hypoxia. Ischemia and hypoxia will promote glycolysis and transcription of inflammatory factors released into the blood.

Deficient AMPK Signaling: When the AMPK self-maintenance mechanism is in a weakened state, although the AMPK pathway is not completely inhibited, it leads to decreased energy metabolism. Both oxidative phosphorylation and glycolysis will have reduced ATP production capacity, leading to a decline in mitochondrial functionality. Simultaneously, due to decreased ATP levels, ATP generation in erythrocytes will also decrease, resulting in erythrocyte deformability disorders, causing hypoxia-induced glycolysis and release of inflammatory factors into the blood. At the same time, as DNA repair-related genes are downstream of the AMPK pathway, their decreased expression will lead to reduced gene repair efficiency, increased genomic instability, and weakened inhibition of NF-κB, which also triggers the secretion of inflammatory factors into the blood.

2.3.2 Mitochondrial functional decline caused by mTOR pathway imbalance

Excessive mTOR Signaling: The mTOR pathway promotes itself through ROS free radicals generated during anabolic metabolism, which oxidize and modify the PTEN pathway. Persistent stimulation by ROS free radicals induces high NRF2 expression, leading to the downstream HO-1 pathway decomposing heme to form free iron. Free iron further promotes oxidative stress by generating hydroxyl radicals. This pathway causes erythrocyte deformability disorders through oxidative stress, leading to microcirculatory disturbance, and achieves mitochondrial functional decline through hypoxia. Simultaneously, excessive ROS radicals inhibit mitochondrial metabolic efficiency, and the mTOR pathway itself inhibits the AMPK pathway. ROS itself is also a pro-inflammatory signal. Ischemia and hypoxia caused by decreased erythrocyte deformability can further produce inflammatory factors via microcirculatory disturbance, forming a combined force that jointly inhibits mitochondrial function.

Deficient mTOR Signaling: This pathway leads to decreased anabolic metabolism, causing abnormalities in the arginine metabolic pathway, resulting in decreased nitric oxide levels and reduced erythropoiesis. This leads to microcirculatory disturbance, causing ischemia and hypoxia, promoting inflammation, and leading to mitochondrial functional decline due to inflammatory factors. However, unlike excessive AMPK expression, this pathway originates from a malfunction of mTOR's own self-maintenance mechanism and does not imply that AMPK pathway expression is too high.

2.3.3 Mitochondrial functional decline caused by PGC-1α pathway imbalance

Excessive PGC-1α Signaling: This pathway, through its antagonism with PPARα, inhibits the efficiency of the TCA cycle, causing cells to fall into a state of reduced ATP output. This pathway can also inhibit erythrocyte energy metabolism. Simultaneously, by limiting the synthesis of AKG and acetyl-CoA, it induces epigenetic abnormalities, leading to decreased nitric oxide synthesis, reduced erythrocyte deformability, and a reduction in erythrocyte count. The hypoxia-inflammatory factor pathway, combined with its own weakening of the TCA cycle, will jointly cause mitochondrial functional decline.

Deficient PGC-1α Signaling: This pathway leads to decreased NRF1 expression, a decline in mitochondrial quality and quantity, and a decrease in the entire antioxidant network's basal antioxidant performance against oxidative stress. However, this pathway can also cause mitochondrial functional decline due to oxidative stress and electron leakage. Simultaneously, it interferes with erythrocyte energy metabolism, increases the risk of erythrocyte oxidative stress, leading to affected erythrocyte deformability. Mitochondria will experience functional decline through the hypoxia-inflammation pathway, and also through electron leakage oxidative stress. If this bias is too high, it may lead to a decrease in mitochondrial quantity and quality even in adolescence.

2.3.4 Mitochondrial functional decline caused by PPARα pathway imbalance

Excessive PPARα Signaling: Overexpression of this pathway triggers oxidative stress and simultaneously inhibits NRF1/NRF2 expression by excessively binding the PGC-1α pathway, achieving oxidative stress effects. This pathway can affect erythrocyte deformability through oxidative stress, forming microcirculatory disturbance. Mitochondrial functional decline occurs due to inflammatory factors induced by hypoxia and electron leakage.

Deficient PPARα Signaling: This pathway mainly affects the TCA cycle, leading to a decrease in cellular ATP generation, and simultaneously affects the generation of AKG and ketone bodies. A decrease in AKG will impair the overall cellular demethylation function, leading to epigenetic disorder. Genes related to nitric oxide production become inhibited in demethylation and cannot be expressed, thus reducing nitric oxide levels, causing decreased erythrocyte deformability, forming microcirculatory disturbance. Mitochondrial functional decline occurs due to inflammatory factors induced by hypoxia, combined with its own weak expression.

Summary: Theoretically, a perfect central axis should produce more energy during the TCA cycle, and promote mitochondrial regeneration and antioxidant function regeneration during the PGC-1α phase. However, this paper deduces that in reality, such a perfect central axis is very difficult to maintain normally and stably. For example, just one instance of staying up late can disrupt the operation of this central axis, causing its imbalance through hormones, hypoxic microcirculatory disturbance, and oxidative stress.

Simultaneously, the daily diet, such as vegetables containing ferulic acid and antioxidants, can correct this process. The entire process exhibits a dynamically changing state, like a constantly swinging pendulum. Seeking the right path can improve the state of the central axis. The central axis itself provides a reasonable explanation for the appearance of inflammatory factors in 9-17 year olds and their different emergence models, where metabolic errors in biological functions lead to inflammation.

2.4 Correspondence of central axis proportional imbalance with current mainstream aging theories and the rationale.

I. AMPK Imbalance: Dysregulation of the Energy Sensing Center

When AMPK is in a "too weak" state, it directly corresponds to the theory of " autophagy dysfunction and proteostasis imbalance ." The rationale is that AMPK is the primary kinase for sensing energy crisis (increased AMP/ATP ratio) and initiating autophagy to remove damaged components and recycle resources. Its insufficient activity means the cell cannot activate this crucial "quality control and recycling system" under energy stress. Simultaneously, AMPK's regulation of the balance between protein synthesis and degradation also fails, jointly leading to the accumulation of misfolded proteins and senescent organelles within the cell, dismantling cellular homeostasis from the inside. This is the source of garbage accumulation in aging cells—directly corresponding to the "Autophagy Dysfunction" and "Proteostasis Imbalance" theories.

When AMPK is in a "too strong" state, it points to the pathological logic of " anabolic failure and nutrient utilization disorder ." The physiological role of AMPK is "energy conservation" and "catabolism." Persistently overactive AMPK signaling excessively inhibits its key target mTORC1, which is the main "anabolic" switch driving the biosynthesis of proteins, lipids, etc. Therefore, the abnormal hyperactivity of AMPK is not beneficial but creates a false and persistent state of "cellular famine," inappropriately shutting down the anabolic pathways necessary for cell growth, repair, and regeneration, leading to impaired protein-driven cell function maintenance, repair, and renewal despite sufficient genes and energy—directly corresponding to the "Anabolic Failure" and "Nutrient Sensing Dysregulation" theories.

II. mTOR Imbalance: Uncontrolled Master Switch of Growth Signals

When mTOR is in a "too strong" state, this is the direct molecular interpretation of the " nutrient sensing dysregulation and cellular senescence " theory. mTORC1 is the signaling hub most sensitive to nutrients and growth factors. Its sustained hyperactivity means the cell erroneously perceives itself in a nutrient-rich environment, uncontrollably driving anabolism, consuming large amounts of resources, and producing metabolic waste. More importantly, it strongly inhibits autophagy and impedes the normal apoptosis program of damaged cells, ultimately pushing cells towards a state of metabolic activity but functional abnormality, secreting large amounts of inflammatory factors, becoming an engine of tissue inflammation and dysfunction—directly corresponding to the "Nutrient Sensing Dysregulation" and "Cellular Senescence" theories.

When mTOR is in a "too weak" state, it corresponds to " anabolic failure and impaired tissue regeneration ." mTOR signaling is the fundamental command for all constructive cellular activities like growth, proliferation, and protein synthesis. Its insufficient signal means the cell loses the fundamental driving force to execute repair and renewal. Whether it's muscle protein synthesis, healing of damaged tissues, or immune cell proliferation, all will stagnate, directly manifesting as age-related tissue atrophy, delayed wound healing, and decreased immune function—directly corresponding to the "Anabolic Failure" theory.

III. PGC-1α Imbalance: Command Disorder of the Mitochondrial Factory

When PGC-1α is in a "too weak" state, it directly corresponds to the core of the " mitochondrial dysfunction " theory. PGC-1α is the master transcriptional co-activator for mitochondrial biogenesis, regulating a series of mitochondrial generation and antioxidant genes, including NRF1/2. Its low expression prevents the construction of new mitochondrial "factories" and the renewal of old "equipment," manifesting as reduced mitochondrial quantity, decreased quality, and lowered respiratory efficiency. This is not only an energy crisis at the cellular level but also the starting point of the systemic antioxidant defense network collapse—directly corresponding to the "Mitochondrial Dysfunction" theory.

When PGC-1α is in a "too strong" state, it may lead to " metabolic rhythm disorder and reductive stress/signaling interference ." Although less studied, theoretically, the persistent overactivation of PGC-1α disrupts the dynamic balance between mitochondrial biogenesis and clearance, oxidation and antioxidation. It may force cells to consume large amounts of resources to build mitochondria when unnecessary, and may excessively suppress normal reactive oxygen species signals, which are essential for many physiological signal transductions. This imbalance interferes with the cell's metabolic flexibility and normal signal transduction rhythm—linking to the "Metabolic Disorder" and "Signal Integration Dysregulation" theories.

IV. PPARα Imbalance: Dysfunctional Speed Regulation of the Metabolic Engine

When PPARα is in a "too weak" state, it is the direct driver of the " loss of metabolic flexibility " (the molecular basis of systemic glycolipid metabolic disorder) theory. PPARα is the core transcriptional regulator of fatty acid oxidation and the TCA cycle in tissues like the liver and muscle. Its weakened function means that fatty acids, an important fuel source, cannot be effectively "burned," forcing cells to rely more on glucose metabolism. This rigidity and switching failure of metabolic pathways is the upstream culprit for insulin resistance, ectopic lipid accumulation, and systemic metabolic inefficiency during aging—directly corresponding to the "Loss of Metabolic Flexibility / Glycolipid Metabolic Disorder" theory, and initiating the "Epigenetic Alteration" pathway.

When PPARα is in a "too strong" state, it is closely associated with " oxidative stress and lipotoxicity ." Excessively activated PPARα indiscriminately drives the influx of fatty acids into mitochondria for β-oxidation. If this process exceeds the processing capacity of mitochondria or the carrying limit of the electron transport chain, it leads to massive production of reactive oxygen species, exacerbating oxidative damage. Simultaneously, intermediate products of incomplete lipid oxidation may accumulate, producing lipotoxicity and further impairing cell function—directly corresponding to the "Free Radical/Oxidative Stress" theory.

2.5 Chronic hypoxic microenvironment drives stem cell aging, the primary driver of stem cell aging.

The chronic hypoxic microenvironment continuously acts on stem cells through microcirculatory disturbance, triggering metabolic reprogramming and a cascade decompensation of the telomere regulatory network. This process has significant temporal dependency: Telomerase reverse transcriptase (TERT), whose expression level directly determines telomerase activity. Literature [177] indicates that moderate intermittent hypoxia can induce TERT activity and telomere stability, which explains the improvement of telomeres by a single hypoxic event. Literature [133] provides reverse evidence, showing FBP1 specifically removes TERT phosphorylation modification, blocking its nuclear translocation or telomere recruitment, proving that TERT is crucial for telomere elongation.

However, hypoxia is not always beneficial. Literature [173] points out that when erythrocyte deformability declines, oxygen affinity increases, and oxygen release capacity decreases. Therefore, it can be inferred that within the same time window, due to increased oxygen affinity and decreased oxygen release of erythrocytes, the oxygen available to local tissues under the metabolic background of that same time window will decrease, forming persistent hypoxia. When cells transition to persistent hypoxia, the proportion of glycolytic metabolism increases. Literature [179] points out that under hypoxic conditions, through the fermentation branch of the glycolytic pathway, NADH is used to reduce pyruvate to lactate by cytoplasmic lactate dehydrogenase (LDH), and also points out that lactate regulates pro-inflammatory cytokine expression through the NF-κB pathway.

Literature [180] points out that the expression level of nuclear factor kappa B (NF-κB) increases, and NF-κB can bind to the TINF2 promoter, thereby increasing the expression of TRF1-interacting nuclear factor 2 (TIN2).

When TIN2 is overexpressed, it inhibits telomere elongation. Literature [178] points out that TIN2 overexpression can prevent telomere elongation in various human cell lines. Literature [132] jointly verifies this point: high TIN2 expression leads to telomere shortening.

Therefore, it can be inferred that the sustained increase in the proportion of glycolytic metabolism induced by continuously insufficient oxygen supply within the same time window will have the property of inhibiting stem cell self-renewal, leading to replicative senescence.

2.6 Microcirculatory disturbance intensity and central axis imbalance ratio, and alternative aging entry pathways.

Although theoretically, any non-steady-state pathway will eventually lead to microcirculatory disturbance, the disturbance itself may have significant temporal differences depending on the pathway causing it. Based on the intensity of the central axis imbalance itself, the degree of microcirculatory disturbance varies significantly among individuals. Only some will exhibit microcirculatory disturbance in adolescence, entering the stage of mitochondrial functional decline through this path.

In certain aging subtypes, for example, states characterized by high mTOR expression and low PGC-1α expression, the accumulation of senescent cells and their Senescence-Associated Secretory Phenotype (SASP) can itself act as an upstream driver, persistently inducing mitochondrial functional decline. Research has shown that various inflammatory factors can directly impair mitochondrial energy metabolism and homeostasis maintenance by inhibiting mitochondrial biogenesis, interfering with electron transport chain activity, and disrupting mitochondrial dynamic homeostasis [157]. Further molecular mechanism studies show that in inflammation-driven senescent cells, impaired mitochondrial integrity leads to the abnormal leakage of mitochondrial RNA into the cytoplasm. This process activates innate immune sensor pathways like RIG-I/MDA5-MAVS, thereby amplifying SASP production and forming a self-sustaining cycle of inflammation and mitochondrial functional damage [156]. In this type, mitochondrial functional decline does not originate from initial energy supply deficiency or microcirculatory disturbance but is a direct result of long-term inflammatory signal input.

It can be said that while microcirculatory disturbance may not be obvious in everyone during early aging, mitochondrial functional decline will first be realized through various pathways, thus initiating the entire cascade collapse of aging from the first cause to the sixth cause—a self-reinforcing, self-maintaining, self-locking aging metabolic homeostasis. However, microcirculatory disturbance is the easiest feature to reveal; its eighty non-steady-state correlations are stable. When the central axis imbalance is strong enough, microcirculatory disturbance will inevitably be revealed.

Therefore, the first cause is the decline in mitochondrial functionality itself. Its core lies not in the appearance of previous traditional aging theories, but in the fact that the first cause itself forms a convergence of the damage pathways caused by multiple aging factors on the body. The decline in mitochondrial functionality, the first cause, is the node where multiple aging factors converge and drive the cascade collapse of the aging process. Once this first cause pushes the aging process to the second cause, it itself becomes a supporting role to the second cause, resulting in a switch of the primary aging factors.

2.7 Model of the Sodium-Potassium Pump's Functional Impairment Due to Decreased ATP Levels Affecting Ion Channels.

Literature [137] points out that the sodium-potassium pump requires ATP for energy. Based on this, it can be inferred that when the ATP produced by mitochondria drops to a level insufficient to meet the sodium-potassium pump's demand, the pump's energy supply decreases, leading to a reduced efficiency of potassium ion entry into the cell against its gradient. The intracellular potassium ion concentration decreases. When intracellular potassium ion concentration drops, the cell's capacity to maintain potassium ion efflux decreases. Literature [143] points out that in immune cells, reduced potassium efflux and cell membrane depolarization trigger calcium influx. Literature [136] similarly points out that in vascular smooth muscle, inhibition of potassium efflux and cell membrane depolarization trigger calcium influx. Through this common mechanism in two unrelated cell systems, it can be inferred that this is a shared mechanism of human cells. Literature [138] points out that the plasma membrane calcium pump, driven by ATP, pumps calcium ions out of the cell against their gradient. It can be inferred that if intracellular ATP levels decrease, the function of pumping calcium ions out will also decline. Literature [141] points out that the sodium-calcium exchanger NCX does not depend on ATP; it expels one calcium ion and imports three sodium ions by utilizing the sodium ion gradient. Literature [251] points out that aging leads to a significant increase in intracellular sodium concentration, accompanied by decreased cellular water content and increased cytoplasmic colloidal density.

Therefore, it can be inferred that when cellular ATP levels decrease, the function of the sodium-potassium pump declines due to a lack of ATP. This decline leads to prolonged depolarization and repolarization times, while hyperpolarization time remains unchanged. This results in more calcium ions entering the cell during depolarization. For survival needs, the cell will expel a calcium ion at the cost of importing three sodium ions through the NCX pathway. During this process, cellular sodium ion levels increase. The process of repolarization, involving pumping potassium in and sodium out via the sodium-potassium pump, cannot completely eliminate the negative effects of this pathway, leading to an age-related increase in intracellular sodium concentration.

2.7.1 Convergence of Multi-factorial Mitochondrial Functional Decline to Microcirculatory Disturbance, Metabolic Switch Elevating Lactate Levels, Inhibiting Nitric Oxide and Forming a Self-Perpetuating Cycle.

When the proportion of ATP produced by mitochondrial oxidative phosphorylation decreases, cells, needing to maintain metabolism, will drive glycolysis to compensate for the insufficiency of oxidative phosphorylation.

The metabolic switch increases the proportion of glycolytic metabolism, and the byproduct lactate will similarly increase. Lactate is not just metabolic waste but also an efficient signal regulatory factor. Lactate can promote vascular endothelial growth factor (VEGF) expression through the HIF-1α-VEGF pathway [168]. Previous studies examining individuals aged twenty to eighty-five did detect increased levels of vascular growth factors in the blood [167]. However, when persistent angiogenic factor levels increase while blood vessels need to maintain homeostasis, this involves the negative feedback regulation mechanism of angiogenic factors. According to this study [169], sustained stimulation of endothelial cells with VEGF leads to the downregulation of Flk-1 protein. This results in impaired eNOS activation and NO release upon subsequent VEGF challenge. Consistent with VEGF-stimulated Flk-1 degradation, it was demonstrated that VEGF stimulates Flk-1 ubiquitination, and Cbl mediates this effect through its ubiquitin ligase activity. This study proves that with increased angiogenic factor levels, the signaling quality of angiogenic factors declines.

Nitric oxide (NO) is a key substance promoting vasodilation and improving erythrocyte deformability, acting downstream of VEGF [169]. The increase in angiogenic factor levels will, through a negative feedback mechanism [169], lead to an age-related decrease in NO levels [170][171]. Subcutaneous blood supply depends on capillaries. The decrease in NO will lead to structural hypoxia in subcutaneous tissues. Although this hypoxia can induce increased levels of angiogenic factors, the blood angiogenic factors are already above normal levels, inducing desensitization [167][169]. Meanwhile, the body will also increase secretion of the inhibitory factor endostatin in response to excessive angiogenic factors [172]. Therefore, in a state of desensitized pro-angiogenic signaling and increased anti-angiogenic signaling, subcutaneous capillary tissues prone to structural hypoxia will exhibit a tendency towards reduced vascular density.

This pathway leads to weakened nitric oxide, and the consequent decrease in erythrocyte deformability and reduced oxygen release efficiency [173] will inevitably, because oxygen is a necessary substrate for the NAD+/NADH cycle and the FAD/FADH2 cycle, result in decreased efficiency of the FAD/FADH2 cycle, slowed lipid metabolism, and obstructed AKG and ketone body generation. The decreased efficiency of the NAD+/NADH cycle will force cells to increase the proportion of glycolytic metabolism as compensation. At the overall metabolic cycle level, this forms a harmful negative feedback loop.

Clarification: This mechanism was placed in the third cause, metabolic switch subsection, in the old theory. However, its mechanism may be a key convergence node linking the first and second causes. Therefore, in this version, it has been elevated to the stage of the first cause. Nevertheless, in the third cause section, this content is retained to maintain the flow of the preceding and following text.

2.7.2 Decreased Mitochondrial ATP Production Efficiency and Erroneous Ratio of GR Nuclear Translocation Signals.

Literature [288] points out that dysfunction of mitochondrial DNA polymerase γ (POLG) leads to alterations in mitochondrial DNA, resulting in the loss of mitochondrial oxidative phosphorylation (OXPHOS) and mitochondrial ATP generation. Total cellular ATP is generated by two energy pathways: glycolysis and mitochondrial OXPHOS. Mitochondrial dysfunction leads to reduced mitochondrial ATP generation, inducing compensatory upregulation of cytoplasmic glycolysis, thereby increasing the contribution of glycolysis to total cellular ATP generation.

Literature [289] indicates that through the glycolysis process, one glucose molecule is broken down into two pyruvate molecules. Depending on the microcellular environment (especially oxygen supply, energy demand, and the presence of mitochondria), pyruvate has several different fates:

In cells containing mitochondria, pyruvate can enter the citric acid cycle in the mitochondrial matrix and undergo oxidative phosphorylation. Because it relies on oxygen as the final electron acceptor, oxidative phosphorylation cannot occur under hypoxic conditions. Furthermore, as the enzymes for the citric acid cycle and electron transport chain are located inside mitochondria, cells lacking mitochondria (like erythrocytes) cannot rely on oxidative phosphorylation for energy production.

In erythrocytes and hypoxic tissues, pyruvate remains in the cytoplasm and is converted to lactate, a process called anaerobic glycolysis. This final reaction allows the regeneration of NAD+, a cofactor that must be present at sufficiently high intracellular concentrations for earlier glycolytic reactions to remain favorable. However, compared to oxidative phosphorylation, anaerobic glycolysis is significantly less efficient, netting 2 ATP molecules per glucose molecule (compared to 32 ATP in oxidative phosphorylation).

Literature [290] points out that AMPK is involved in maintaining bioenergetic homeostasis and may therefore regulate energy recovery following excitotoxicity or OGD-induced energy crisis. We and others have previously demonstrated that ATP depletion during excitotoxic injury increases protein levels of active threonine-172 phosphorylated AMPK, indicating higher AMPK activity. To directly monitor AMPK activity in a single-cell system, we used a FRET-based AMPK activity reporter. The probe contains a synthetic peptide that is phosphorylated by AMPK, altering probe conformation and increasing FRET, thereby enhancing the ratiometric fluorescent signal. As a positive control for this probe, we confirmed that administration of the AMP "mimetic" AICAR or exposure of CGNs and cortical cells to 2-DG increased the AMPKAR ratiometric fluorescent signal, consistent with other measurements observing elevated AMPK following these drug exposures. Using this probe, we found that AMPK activity increased rapidly and transiently during glutamate treatment in CGNs and NMDA treatment in cortical cells.

Literature [291] points out that AMPK induces acetylation of importin α1 at the Lys22 site in a p300-dependent manner and directly phosphorylates its Ser105 site. These modifications work together to enhance the nuclear import function mediated by importin α1.

Literature [292] points out that KPNA2 interacts with KPNB1 and upregulates its expression to promote M2 polarization of macrophages in the tumor microenvironment, thereby accelerating the proliferation and metastasis of gastric cancer cells. The interaction between KPNA2 and KPNB1 was confirmed through Co-IP and IF detection. Knocking down KPNB1 reversed a series of cellular phenotypes caused by KPNA2 overexpression. This functionally strongly proves that the role of KPNA2 largely depends on its regulation of KPNB1.

Literature [293] points out that ovariectomized mice exhibited elevated nuclear GR, decreased mitochondrial GR, and increased PBR expression in BMSCs. High-dose dexamethasone impaired osteogenic differentiation, manifested as nuclear GR accumulation, reduced mitochondrial translocation, and increased PBR expression. Co-immunoprecipitation confirmed a direct interaction between mitochondrial GR and PBR. Importazole reduced nuclear GR levels, promoted bone formation, and alleviated osteoporosis, while Emapunil enhanced GR mitochondrial translocation, improved mitochondrial function, and strengthened bone health.

Based on the above literature, it can be inferred that within the same time window, the amount of ATP produced by glycolysis is less than that produced by oxidative phosphorylation. This pathway leads to a prolonged state where ATP is at a low level, increasing the time AMPK is activated by low ATP levels. This step increases KPNA2 gene expression, raising importin α1 levels. Elevated importin α1 drives KPNB1 gene expression to produce importin β. The result of this pathway is that even if glucocorticoid levels do not change, the ratio of its signaling acting on mitochondria versus the cell nucleus will change, still leading to osteoporosis, with bones in areas of faster metabolism being affected first. The content of this subsection can explain the differential skeletal aging observed in literature [294].

2.8 ATP Decline in Cells Reduces Sodium Pumping Capacity, Interstitial Fluid and Extracellular Matrix Cannot Return to Blood via Atypical Pathways.

Literature [146] points out that a high-salt diet increases sodium content in interstitial fluid and the extracellular matrix, discovering that under high-salt conditions, extracellular sodium transfers intracellularly. As mentioned in Section 2.7 above, a decrease in ATP leads to functional decline of the sodium-potassium pump. Literature [252] points out that sodium content in skin and muscle tissues increases with age, inconsistently with blood levels, and simultaneously indicates that osmotically inactive skin Na+ can be mobilized by salt deprivation, thereby reducing the content of negatively charged skin glycosaminoglycans. Literature [253] points out that cartilage also contains glycosaminoglycans.

Literature [150] and [149] indicate that the assembly of elastin requires precise hydrophobic interactions and hinges. Literature [151] points out that heat and sodium can affect hydrophobic structures. Literature [254] indicates that liver aging drives aging in other organs by releasing transforming growth factor (TGF). Literature [255] points out that TGF drives glycosaminoglycans. Literature [256] points out that hypoxia drives glycosaminoglycan synthesis. Literature [152] points out that high sodium itself is a pro-inflammatory signal. Literature [257] points out that high sodium itself inhibits the lymphatic pathway's sodium reclamation function. Literature [258] points out that M1-polarized macrophages secrete matrix metalloproteinases (MMPs), degrading collagen. Literature [259] points out that inflammatory factors can drive macrophage M1 polarization.

Therefore, it can be inferred that during aging, TGF drives glycosaminoglycans, which have the effect of immobilizing sodium through their negative charge. This leads to increased sodium content in the skin and cartilage, forming a differential change in sodium content between the blood and the extracellular matrix. This differential change causes high-sodium interstitial fluid to inhibit the clearance function of lymphatic interstitium. Sodium, based on the ion gradient, will move towards the vascular cells, which act as an ionic low-concentration sink, and be pumped into the blood by vascular cells, reducing sodium load. However, during aging, vascular cells also experience reduced pumping efficiency due to a lack of ATP, leading to a state dominated by the glycosaminoglycan negative charge aggregation effect, where blood sodium ions preferentially transfer to the extracellular matrix.

In human articular cartilage, spinal cartilage, blood vessels, and skin, collagen and elastin are present. When the sodium content bound to glycosaminoglycans increases, the pro-inflammatory signals formed by sodium and its effect on hydrophobic structures jointly lead to the decline of elastin and collagen. In bones, this forms decreased structural toughness of articular and spinal cartilage, and inflammation-induced protein degradation, leading to osteoarthritic degenerative changes. In blood vessels and skin, it promotes the decline of skin and vascular elasticity. Hypoxia promoting glycosaminoglycans can explain, based on differences in oxygen release, whether non-age-related, pathological functional decline occurs in joints, spine, skin, and blood vessels.

2.9 Model of the Effect of Reduced Sodium-Potassium Pump Potassium Flux on Cell Membrane Receptors.

Literature [160] points out that the Growth Hormone Releasing Hormone Receptor (GHRHR) maintains depolarization by inhibiting delayed rectifier potassium channels to reduce potassium efflux, while the Somatostatin Receptor (SSTR) activates GIRK channels promoting potassium efflux and inducing hyperpolarization [161]. Therefore, it can be inferred that when ATP decline leads to slower refilling of the potassium pool by the sodium-potassium pump, causing prolonged depolarization time while hyperpolarization remains unchanged, a phenomenon of receptor blunting occurs. Prolonged depolarization means a longer GHRHR signaling time, leading to more vigorous growth hormone secretion. However, since growth hormone secretion is pulsatile and requires a large amount of ATP for secretion within a single time window, when sodium-potassium pump function decreases due to ATP decline, this results in decreased pulsatile growth hormone levels, increased basal, constant growth hormone levels, and the blunting/desensitization of relevant growth hormone receptors.

Simultaneously, as the downstream pathway of nuclear estrogen receptors can improve sodium-potassium pump function [145], this becomes a connection point for gender differences in aging. Because estrogen receptors improve the sodium-potassium pump, maintaining cell membrane receptor density, including that of the cytokine receptor family's growth hormone receptor GHR, the pro-aging effects related to sodium-potassium pump issues are lower in female individuals compared to age-matched male individuals.

Literature [143] points out that when Kv1.3 or KCa3.1 are inhibited, membrane potential depolarizes, directly inhibiting CRAC (Orai1)-mediated Ca²⁺ influx, leading to reduced IL-2 production and impeded proliferation. Therefore, it can be inferred that prolonged depolarization time will weaken immune function to a certain extent.

Literature [144] points out that long-term depolarization upregulates inhibitory G-protein signaling. From this, it can be inferred that functional decline of the sodium-potassium pump can inhibit the normal function of most receptors other than nuclear receptors. However, this effect is more confined to the middle and late stages of aging and cannot constitute a primary pro-aging factor in early aging. Literature [260] points out the blunted growth hormone secretion in aged individuals. Females <50 years: basal secretion (mU/L·24h): 15.3; pulsatile secretion (mU/L·24h): 128. Females ≥50 years: basal secretion (mU/L·24h): 19.5 (↑27%); pulsatile secretion (mU/L·24h): 77 (↓40%). Males <50 years: basal secretion (mU/L·24h): 7.0; pulsatile secretion (mU/L·24h): 78. Males ≥50 years: basal secretion (mU/L·24h): 7.5; pulsatile secretion (mU/L·24h): 79.

Thus, it can be deduced that the increase in basal growth hormone secretion caused by depolarization exists but has age limits. Beyond the current age stage, as aging deepens and the pituitary gland ages, a dual decline in both basal and pulsatile growth hormone will occur.

2.10 Self-locking Mechanism of the Sodium-Potassium Pump on ATP.

The functional decline of the sodium-potassium pump pushes up the sodium ion concentration in the extracellular matrix. This process itself is a pro-inflammatory signal [152], with literature pointing out that elevated sodium levels in the ECM induce the transcription of inflammatory factors. "TNF-α, via TNFR1, recruits TRADD/RIP1, prompting CypD-dependent sustained opening of the mPTP, leading to a 45% decrease in mitochondrial membrane potential and a 38% reduction in ATP synthesis; CypD deletion or cyclosporin A treatment can block this effect, directly proving that TNF-α activates mPTP is a key mechanism for membrane potential collapse and energy inhibition" [158][159]. From this point, the first cause forms a logically closed loop, capable of self-reinforcement, self-maintenance, and self-perpetuation, becoming a pro-aging factor.

3.1 The Second Cause of Aging: Glycolipid Metabolic Disorder

The decline in mitochondrial function will lead to a decrease in the efficiency of normal cellular fat metabolism, primarily targeting organs capable of direct fatty acid metabolism, such as the heart, liver, and muscles.

The core mechanism is that the final step of fatty acid β-oxidation, involving FADH, cannot be oxidized. The problem might be a decrease in blood oxygen release within the same time window, as indicated in literature [173] regarding altered erythrocyte oxygen affinity, reduced oxygen release, and increased oxygen affinity. Alternatively, as indicated in literature [159], TNF-α-induced oxidative stress damages the MPTP proteins adenine nucleotide translocator and voltage-dependent anion channel, altering redox homeostasis and leading to pore opening. Literature [158] points out that sustained mPTP opening leads to mitochondrial energy metabolism disorder.

Therefore, combining the various driving pathways of the first cause mentioned above, it can be inferred that the emergence of the second cause is a cascade collapse triggered by the decline in mitochondrial functionality (the first cause). Simultaneously, it can be inferred that in a metabolic context where hepatic fatty acid metabolism and the resulting ketone body supply decline, the body's cells will increasingly rely on blood glucose to maintain overall ATP levels.

3.1.1 Decline in Lipid Metabolism: Reduction of Free Carnitine and Accumulation of Multiple Carnitines

Mitochondria are the primary site for fatty acid β-oxidation, responsible for converting long-chain fatty acids into energy. Literature [86] points out that free L-carnitine is crucial for transporting fatty acids into the mitochondrial matrix and is essential for fatty acid metabolism. Literature [87] demonstrates that various acylcarnitines accumulate due to reduced fatty acid β-oxidation, causing damage to mitochondrial function. This forms a self-locking mechanism for the second cause and simultaneously demonstrates the negative impact on the human body of the altered metabolic ratio between glucose and fatty acids, specifically the decrease in lipid metabolism proportion.

3.2 Increased Proportion of Glucose Metabolism: Accumulation of Advanced Glycation End Products (AGEs) and Initiation of Inflammation

In the shared metabolic state of most human cells, it can be observed that even with sufficient blood glucose, cells still opt to use some ketone bodies for energy supply; this is the basis of cellular metabolic flexibility. Literature [92] points out that in non-obese, non-diabetic healthy adults, a portion of the body's energy in the fasting state comes from the oxidation of free fatty acids (FFA). Therefore, it will become more inclined to obtain energy through glucose oxidative phosphorylation. Literature [88] points out that accelerating carbohydrate metabolism directly inhibits fatty acid oxidation, with glucose oxidation increasing from a basal 6.2 +/- 0.8 to 22.3 +/- 1.4 mumol.kg-1.min-1 (P < 0.01). Total (indirect calorimetry) and plasma fatty acid oxidation (isotope determination) decreased from 2.6 +/- 0.2 to 0.4 +/- 0.3 (P < 0.01) and 2.2 +/- 0.2 to 1.4 +/- 0.1 μmol.kg-1.min-1 (P <0.05), respectively.

Therefore, by combining the phenomena from these two papers, it can be concluded that the decline in lipid metabolism caused by mitochondrial functional decline will reversely reinforce the proportion of glucose metabolism in the human body.

Literature [181] points out that the aerobic oxidation of glucose and other biomolecules within cells to produce carbon dioxide and water is not entirely clean. Molecular oxygen, even in its most stable triplet ground state, contains two unpaired electrons, which determines the easy emergence of reactive oxygen species (ROS) as alternative partial reduction products instead of water. Literature [182] points out that ketone-based metabolism produces less destructive reactive oxygen species at the mitochondrial and cellular level compared to glucose metabolism.

Therefore, it can be deduced here that in a metabolic background where ketone body levels decline, the glucose metabolic pathway will produce more ROS radicals in a state of mixed glycolipid metabolism.

Based on literature [181], it is indicated that the level of free radicals is positively correlated with the accumulation of advanced glycation end products (AGEs). It also points out that this pathway activates NOX-2, mitochondrial ROS, and NF-κB through AGE–RAGE binding, amplifying TNF-α/IL-6/ICAM-1 signals; ROS, in turn, promotes new AGE formation, forming a 'glycation-oxidation-inflammation' self-perpetuating cycle. Inflammation, based on the two core mechanisms mentioned in [159] and [158]—where TNF-α-induced oxidative stress damages MPTP proteins, altering redox homeostasis and causing pore opening, and sustained mPTP opening leads to mitochondrial energy metabolism disorder—will strengthen the effect of mitochondrial functional decline in reverse.

Therefore, glycolipid metabolic disorder not only reflects a change in the energy supply mode but is also the first core stage in the amplification of erroneous signals from the steady-state collapse that the human body inevitably experiences, starting from the convergence node of mitochondrial functional decline in aging.

3.3 Fat Accumulation Dilutes Vitamin D3 within Fat Reserves, Shifting Adipocyte Extracellular Vesicles Towards Pro-Inflammatory State.

Literature [120] points out that Vitamin D is a fat-soluble vitamin. After ingestion, most of it is taken up by adipose tissue and stored long-term. However, this form of Vitamin D3 has low bioactivity, yet this storage of Vitamin D3 in the body is crucial for inflammation regulation.

When body fat percentage is healthy, the concentration of Vitamin D3 (cholecalciferol) within adipocytes is relatively full, forming a non-genomic weak regulation of fat cells through its quantity. Literature [122] points out that 1α,25-(OH)₂D₃, upon binding to membrane-localized VDR (mVDR), activates the PLC-IP₃ pathway, prompting the endoplasmic reticulum to release Ca²⁺, rapidly increasing cytosolic free Ca²⁺; the Ca²⁺/CaM complex binds and activates CaMKKβ, which directly phosphorylates the Thr172 site of the AMPKα subunit, leading to a rapid increase in AMPK activity within minutes; activated AMPK then phosphorylates and inhibits NF-κB p65 nuclear translocation, while reducing the expression of pro-inflammatory genes like IL-6 and IL-1β, thus constituting Vitamin D's non-genomic anti-inflammatory mechanism.

Therefore, it can be inferred that when glycolipid metabolic disorder progresses continuously, leading to fat accumulation such as visceral fat, Vitamin D3 cholecalciferol is diluted in the expanded adipose tissue, causing a decrease in its intracellular concentration. Exogenous supplementation would require extremely high doses to restore its biological concentration to youthful levels, leading to the failure of its original anti-inflammatory non-genomic regulatory mechanism. This triggers adipocytes to shift towards a pro-inflammatory state, and the extracellular vesicles they secrete also undergo a phenotypic switch, from anti-inflammatory to pro-inflammatory.

These pro-inflammatory vesicles further promote lipolysis, breaking down stored fat into the blood. This mechanism can be deduced as the body's metabolic regulatory mechanism to cope with local excess body fat. However, in the context of glycolipid metabolic disorder and decreased fat metabolic efficiency, this mechanism forms an erroneous regulatory function, failing to achieve the lipolytic fat-reducing effect, and instead acts as a persistent negative factor through sustained low-grade inflammatory signals, raising the level of inflammatory factors in the body. Literature [183] supports this view, based on the fact that obese patients have higher levels of inflammation compared to normal-weight individuals.

3.4 The Metabolic Core of the Second Cause of Aging: Functional Decline of the α-Ketoglutarate (AKG) Axis

α-Ketoglutarate (AKG) is an intermediate in the tricarboxylic acid (TCA) cycle, a key nexus linking energy metabolism, epigenetic regulation, and the synthesis of cysteine, the precursor for the cellular antioxidant glutathione. Its levels primarily originate from intracellular self-synthesis through the TCA cycle and liver synthesis and release into the blood. Literature [184] provides strong evidence for the release of AKG from the liver into the blood, while confirming that increasing the level of fat metabolism through fasting can raise blood AKG levels.

3.4.1 Decreased AKG Levels Impair Epigenetic Demethylation Efficiency, Forming Epigenetic Drift.

Literature [185] points out that α-ketoglutarate (α-KG), as an essential co-substrate for the Fe(II)/α-KG-dependent dioxygenase family (including TET1-3 and ALKBH1-8), catalyzes the sequential oxidation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC) by providing oxidative equivalents. Subsequently, it achieves active DNA demethylation through the base excision repair pathway mediated by thymine DNA glycosylase (TDG), thereby reversing abnormal hypermethylation states and reactivating downstream gene expression.

Therefore, it can be inferred that a decrease in AKG levels will impair the efficiency of epigenetic demethylation, forming epigenetic drift. Literature [186] provides the core mechanism, replicating the aforementioned hypermethylation drift within 7 days, accompanied by typical aging phenotypes such as AMPK↓, mTOR↑, and enhanced secretion of SASP factors. Supplementation with exogenous AKG or restoration of TET expression reverses the drift and reduces the release of inflammatory factors, confirming the correlation between AKG and epigenetic drift.

3.4.2 Decreased Synthesis of the Key Antioxidant Precursor Cysteine Due to Decreased AKG Levels.

Cysteine is a key raw material for glutathione synthesis [186]. The synthesis of cysteine requires serine to provide the carbon skeleton, which is generated from homocysteine through a two-step transsulfuration reaction catalyzed by CBS/CTH [186]. Literature [187] points out that serine biosynthesis is located in the cytoplasmic segment downstream of glycolysis. 3-PG is first oxidized by phosphoglycerate dehydrogenase (PHGDH) to 3-phosphohydroxypyruvate, then catalyzed by phosphoserine aminotransferase (PSAT1) to 3-phosphoserine, and finally dephosphorylated by phosphoserine phosphatase (PSPH) to produce serine.

AKG mediates the transamination process of PSAT1. If AKG levels decline, the flux through PSAT1 will decrease. Literature [188] precisely points this out: the "cell-autonomous" function of Psat1 is to transfer the amino group from glutamate to α-KG, which then proceeds to synthesize glutamine. Once α-KG or glutamine is scarce, the transamination reaction stalls due to a lack of amino donors/acceptors, causing a synchronous drop in Psat1 flux.

Therefore, it can be inferred that if AKG levels decline, the metabolic pathway of serine will be obstructed, subsequently leading to an increased ratio of homocysteine in the blood and decreased cysteine levels. Ultimately, this results in the declining metabolic steady-state of the human body's functions during the aging process.

3.4.3 Decreased α-Ketobutyrate Levels, Weakening NAD+ Regeneration and Related Signaling Pathways.

Literature [189] points out that homocysteine condenses with serine to form cystathionine, a reaction catalyzed by cystathionine-β-synthase (CBS), the rate-limiting step of the pathway. Cystathionine is then hydrolyzed by cystathionine-γ-lyase (CGL) to produce cysteine and α-ketobutyrate. Literature [190] points out that α-ketobutyrate increases NAD+ production via lactate dehydrogenase LDH-1.

According to literature [191], Sirtuins (SIRTs) are class III histone deacetylases dependent on nicotinamide adenine dinucleotide (NAD⁺). Members of this gene family, SIRT1 through SIRT7, each have unique subcellular localizations and functional characteristics: SIRT1, primarily located in the nucleus and cytoplasm, regulates DNA damage repair, apoptosis inhibition, and metabolic homeostasis by deacetylating key proteins like p53, FOXO transcription factors, and PGC-1α; SIRT2 shuttles between the cytoplasm and nucleus, primarily deacetylating α-tubulin and histones H3 and H4, regulating cell cycle progression and microtubule dynamics; SIRT3, SIRT4, and SIRT5 are localized in mitochondria, where SIRT3 enhances antioxidant defense and regulates oxidative phosphorylation by deacetylating SOD2, SIRT4 mainly exhibits ADP-ribosyltransferase activity regulating insulin secretion and amino acid metabolism, and SIRT5 controls the urea cycle and cellular respiration through its potent desuccinylase activity; SIRT6 and SIRT7 are localized in the nucleus, with SIRT6 maintaining genomic stability and DNA repair by deacetylating H3K9, H3K18, and H3K56 while also possessing ADP-ribosyltransferase activity, and SIRT7, mainly located in the nucleolus, regulates ribosomal DNA transcription and chromatin structure by deacetylating H3K18ac and H3K36ac, protecting homologous recombination from damage. These sirtuin members, through their specific enzymatic activities and substrate selectivities, play coordinated and unique roles in metabolic regulation, stress response, aging processes, and disease pathogenesis.

Therefore, it can be inferred here that when serine decreases due to declining AKG levels, the downstream conversion efficiency of homocysteine to cysteine decreases. The metabolic intermediate α-ketobutyrate synchronously decreases, subsequently leading to a decrease in NAD+ levels, forming a negative signal regulation spreading from a single point to multiple targets.

3.5 The Arachidonic Acid-Nuclear Membrane Mechanics Axis, the Second Factor in Stem Cell Replicative Senescence.

Cysteine is a precursor substance for glutathione [186]. As stated in paragraph 3.4.2, its levels at this stage have already been affected by impaired metabolic synthesis due to glycolipid metabolic disorder. Paragraph 3.4.3 indicates that α-ketobutyrate's precursor homocysteine metabolism is hindered, causing a decline in NAD+ levels. Paragraph 3.2 indicates that the increased proportion of glucose metabolism drives up oxidative stress. These three metabolic pathways jointly increase the pressure on intracellular antioxidant resources.

Therefore, through the mechanism in literature [224] stating that glutathione can regenerate VC, and literature [192] stating that VC can regenerate VE through electron transfer, it can be inferred that the aging model described in the current hypothesis shows an impact on the ratio of oxidized to reduced Vitamin E on the cell membrane, with the proportion of oxidized VE increasing.

Literature [193] points out that oxidation of the cell membrane can lead to a decrease in membrane fluidity, and the reduced form of VE can prevent oxidation. Therefore, an increase in the proportion of oxidized VE indicates membrane oxidation, which will lead to decreased cell membrane fluidity.

Literature [166] points out that the lateral migration and aggregation of insulin receptors on the cell membrane depend on lipid fluidity; membrane fluidity is dynamically regulated by lipid composition and acts as a 'lipid switch' determining the initiation strength and duration of insulin signaling. Therefore, it can be inferred that when the proportion of oxidized VE increases and the cell membrane is oxidized, the decrease in membrane fluidity will inhibit the activation and transduction of insulin receptor signals, forming insulin resistance.

Literature [125] indicates that the FADS2 gene encodes Δ6-desaturase, the rate-limiting enzyme in the metabolic pathway from linoleic acid (LA) to arachidonic acid (AA), and insulin upregulates the FADS2 gene encoding Δ6-desaturase.

Literature [124] points out that the arachidonic acid pathway endogenously activates RhoA, leading to H3K9me2-mediated heterochromatin loss and dysfunction, thereby driving hematopoietic stem cell aging.

Therefore, combining the above literature, it is inferred that during aging, the increased oxidative load and declining antioxidant function driven by glycolipid metabolic disorder elevate the level of oxidized VE on the cell membrane, causing membrane oxidation and desensitization of the insulin receptor. The insulin resistance formed by this desensitization weakly drives up insulin levels.

Subsequently, the increase in insulin levels drives the expression of Δ6-desaturase (FADS2), increasing the conversion flux from linoleic acid (LA) to arachidonic acid (AA). This endogenously activates RhoA through the arachidonic acid pathway, leading to H3K9me2-mediated heterochromatin loss and dysfunction, thereby inhibiting hematopoietic stem cell function [124][125]. Through the membrane-nucleus mechanics, cell membrane oxidation, and the commonality of the hematopoietic stem cell microenvironment with other stem cells, it can be inferred that this mechanism has the potential to extend outward, encompassing the replicative senescence of other non-hematopoietic stem cells.

3.6 Vitamin E (VE) Decline Due to Decreased Glutathione Synthesis Leads to Decreased Mitochondrial Burst Energy Metabolism.

When the level of oxidized VE on the cell membrane is too high, the cell membrane becomes oxidized, which drives the activity of SREBP genes. As pointed out jointly in literature [73] and [75], elevated levels of oxysterols can relieve INSIG-mediated inhibition, promoting the nuclear translocation of SREBP-2 and upregulating the expression of cholesterol synthesis genes.

Simultaneously, literature [75] points out that the synthesis of coenzyme Q10 and cholesterol share the mevalonate (EVA) pathway. Therefore, it can be inferred here that if the expression of the cholesterol synthesis gene SREBP is upregulated due to oxidative pressure, the flux of the EVA pathway will be more biased towards synthesizing cholesterol rather than CoQ10.

Literature [76] indicates that for athletes or those needing sudden bursts of high-intensity exercise, insufficient CoQ10 limits the capacity for rapid mitochondrial ATP generation; supplementing CoQ10 can restore the maximum oxidative phosphorylation rate and reduce dependence on anaerobic glycolysis.

In the field of biological metabolic timing, this can be understood as: within the same time window, the upper limit of energy production by mitochondrial energy metabolism through oxidative phosphorylation is dependent on the sufficiency of CoQ10.

Literature [46] points out that growth hormone secretion exhibits a high-amplitude, intermittent, pulsatile release pattern. In the field of biological metabolic timing, this can be understood as: within the same time window, the strength of a growth hormone secretion pulse is not limited to the strength of promoting signals or whether receptors have become blunted/desensitized, but is also directly related to instantaneous energy, i.e., the burst power of ATP production. Literature [194] also corroborates this point: the transport of growth hormone from the Golgi apparatus to the release site and its subsequent secretion is completed within 5–7 minutes and primarily depends on oxidative phosphorylation; inhibiting mitochondrial ATP synthesis (oligomycin, dinitrophenol) can reduce the release rate by 60–70% without affecting protein synthesis.

Therefore, it can be inferred that when the disordered glycolipid metabolic network increases oxidative stress, elevating oxidized VE and creating a vulnerability in the antioxidant defense, the process of cholesterol oxidation promoting cholesterol synthesis will weaken growth hormone synthesis by reducing CoQ10 synthesis. This results in a CoQ10-dependent decline in growth hormone due to insufficient burst energy during the extremely short secretion window, without involving decreased promoting signals or receptor desensitization.

4 The Third Cause of Aging: Decline in Growth Hormone (GH) Levels and Cliff-like Senescence.

The functional decline of the Growth Hormone (GH)-Insulin-like Growth Factor-1 (IGF-1) axis is a landmark event in the aging process. Its starting point primarily relies on the decline in CoQ10 levels, which triggers a decrease in the cell's instantaneous ATP production capacity, leading to a decline in GH pulsatile levels. However, the true node where it replaces the second cause and becomes the current primary aging factor is when the GH pulse can no longer induce effective conformational changes in cell membrane receptors. This situation results in a drastic decline in GH's regulatory signals to the body.

4.1 The Effect of Decreased Growth Hormone (GH) Levels on NRF1 and Mitochondrial Quantity.

The pulsatile concentration of GH drives conformational changes in cell membrane growth hormone receptors [195]. The GH-IGF-1 axis maintains NRF1 expression through the PGC-1α pathway [79], and NRF1 sustains antioxidant function and mitochondrial biogenesis [69,81,157]. Literature [65,63,62] points out NRF1's role in maintaining antioxidant function.

The signaling pathways activated by conformational and non-conformational changes of the GH receptor are different [80]. The conformational change pathway involves the JAK2-STAT5 pathway [80], and JAK2-STAT5 signaling is an upstream signal for PGC-1α-NRF1 [100]. Literature [80] indicates that if GH only binds through the high-affinity site-1 without causing significant rotation, the JAK2-STAT signal is weak. Therefore, it can be inferred that when GH levels drop to a point insufficient to induce conformational changes, humans will experience a drastic decline in NRF1-maintained mitochondrial biogenesis and antioxidant function, forming a self-sustaining, self-stabilizing, self-amplifying erroneous metabolic mechanism.

4.2 The Effect of GH-Deiodinase-T4/T3 Pathway Obstruction on Carnitine Synthesis.

Literature [81] points out that intervention through the GH-IGF-1 pathway, restoring its signaling, can increase T3 levels and decrease T4 levels. Literature [82] reviews how the GH-IGF-1 pathway promotes the conversion of T4 to T3 by enhancing the activity of type II deiodinase (D2). Literature [196] indicates that T3 promotes carnitine synthesis by transcriptionally upregulating hepatic γ-butyrobetaine hydroxylase (BBH).

Therefore, at this step, it can be inferred that the weakening of the GH-IGF-1 pathway synchronously affects carnitine synthesis, impairing fat metabolism efficiency, and further locking and strengthening the lipid metabolism disorder inherent in the second cause (glycolipid metabolic disorder), forming a self-locking erroneous metabolic homeostasis.

Simultaneously, carnitine is an important transporter for fatty acids entering mitochondrial metabolism [86]. Its reduced level means that the quantity of the raw material (fatty acids) for mitochondria to produce AKG and ketone bodies decreases, forming inhibitory effects on AKG and ketone body generation.

4.3 Decreased T3, Increased T4 Ratio Co-regulates Abnormal Expression of NF-κB Downstream Gene Spectrum, Shifting Towards Pro-inflammatory Factor Expression.

During aging, the balance between thyroid hormones thyroxine (T4) and triiodothyronine (T3) and the switching of their action pathways is a core link leading to the dysregulation of the NF-κB signaling pathway.

1. Interference with p65-DNA binding efficacy: TR can competitively hinder the binding of p65 to κB sites on its target promoter.

2. Alteration of co-regulator recruitment landscape

This mechanism primarily operates when T3, at physiological concentrations, enters the cell and mainly binds to its nuclear receptors (TRα/β), forming a T3-TR complex. This complex does not directly inactivate NF-κB but, through protein-protein interactions with the p65 subunit (RelA), interferes with p65-DNA binding efficacy [105]. Furthermore, it alters the co-regulator recruitment landscape, excluding histone acetyltransferases (HATs) like CBP/p300, weakening chromatin opening, and recruiting NCoR/SMRT-HDAC3 complexes to promote local chromatin compaction. Strongly pro-inflammatory genes like IL-1β and TNF-α, which are highly dependent on p300, are thus preferentially silenced. Ultimately, even if NF-κB is partially activated for immune surveillance needs, the intensity of its driven transcriptional output for pro-inflammatory factors is biased towards low levels, coexisting with the output of anti-inflammatory factors.

This mechanism demonstrates the unique nature of T3's inflammatory control. Compared to other anti-inflammatory mechanisms that primarily focus on inhibiting NF-κB, this pathway primarily works by altering the transcriptional spectrum downstream of NF-κB.

However, in the context of aging mentioned earlier, growth hormone declines, cortisol levels rise, and during the conversion of T4 to T3, more T4 is converted to the bio-inactive reverse T3 (rT3). In this metabolic disorder, the body experiences a T3 shortage. This point will cause the TR pathway to lose its regulatory control over the downstream spectrum of the NF-κB pathway, leading NF-κB to exhibit a greater tendency to transcribe inflammatory factors.

Simultaneously, the relatively elevated T4 instead binds to integrin αvβ3 on the cell membrane, activating the PI3K-AKT signaling cascade, thereby triggering potent ROS production, leading to the release of NLRP3 inflammasomes and pro-inflammatory cytokines.

Ultimately, this pathological shift from the "T3-TR anti-inflammatory axis" to the "T4-integrin αvβ3 pro-inflammatory axis" causes a fundamental reprogramming of the downstream gene expression spectrum regulated by NF-κB. The transcriptional output shifts from anti-inflammatory factor dominance to a pattern more prone to massively expressing pro-inflammatory factors like IL-1β and TNF-α, thus becoming one of the significant sources of inflammatory factors in the body.

Literature [105] comprehensively elaborates on the functional differences between T3 and T4 in anti-inflammatory and pro-inflammatory roles.

Therefore, this section allows the inference that the decline of the GH-IGF-1 signaling pathway will, following a decrease in T3 levels, create a pro-inflammatory effect. This can explain the observed increase in inflammatory levels accompanying the aging process.

4.4.1 The Regulatory Network of Triiodothyronine (T3) and Protein Quality Control

T3's regulation of protein quality control is mainly achieved by activating the transcription factor FOXO3a. As indicated in literature [36], T3 directly activates FOXO3a via the Thyroid Hormone Receptor-PI3K axis. Literature [197] points out that FOXO3 can directly regulate the transcription of autophagy pathway genes ATG12, BNIP3, PINK1, etc., by binding to their promoter regions, simultaneously activating macroautophagy and mitophagy. The result is the timely clearance of protein aggregates.

Therefore, it can be inferred here that a decrease in T3 hormone levels not only leads to uncontrolled inflammation but also results in impaired protein quality control mechanisms and the accumulation of damaged mitochondria. This is the first factor contributing to the impairment of protein quality control mechanisms.

4.4.3 Disruption of the TH-AMPK Positive Feedback Loop and Central Axis Imbalance.

Literature [35] points out that thyroid hormone (T3) transiently triggers the AMPK-ULK1 axis by increasing mitochondrial reactive oxygen species (ROS), selectively inducing mitophagy. Simultaneously, literature [198] points out that the AMPK pathway can directly phosphorylate TFEB, promoting its transcriptional activity.

Therefore, based on these two studies and inferred through the central axis theory, during the decline of T3 levels, the body's autophagy function is comprehensively reduced. At this stage, the body's central axis undergoes a constrictive collapse. The signaling rhythm of AMPK will experience a metabolic decline in its self-maintenance homeostasis due to the drop in T3 levels. The central axis exhibits a convergent and rigidifying change during aging: the AMPK pathway is inhibited, and the mTOR pathway's signal is enhanced.

If the central axis in the first cause stage was a neutral pendulum, then during the constrictive collapse of the central axis caused by the T3 decline in the third cause stage, the central axis is already a tilted pendulum that continues to swing.

4.4.4 Lysosomal Dysfunctional Hyperactivity: The Synergistic Collapse of the Autophagy-Lysosome Network Triggered by T3 Signal Attenuation, Resulting in Decreased Stem Cell Self-Renewal and Replicative Senescence.

Literature [126] points out that aged hematopoietic stem cells (HSCs) exhibit high acidity. By inhibiting excessive lysosomal acidification and increasing TFEB expression, autophagy can be restored, simultaneously improving HSC self-renewal. Literature [36] indicates that FOXO3 directly drives the expression of autophagy genes, and TFEB is one of its downstream genes. Literature [37] points out that T3 hormone can drive FOXO3 expression. Concurrently, literature [33] describes the phenomenon of accumulating backlog due to reduced flux in the autophagy-to-lysosome process.

Combining these four papers and the mechanisms from 4.4.3 regarding T3 promoting AMPK [35] and AMPK promoting TFEB [198], the following deduction can be made: the decline in GH-IGF-1 signaling leads to decreased T3. The decrease in T3 causes reduced FOXO3 expression, leading to a comprehensive decline in the expression of autophagy pathway genes. However, due to cellular stress caused by the accumulation of misfolded proteins, genes related to lysosomal biogenesis are excessively promoted, resulting in an over-acidified state of stem cell lysosomes. This means the cell's capacity to package, load, and destroy misfolded proteins is comprehensively reduced. Yet, the stress signal from the accumulation of misfolded proteins increases the synthesis of lysosomes, the destruction pathway. However, because the packaging and loading pathways are not restored, the flux of misfolded proteins to lysosomes decreases, while the misfolded protein stress signal is persistently maintained. This ultimately triggers cellular over-acidification, leading to decreased HSC self-renewal. Given that different stem cells all possess lysosomes and share characteristics of high acidity, this mechanism has the basis to be extrapolated to other stem cells. Literature [36] corroborates this point: in adult mouse neural stem cells, FOXO3 directly binds to the promoter regions of a set of core autophagy genes (e.g., Map1lc3b, Becn1, Atg12), transcriptionally upregulating them to maintain autophagic flux and protein homeostasis. Once FOXO3 is lost, the autophagy network collapses, protein aggregation increases, and stem cell function rapidly ages.

4.5 Metabolic Pathway Switch: From Oxidative Phosphorylation to Glycolysis Energy Crisis.

The ATP output of mitochondria is key to maintaining cellular homeostasis. Studies [199][200] indicate that in cells with mitochondrial damage, the AMPK pathway promotes ATP production through glycolysis via HIF-1, while in cells with normal mitochondrial function, it promotes oxidative phosphorylation metabolism. Literature [3] points out that when a cell faces an energy crisis, the ATP/AMP ratio decreases, activating AMPK.

Therefore, combining the content of these two papers, it can be inferred that when cellular energy supply from oxidative phosphorylation is insufficient, the cell will increase the proportion of glycolytic metabolism within the same time window to cope with this imminent energy crisis. However, glycolysis occurs in the cytoplasm. While it can rapidly break down glucose to pyruvate, netting 2 molecules of ATP, it also produces a large amount of lactate catalyzed by lactate dehydrogenase (LDH). Literature [22] demonstrates, using the glycolytic mode of tumor cells, that glycolytic metabolism produces lactate. Literature [201] validates two points in mice: lactate levels increase with age. In mice with mitochondrial DNA mutations, the rate of lactate increase in the cerebral cortex between 6–9 and 35–38 weeks of age was 2.1% per week. In the striatum, lactate levels in mtDNA mutation mice aged 6 to 9 weeks were also twice as high, and these levels remained elevated as the mtDNA mutation mice aged. During normal aging, we found that lactate levels determined by 1H-MRS increased in later life; between 20 and 42 weeks of age, the average increase was 1.6% per week in the cerebral cortex and 1.7% in the striatum. Simultaneously, this paper also validates the inference that mitochondrial functional decline triggers glycolytic metabolism.

4.5.1.1 The Impact of Metabolic Switch on Epigenetics: Acetyl-CoA Decline as the Second Factor in Epigenetic Drift.

Accompanied by the decline in oxidative phosphorylation metabolism and the increased proportion of glycolytic metabolism, pyruvate, a key precursor for acetyl-CoA, must be catalyzed by the mitochondrial pyruvate dehydrogenase complex (PDC). However, mitochondrial functional impairment limits the efficiency of this process. Consequently, within the same time window, the pyruvate flux generated by glycolysis does not actually enter the mitochondria but is instead converted to lactate and expelled from the cell through the pathway of pyruvate regenerating NAD+.

This point can be used to explain the phenomenon mentioned in literature [201] of lactate increasing with age. Therefore, it can be inferred that the decline in acetyl-CoA levels is caused by the restriction of pyruvate metabolism due to decreased oxidative phosphorylation. Literature [106] points out that acetyl-CoA is an essential substrate for histone acetylation; a decrease in its level directly leads to insufficient histone acetylation modification, subsequently affecting chromatin openness and gene transcriptional activity, forming transcriptional inhibition at the epigenetic level.

4.5.2.1 The metabolic pathway switch affects NADH to NAD+ metabolism, causing the CD38-NAD+-AMPK inflammatory signal reversal pathway to fail.

Literature [41] indicates that CD38, as an inflammation-sensitive molecule, its expression can be directly induced by classic inflammatory factors like TNF-α and IL-6, thereby rapidly mediating the regulation of NAD+ levels under inflammatory conditions. CD38 catalyzes the hydrolysis of NAD+ to generate ADP-ribose (ADPR) and cyclic ADP-ribose (cADPR). cADPR can be hydrolyzed by the ectonucleotide pyrophosphatase/phosphodiesterase CD203a (NPP1) to form AMP [202]. AMP can drive the AMPK signaling pathway [203], and the AMPK signaling pathway has the effect of inhibiting NF-κB. Literature [56] supports this: AMPK blocks NF-κB nuclear translocation by inhibiting the NLRP3 inflammasome.

Therefore, it can be inferred that this mechanism serves as a reversal of inflammatory signals—a stress emergency stop mechanism. Activation of this mechanism will effectively improve the body's inflammatory state.

However, if this anti-inflammatory mechanism is continuously activated, the CD38-NAD+-AMPK pathway will consume a large amount of NAD+, leading to a persistent decline in the flux of the AMPK self-maintenance axis (NAD+-SIRT1-AMPK pathway). This shortens the window for cells to enter gene repair, causing a tendency towards genomic instability. Concurrently, the central axis shifts again, and the positive anti-aging pathways triggered by the SIRT gene family are once again comprehensively inhibited, creating an amplified aging effect. It is important to note here that this mechanism is not a negative one but a self-protective mechanism. Its core problem stems from the increased concentration of inflammation, and the negative consequences result from the compensatory effects of altered flux.

Literature [250] points out that iNKT immune cells depend on CD1d for antigen presentation. Under α-GalCer stimulation, iNKT cells exhibit impaired proliferation and IFN-γ production capacity, and PD-1 levels increase. Blocking experiments show that most of these functional defects are unrelated to PD-1. Simultaneously, literature [249] points out that iNKT cells exhibit unique immunometabolic characteristics, and AMP-activated protein kinase (AMPK) is essential for their function. AMPK deficiency impairs the physiological function of AT-iNKT cells. Concurrently, literature [248] points out that activating iNKT cells can efficiently clear senescent cells.

Therefore, it can be inferred that iNKT immune cells possess the ability to bypass immune checkpoints. If NAD+ in the blood is diverted by conventional cells for anti-inflammatory purposes within the same time window, the NAD+ available to iNKT cells decreases, weakening AMPK promotion. This step weakens the function of iNKT immune cells in clearing senescent cells. As blood NAD+ levels decline during aging, the iNKT pathway for clearing senescent cells in the immune system will gradually be inhibited, leading to an increased rate of senescent cell accumulation.

4.5.2.3 The increased proportion of glycolytic metabolism due to metabolic switch further promotes stem cell replicative senescence through TIN2.

Section 2.5 previously demonstrated that hypoxia-induced sustained glycolytic metabolism can trigger stem cell replicative senescence. Therefore, against the backdrop of an unbalanced proportion of glycolytic metabolism due to metabolic switch, it can be inferred that the increased proportion of aerobic glycolysis may have the same effect as anaerobic glycolysis, reinforcing this core factor driving stem cell aging.

4.5.2.4 The increased proportion of glycolytic metabolism and changes in substrate flow involved in the Pentose Phosphate Pathway within the glucose metabolic network.

The substrate of the Pentose Phosphate Pathway (PPP), glucose-6-phosphate (G6P), faces competitive diversion among three destinations during aging: 1. Glycolysis for energy (coping with ATP crisis); 2. Glycogen synthesis (energy storage); 3. PPP generation of the co-activator factor resource pool (NADPH and ribose-5-phosphate). When metabolic pathways are forced to tilt towards glycolysis due to declining mitochondrial function, G6P is massively diverted to pathway ①, exerting a continuous siphoning effect on the substrate supply for the PPP. Literature [162] confirms the three metabolic pathways of the PPP.

Therefore, it can be inferred that although this diversion changes slowly in instantaneous concentration, it leads to a decrease in the regeneration rate of NADPH and ribose-5-phosphate, limiting the upper driving demand of the four-gene program and creating a "metabolic flux supply-demand imbalance." The expression of AMPK, mTOR, PPARα, and PGC-1α does not depend on static stocks of substrates but on the continuous delivery rate of co-activator factors. When the delivery rate lags, the self-maintenance mechanisms of the four factors fall into a state of "relative energy supply deficiency."

The contraction of resource pool availability forces the originally rhythmically alternating four genes from "synergistic homeostasis" into "competitive involution": the strengthening of each party's self-maintenance mechanism (e.g., excessive mTOR activation) comes at the expense of compressing the repair and regeneration rates of the other three. This process compresses the central axis from a resilient oscillating system into "tendential rigidity," escalating epigenetic inertia from "biased tendency" to "self-sustaining pathway solidification," systematically reinforcing the aging tendency driven by the first cause.

Simultaneously, as NADPH serves as the electron donor for glutathione reductase (GR) and thioredoxin reductase (TrxR), it can directly regenerate GSH and reduced thioredoxin. Its declining level will further decrease the cellular antioxidant function already compromised by the disordered glycolipid metabolic network (the second cause). The protein disulfide isomerase (PDI)-ERO1α oxidative folding system in the endoplasmic reticulum relies on the reducing power provided by TrxR to continuously reactivate oxidized PDI into active isomerase. The decline in NADPH levels reduces the rate at which oxidized PDI is reduced, causing a sharp increase in the rate of disulfide bond mismatches in nascent peptide chains, intensifying the imbalance of intracellular proteostasis at the folding stage. This constitutes the second mechanism of proteostasis imbalance.

4.5.2.5 The decline in NADPH levels and T3 levels triggers compensatory acceleration of histone synthesis, but further worsens proteostasis imbalance.

The insufficient reducing power supply at the folding end (governed by NADPH) and the declining clearance function (maintained by T3) simultaneously appear. This dual decline in folding and clearance leads to the "net available amount" of functional proteins persistently falling short of cellular metabolic demands. Consequently, the cell misidentifies this roughness as a genuine lack of effective functional proteins, rather than recognizing the issue of protein quality itself. This activates stress signals like IRE1α-XBP1s, non-rhythmically upregulating the transcription of histones H3/H4, attempting to meet the demand for effective functional proteins through a higher transcription rate. While this logic can restore the synthesis of effective functional proteins in early aging, as the rate of histone transcription increases, this process itself similarly affects protein quality control.

Thus, a vicious cycle forms: insufficient cellular effective functional proteins → increased histone transcription rate to compensate → but the transcribed proteins are ineffective misfolded proteins → effective functional proteins remain insufficient → histones continue to increase transcription speed to meet the most basic survival needs of the cell for effective functional proteins. This is the third mechanism of proteostasis imbalance.

4.5.2.6 The decline in PPP flux triggers changes in cellular hyaluronic acid molecular weight levels, forming a pro-inflammatory mechanism.

In the human body, hyaluronic acid (HA) can be categorized into two types based on molecular weight: low molecular weight HA (LMW-HA, 10–300 kDa) and high molecular weight HA (HMW-HA, ≳1000 kDa). When PPP flux is squeezed by glycolysis, although HA itself will not decrease because glycolysis intermediates (glucose-1-phosphate leading to UDP-glucuronic acid via the glucuronic acid pathway, and fructose-6-phosphate leading to UDP-N-acetylglucosamine via the amino sugar synthesis pathway) sustain its production, the squeezing of PPP flux leads to a decline in NADPH levels, triggering a shift in HA molecular weight from high to low molecular weight forms.

HMW-HA binds to CD44 with high affinity, can block TLR4 dimerization, and inhibits the NF-κB pathway, manifesting anti-inflammatory effects, stabilizing the extracellular matrix, and maintaining tissue barrier function. Literature [163][164] demonstrated the anti-inflammatory properties of HMW-HA.

LMW-HA binds to TLR2/4 and RHAMM, activating the MyD88-NF-κB and ERK1/2 signaling pathways, inducing the expression of IL-1β, TNF-α, and MMP-9, manifesting pro-inflammatory, pro-cell migration, and pro-angiogenic effects. Literature [165][164] demonstrated the pro-inflammatory properties of LMW-HA.

Therefore, the two molecular weight forms of HA constitute functionally "antagonistic-agonistic" opposing signals and can be viewed as functionally opposite bioactive molecules, rather than a single substance. This mechanism can explain the core factor behind the gradual increase in inflammatory factor concentrations with aging and serves as a key explanatory mechanism for the scope of inflammation.

4.5.3 Metabolic Switch Elevates Lactate Levels, Promotes Sustained Increase in Blood Vascular Growth Factor Levels, Inducing VEGF Receptor Desensitization.

The metabolic switch increases the proportion of glycolytic metabolism, and the byproduct lactate is not just metabolic waste but also an efficient signal regulatory factor. Lactate can promote vascular endothelial growth factor (VEGF) expression through the HIF-1α-VEGF pathway [168]. Previous studies examining individuals aged twenty to eighty-five did detect increased levels of vascular growth factors in the blood [167]. However, when persistent angiogenic factor levels increase while blood vessels need to maintain homeostasis, this involves the negative feedback regulation mechanism of angiogenic factors. According to this study [169], sustained stimulation of endothelial cells with VEGF leads to the downregulation of Flk-1 protein. This results in impaired eNOS activation and NO release upon subsequent VEGF challenge. Consistent with VEGF-stimulated Flk-1 degradation, it was demonstrated that VEGF stimulates Flk-1 ubiquitination, and Cbl mediates this effect through its ubiquitin ligase activity. This study proves that with increased angiogenic factor levels, the signaling quality of angiogenic factors declines.

4.5.5 Decreased Erythrocyte Deformability Mediates Metabolic Pathway Switch in Osteoarticular Tissues, Affecting Acetyl-CoA Levels, Epigenetic Disorder Promotes 15-PGDH Expression, Inhibiting Articular Cartilage Regeneration.

Articular chondrocytes maintain stable HIF-1α expression through physiological glycolysis and resulting lactate, thereby promoting COX-2 transcription. However, due to the structurally hypoxic environment within joints, chondrocytes must maintain a stable glycolytic metabolism. Bone joint cells must push the TCA cycle with limited oxygen, and this oxygen concentration is strictly regulated, exhibiting a U-shaped curve. It needs to be maintained in a low-oxygen range, but not too low; both excessively high and low oxygen levels lead to decreased acetyl-CoA generation. Decreased erythrocyte deformability leads to erythrocytes having higher oxygen affinity but reduced oxygen release capacity [173]. This results in a decrease in the oxygen released by erythrocytes entering the joint within the same time window.

Consequently, the intra-articular TCA cycle experiences flow attenuation due to hypoxia, leading to a reduced supply of acetyl-CoA to articular chondrocytes, directly weakening the H3K27ac modification of the COX-2 promoter and causing the synthesis capacity of Prostaglandin E2 (PGE2) to fall below the negative feedback regulation threshold. This step is akin to the epigenetics having given the initiation signal, but at the execution port of acetylation, it is affected by the decreased metabolic flow of acetyl-CoA, possessing high expression potential but unable to convert it into effective gene expression. [128][129]

At this point, the transcriptional inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by PGE2 significantly relaxes. The promoter of this enzyme, which should be silenced due to insufficient histone acetylation, is instead aberrantly occupied by low-grade inflammatory signals (NF-κB/AP-1), forming "de-inhibited transcription." More critically, the ubiquitin-proteasome clearance capacity of aged chondrocytes decreases, causing the degradation rate of 15-PGDH to lag behind its synthesis, ultimately resulting in its net accumulation in the extracellular matrix. The increased level of 15-PGDH in articular cartilage degrades PGE2. Under normal biological levels, a small increase in PGE2 can promote articular cartilage regeneration [127]. However, the increase in local 15-PGDH concentration disrupts the normal ratio between 15-PGDH and PGE2, forming a reverse inhibition of PGE2 by 15-PGDH. Even if PGE2 levels rise in the blood with aging, due to the blood supply differences between the red and white zones of joints, the white zone can only rely on passive diffusion. With poor blood flow signals, it cannot effectively be influenced by blood-borne PGE2 [130]. Even if a small amount of PGE2 can enter the white zone through its small molecular structure, it will still be degraded under the metabolic context of high 15-PGDH concentration, leading to a decline in the self-repair function of articular cartilage. [127]. This study [174] demonstrated that persistent non-intermittent hypoxia can exacerbate osteoarthritis and increase the probability of OA onset, providing strong evidence for decreased erythrocyte deformability mediating the inhibition of cartilage regeneration.

Simultaneously, this mechanism operates at a fundamental level and has the basis to extend to other avascular areas such as the spine.

4.6 Lactate/Ketone Bodies/Immune System, The Dilemma of Immune Clearance in Aging.

Literature [246] points out that both ketone bodies and lactate can enter cells via monocarboxylate transporters (MCTs). Literature [57] indicates that ketone bodies directly inhibit the transcriptional activity of p53 through β-hydroxybutyrylation (Kbhb) modification. Literature [237] points out that increased P53 expression upregulates immune checkpoints. Literature [247] points out that it can similarly upregulate the immune checkpoint PD-L1, inhibiting immune clearance. Literature [58] indicates that ketone body metabolism requires the consumption of NAD+. Literature [54] points out that PARP1 activation consumes NAD+ and activates AMPK. Literature [53] points out that cells excessively express PARP1 when initiating the apoptosis program.

Therefore, it can be inferred that in the dilemma of senescent cell apoptosis, one aspect of decreased immune clearance is caused by a decline in ketone body levels. When the cell apoptosis program is initiated, the cell drives the AMPK pathway via PARP1 using NAD+, enhancing the P53-BAX pathway and inhibiting mTOR to achieve senescent cell apoptosis. When this pathway is blocked due to mTOR activation and poor cell membrane fluidity, the cell would use ketone bodies to enter the senescent cell. The P53 inhibitory effect formed by β-hydroxybutyrylation (Kbhb) modification achieves the suppression of P53-mediated immune checkpoint PD-L1 upregulation and P53-BAX downregulation, thereby inhibiting inflammation and relieving the immune checkpoint PD-L1's suppression on immune cells (NK and T cells), thus completing the immune clearance of senescent cells. However, the occurrence of metabolic switch and the ongoing imbalance caused by increased lactate proportion and decreased ketone body proportion will alter the ratio of lactate to ketone bodies entering the senescent cell. Lactate will increase the immune checkpoint PD-L1 of the senescent cell, assisting the senescent cell in immune evasion, leading to a decrease in the efficiency of senescent cell clearance.

4.7.1 Skeletal Muscle Decline: GH Directly Induces Decorin Expression and Its Anti-Atrophy Mechanism

Literature [83] points out that GH can directly induce the expression of Decorin in skeletal muscle through a non-IGF-1 pathway. Decorin, a small leucine-rich proteoglycan, has the key function of inhibiting Myostatin, a crucial negative regulator of muscle growth.

Therefore, it can be inferred that the decline in GH leads to weakened inhibition of myostatin, resulting in a decrease in skeletal muscle mass, manifesting as age-related muscle loss and symptoms of skeletal muscle decline.

4.7.2 Loss of Skeletal Muscle Function as an Anti-Inflammatory Endocrine Organ

Literature [84] points out that IL-6 induced by exercise in muscles possesses anti-inflammatory properties. Literature [245] indicates that muscles can secrete the anti-inflammatory factor IL-10. Literature [246] points out that TNF-α increases myostatin expression via the NF-κB-dependent pathway.

Therefore, it can be inferred that this constitutes a multiple vicious cycle. When GH declines, the inhibitory pathway on myostatin weakens, and the control over inflammatory factor secretion further fails. TNF-α will further enhance the myostatin pathway, inhibiting muscle regeneration. Simultaneously, inflammation inhibits mitochondrial functionality, further reducing the instantaneous ATP generation capacity, leading to a further decline in GH pulsatile levels.

Concurrently, accompanying the loss of muscle mass and the lipid metabolism predicament jointly driven by the second and third causes, this itself symbolizes an increase in pro-inflammatory fat levels and a decrease in inflammation-suppressing muscle levels. Hence, it can be inferred that the proportional change in muscle and fat levels in the body, coupled with the decreased efficiency of muscle in consuming fat, makes it easier for fat to accumulate, creating an inflammatory environment.

From this, it can be concluded that the decline of skeletal muscle is not only a loss of muscle function but also a crucial link in the collapse of the systemic anti-inflammatory defense. Acting as a direct effector and amplifier downstream of the GH-IGF-1 axis, it transforms the attenuation of hormonal signals into a tangible, vicious cycle of uncontrolled inflammation and erroneous metabolic evolution of the body's functions.

4.7 Failure of the Conventional Anti-Inflammatory Pathway of Growth Hormone.

Literature [100] points out that GH signaling can be rapidly initiated through three pathways: JAK2-STAT5, PI3K-Akt, and MAPK-ERK, enhancing cell survival, promoting proliferation, and inhibiting apoptosis. Literature [204] indicates that C-Jun N-terminal kinases (JNKs) belong to the mitogen-activated protein kinase (MAPK) family. Therefore, when growth hormone drives the MAPK pathway, the MAPK-JNK pathway will also be driven. Literature [205] indicates that a decrease in JNK signaling triggers inflammation. Literature [206] points out that activating JNK upregulates interleukin-10. However, there are counterexamples; literature [207] points out that inhibiting JNK can decrease inflammation.

Therefore, it can be inferred here that the activity of JNK exhibits a U-shaped biphasic pro-inflammatory nature. During the decline of GH signaling, the JNK signal will trigger inflammation through over-suppression.

Literature [208] points out that the PI3K-Akt pathway of GH signaling can initiate the expression of the ST6GAL1 gene. Concurrently, literature [101,104] points out that ST6GAL1, as a sialyltransferase, plays a key role in cell membrane glycosylation modification. Its upregulation can reduce the affinity of membrane receptors for inflammatory ligands like TNF-α and IL-6, thus achieving "feedforward inhibition" of inflammatory signals. This axis constitutes the anti-inflammatory homeostatic pathway of GH.

Therefore, it can be inferred here that as GH secretion declines during aging, the weakening of the PI3K-Akt-ST6GAL1 pathway and the MAPK-JNK pathway of GH forms a dual pro-inflammatory effect, triggering a sustained low-grade inflammatory state [102,103,104].

4.8 Co-Regulation of Immunosenescence by GH Signaling and Glucocorticoids

4.8.1 GH Decline Directly Leads to Thymic Atrophy and its Synergy with Cortisol for Fatty Infiltration of the Thymus.

Literature [107] points out that IGF-1 increases the number of thymocytes in PSGL-1KO mice. Literature [209] points out how GH affects T-cell development and immune reconstitution post-transplantation.

Therefore, combining the content of these two papers, it can be inferred that thymic atrophy during aging is related to the weakening of the GH-IGF-1 axis signal. Simultaneously, literature [108] points out that low growth hormone and high glucocorticoid levels lead to increased visceral fat. Literature [109] finds that BMI is positively correlated with thymic fatty infiltration, and the thymus of obese patients shows accelerated degeneration. Literature [110] points out that damage to the thymic microenvironment leads to the exhaustion of naive T-cell output, with obesity being an important factor.

Therefore, combining these three papers, it can be inferred that the weakening of the GH-IGF-1 signal leads to fat accumulation. High glucocorticoids promote the transfer of fat to the viscera, forming a fatty infiltration of the immune organ, the thymus, destroying the thymic regeneration microenvironment. Obese patients will exhibit stronger immunosuppression at this stage.

Summary: The weakening of the GH-IGF-1 signal not only inhibits the regeneration of the thymus itself but also, through glucocorticoids, directs erroneous fat accumulation in the thymus, destroying the thymic regeneration microenvironment.

4.8.2 GH Deficiency Synergizes with Cortisol to Damage the Bone Marrow Immune System.

A similar process also occurs in the bone marrow, the root of the immune system. Literature [111] points out that mesenchymal stem cells (MSCs) are precursor cells for both osteoblasts and adipocytes, with a bidirectional competitive relationship in their differentiation. It also points out that osteoporosis involves adipocyte occupation and active secretion of RANKL to promote osteoclast activation, damaging bone homeostasis. Literature [210] points out that cortisol drives the transformation of MSCs into adipocytes, and bone marrow adipose tissue (BMAT) is a dynamic fat organ within the bone marrow microenvironment, integrating energy storage, endocrine function, and immune regulation. Literature [112] indicates that BMAT induces oxidative stress in hematopoietic stem cells (HSCs) through excessive secretion of free saturated fatty acids, causing mitochondrial dysfunction and inhibiting HSC self-renewal capacity, leading to immunosuppression.

The preceding text has detailed the failure of multiple inflammatory factor control mechanisms, and literature [211] points out that elevated levels of inflammatory factors drive up glucocorticoid levels.

Therefore, it can ultimately be inferred that: the metabolic homeostasis imbalance (first cause) drives up inflammatory factors. The glycolipid metabolic disorder (second cause) and the declining GH levels (third cause) jointly drive the failure of multiple inflammation control points, forming a chronic inflammatory metabolic homeostasis, which collectively drives up glucocorticoid levels. Combined with the failure of GH pulse-induced conformational changes (third cause), this further causes atrophy of immune organs and the invasion of fat tissue into immune organs, initiating the fatty infiltration program and "hollowing out" the thymus and bone marrow from the inside. This constitutes the phenomenon of immunosenescence during the aging process.

4.9 Imbalance of the GH/IGF-1 Signal Ratio: From Physiological Synergy to Pathological Divergence

The incomplete intersection of GH signaling and IGF-1 axis signaling was previously described in Section 4.7, where GH signaling can inhibit myostatin independently of the IGF-1 pathway, thereby promoting muscle growth and maintaining skeletal muscle health. Multiple studies demonstrate that while GH and IGF-1 signals are synergistic, they also exhibit antagonism and independence. Literature [113] points out that inhibiting IGF-1 signaling can improve aging. However, a problem with this paper is its failure to strictly differentiate between GH and IGF-1. IGF-1 is not entirely driven downstream by GH but is synthesized through multiple pathways. For instance, increased insulin levels can drive IGF-1 synthesis, independent of GH signaling [213]. Literature [212] provides contrary empirical evidence showing that GH signaling improves aging. Literature [285] indicates that deficiency of human growth hormone induces skin premature aging.

Combining this with the formation mechanism of insulin resistance mentioned earlier in Section 3.5, and the tendency for insulin levels to slowly increase with age, alongside the previous findings that IGF-1 inhibition improves aging and GH signal enhancement also improves aging, a deduction can be made. During aging, the GH/IGF-1 signal ratio becomes imbalanced in its decline, exhibiting a decoupled and uncoordinated state at the signal level. The regulatory effects attributed to IGF-1 exceed those of GH signaling; the IGF-1 signal becomes background noise in the aging process, while GH experiences a drastic signal weakness due to its inability to effectively achieve conformational changes. Based on the fact that IGF-1 signaling can activate the mTOR signal, it can be speculated that this pathway further enhances mTOR in the aging process, strengthening its self-sustaining homeostasis, forming a continuous mTOR activation signal, increasing the inhibition of the BAX apoptosis pathway, reducing the self-apoptosis probability of senescent cells, and becoming a significant factor in accelerating senescent cell accumulation.

4.10 Decline in GH Pulse Leads to Decreased IGF-1 Signaling in Skin Fibroblasts, Causing Collagen Decline. Inflammatory Factors Synergistically Damage Skin and Drive TGF-β to Protect Blood Vessels.

Literature [214] points out that a decrease in circulating IGF-1 levels in the blood does not affect wound repair maintained by local IGF-1 signaling. Literature [215] indicates that fibroblasts are responsible for collagen production and maintenance. Literature [216] points out that IGF-1 signaling significantly promotes the secretion of COL1 and COL3 by fibroblasts via the PI3K/AKT pathway in a time- and dose-dependent manner.

Therefore, through the above three papers and the content of Section 4.1, it can be inferred that dermal fibroblasts depend on GH pulse-induced conformational changes to form local IGF-1 signals that maintain and promote collagen secretion by dermal fibroblasts. This process is unrelated to the background level of circulating IGF-1 in the blood and is solely governed by the local IGF-1 signal dominated by GH pulsatile secretion. When the third cause becomes the primary pro-aging factor, it directly leads to a drastic decline in the visual effects of skin plumpness and moisture maintained by collagen produced by fibroblasts, forming a visually perceptible cliff-like aging effect. Concurrently, combined with the content of Section 4.6, it can be speculated that this process will be accompanied by a decrease in muscle mass. Literature [219] points out that as IGF-1 signaling decreases, fibroblasts lose their proliferative capacity and their ability to maintain ECM integrity, leading to dermal thinning and reduced skin elasticity.

4.10.1 Synchronous Aging of Blood Vessels and Skin.

The metabolic homeostasis imbalance (first cause) triggers an increase in inflammatory factor levels. Glycolipid metabolic disorder (second cause) promotes a secondary increase in inflammatory factor levels. By the time of the third cause, the core T3 anti-inflammatory mechanism and GH anti-inflammatory mechanism collectively decline. Concurrently, two major senescent cell clearance mechanisms gradually fail. The decrease in GH's guidance on fibroblasts jointly promotes the damaging effects of inflammatory factors on collagen.

Both blood vessels and skin contain fibroblasts. Among the multiple functions of fibroblasts is the production of elastin and collagen [217]. Literature [218] points out that inflammatory factors can destroy collagen. Literature [52] indicates that inflammatory factors can drive the secretion of Transforming Growth Factor-β (TGF-β). Literature [51] indicates that abnormal sustained activation of the TGF-β pathway leads to organ tissue fibrosis. Literature [219] further points out that the TGF-β signaling pathway is another key mediator of fibroblast aging, particularly through its role in fibrosis and ECM remodeling. TGF-β is a potent regulator of fibroblast function, and its signaling through SMAD proteins promotes the expression of ECM components like collagen. In aged fibroblasts, TGF-β signaling is upregulated, leading to excessive ECM deposition and fibrosis, ultimately forming wrinkles and skin hardening.

Combining these papers, it can be inferred that during aging, the increase in inflammatory factors, while destroying collagen, simultaneously promotes the secretion of TGF-β as a negative regulator. This negative regulation can maintain the homeostasis of blood vessels. However, because TGF-β secretion simultaneously exacerbates fibrosis, this triggers increased fibrosis in blood vessels and skin, leading to the phenomena of skin aging and vascular aging. Literature [220] points out that blood vessels and skin exhibit a synchronous aging trend.

5 The Fourth Cause of Aging: Antioxidant Network Collapse

Both NRF1 and NRF2 can bind to the Antioxidant Response Element (ARE). This mechanism provides the basis for their competition at the signaling level [62]. Literature [63] points out that NRF2 is responsible for emergency antioxidant responses, while NRF1 is responsible for maintaining GSH recycling regeneration and proteasome homeostasis; dual gene knockout renders cells extremely sensitive to the pro-oxidant tBHQ. Literature [62] also points out that upon knocking out NRF1, although NRF2 can still be activated, it cannot compensatorily maintain the normal expression of mitochondria-related antioxidant genes, leading to impaired mitochondrial function.

As mentioned earlier in Section 4.1, the third cause, the decline in GH-IGF levels, leads to decreased PGC-1α expression, and NRF1 levels decline accordingly. Therefore, it can be inferred that with aging, the body's antioxidant function is increasingly handed over to NRF2. The typical activation mode of NRF2 involves its release through the oxidation of Keap1 by ROS. This means that when the antioxidant function maintained by NRF1 is lost and only that maintained by NRF2 remains, the activation frequency of NRF2 will increase.

Literature [42] indicates that sustained activation of NRF2 drives the transcription of HO-1, which decomposes heme, increasing intracellular free iron levels and triggering the ferroptosis pathway via oxidative stress.

Based on this, combined with the inference of frequent NRF2 activation, it can be further deduced that although frequent NRF2 expression may not necessarily lead the cell to ferroptosis, it will increase cellular oxidative stress and the cellular antioxidant load. This creates chronic oxidative stress. Chronic oxidative stress promotes the frequent expression of NRF2, accelerating it. Through frequent binding to the ARE element, it can be deduced that NRF2 will inhibit NRF1 expression by competing for the ARE, forming a vicious cycle of self-maintenance, self-reinforcement, and self-perpetuation in a locked state. This is the starting point of the fourth cause.

5.1 The Antioxidant Network, Electron Donor Transfer and Reserves.

Literature [221] indicates that the total amount of Vitamin C in the human body is 3000mg. Literature [222][223] points out that a healthy adult has 1500mg of Vitamin C in its reduced form, ascorbic acid (AA). Literature [224] points out that the synthesis of glutathione can regenerate VC and also indicates that when dehydroascorbic acid (DHA) concentration exceeds 400 μM, it consumes intracellular reduced glutathione (GSH). Literature [225] points out that the DHA/AA ratio changes in the elderly, with the proportion of DHA increasing, and that elderly individuals with low AA are more susceptible to age-related diseases. Literature [226] points out, through pharmacokinetics, the absorption dilemma of reduced VC (AA) in the human body. At low to moderate oral doses (30–180 mg/day), absorption efficiency is as high as 90%, with bioavailability up to 90%. However, exceeding 1000 mg/day causes the fractional absorption rate to drop sharply to less than 50%, primarily due to high saturation of intestinal SVCT1. For oral doses exceeding 400 mg/day, due to limited absorption and increased renal clearance, plasma ascorbic acid only increases modestly. The kidneys reabsorb ascorbic acid through SVCT1 in the proximal tubules; however, once plasma levels exceed the renal reabsorption threshold, the kidneys actively excrete excess ascorbic acid through urine, reducing its systemic retention. Additionally, tissue saturation adds another barrier. Therefore, higher plasma ascorbic acid concentrations do not necessarily lead to elevated intracellular levels, especially in already supplemented tissues, where SVCT2-mediated uptake is strictly controlled. Literature [227] points out that depletion of inducible Thioredoxin 1 (TRX1) slows the reactivation of PTEN in intact living cells. Literature [228] points out that Thioredoxin can regenerate VC. Literature [229] indicates that taking 500mg of VC can promote an increase in the ratio of reduced glutathione in erythrocytes, facilitating glutathione regeneration. Literature [230] points out that the MRP2 (multidrug resistance-associated protein 2) pump mediates the excretion of GSH and GSSG, as well as endogenous and exogenous substances bound to GSH, glucuronic acid, or sulfate. NRF2 overexpression can activate MRP2. Literature [231] points out that exogenous intake of VC can lower the level of GSSG in the blood. Literature [78] indicates that PTEN can inhibit mTOR.

Therefore, we can infer that Vitamin C is the largest electron reserve pool in the human body. Its primary use is to regenerate VE, maintain membrane antioxidant function, and counteract the damage from ROS free radicals produced by endogenous and exogenous oxidants in the blood. Human cells prefer to export reduced VC to form the blood's antioxidant defense line and then reclaim oxidized VC, regenerating it through pathways like glutathione and thioredoxin to maintain the stability of the blood's antioxidant defense.

Once the proportion of oxidized VC in the antioxidant network increases, cells will draw upon reduced glutathione to regenerate VC. This step may lead to increased intracellular GSSG levels and decreased intracellular GSH. However, cells can oxidatively modify Keap-1 to release NRF2, excrete intracellular GSSG via MRP2, and then synthesize GSH to remedy the situation, restoring intracellular reduced glutathione levels. In this pathway, the proportion of oxidized VC in the blood determines whether cells need to initiate emergency rescue via the NRF2 pathway.

Low-frequency rescue via the NRF2 pathway will directly lower blood GSSG levels, while high-frequency rescue will increase blood GSSG levels. Simultaneously, when the proportion of oxidized VC within the cell increases, it will divert NADPH expenditure away from other antioxidant demands, such as the Thioredoxin (Trx) pathway, within the same time window.

The Thioredoxin (Trx) pathway is also a key route for VC regeneration. When the proportion of oxidized VC increases, the main flux of Trx shifts towards VC. The maintenance of PTEN's reduced state will then be disrupted. One core function of PTEN is to degrade phosphatidylinositol trisphosphate (PIP3), thus negatively regulating the PI3K-AKT-mTOR signaling axis. Once PTEN is inactivated by oxidation, its degradation of PIP3 weakens, leading to sustained activation of AKT, which in turn triggers the overactivation of the mTORC1 signaling pathway. This pathway promotes glutathione synthesis by enhancing biosynthetic metabolism.

5.3 The weakening of the antioxidant network, Vitamin A, and the reverse regulatory mechanism of the PTEN-mTOR pathway.

Literature [23] points out that retinol binds to RBP. Literature [25] indicates that reduced Vitamin A (retinol) bound to RBP (holo-RBP) activates the STRA6 receptor. Literature [24] confirms that the holo-RBP/STRA6 complex has a pro-survival (anti-apoptotic) function. Literature [26] confirms that STRA6 activates the ILK/AKT/mTOR signaling axis. Literature [232] points out that oxidized Vitamin A (retinoic acid) can also bind to RBP, but STRA6 cannot take up retinoic acid from this complex as it does with retinol. The uptake of retinoic acid from the retinoic acid/RBP complex requires the participation of CRABP-I (cellular retinoic acid binding protein-I), and cannot be accomplished by STRA6 alone. Literature [27] points out that retinoic acid promotes apoptosis. Literature [78] indicates that PTEN oxidation can activate mTOR. Literature [233] points out that increased mTOR activation enhances the expression of anti-apoptotic proteins. Literature [234] points out that senescent cells maintain high levels of mTOR activity. Literature [235] indicates that VE regulates Bax translocation to the mitochondria, inhibiting Bax-initiated apoptosis. Literature [236] points out that VE deficiency leads to apoptosis sensitivity.

Therefore, it can be inferred that when cellular redox resources are ample and electron transfer is smooth, Vitamin A is generally maintained in its reduced state. Holo-RBP (retinol bound to plasma retinol-binding protein) binds to the membrane receptor STRA6, triggering STRA6-dependent cell membrane signal transduction. This complex can induce the recruitment and activation of JAK2 in the intracellular domain of the receptor after binding, subsequently inducing tyrosine phosphorylation of the STAT family transcription factor STAT5. Tyrosine-phosphorylated STAT5 can directly bind to Raptor, a core component of mTORC1, activating the mTOR signal. However, PTEN, due to ample antioxidant resources, inhibits mTOR, forming an opposing regulatory signal. Because VA's reduced state activates mTOR through a milder pathway, it is more easily regulated by the body, and the signal is more stable compared to the oxidized PTEN pathway.

Similarly, VE in its reduced state inhibits BAX. However, all of this does not inhibit normal cell apoptosis. When a cell undergoes apoptosis, its intrinsic apoptotic program initiates the vigorous activation of the PARP1 gene. PARP1, as a molecular sensor of DNA damage, rapidly consumes the intracellular NAD+ pool through its extraordinary enzymatic activity, aiming to mark and initiate repair by synthesizing poly(ADP-ribose) chains. This step drastically pushes up p53 expression via ADP through the AMPK pathway. The whole system is akin to a slope: when cellular reducing resources are ample, cells do not easily enter the apoptotic program and instead try their best to repair. Moreover, because the cell membrane's degree of oxidation is low and fluidity is sufficient, cells entering the apoptotic program are more easily killed by their own intrinsic apoptotic program.

Conversely, if cellular antioxidant resources are insufficient and electron transfer is abnormal, PTEN becomes oxidized, mTOR is continuously activated, and although VA and VE no longer exert anti-apoptotic effects but instead initiate pro-apoptotic effects, the cell must face two major inhibitory pathways for apoptosis: cell membrane oxidation and sustained mTOR activation. These jointly lead to a decrease in the rate of cell apoptosis, increasing the proportion of senescent cells in the human body.

5.4 Persistent mTOR Signal Inhibits AMPK, Shortening the Expression Window of DNA Repair Enzymes Downstream of the AMPK Pathway and Increasing Cellular Genomic Instability.

Literature [175] points out that there are multiple DNA repair enzymes downstream of the AMPK pathway. Literature [237] points out that increased P53 expression will elevate the expression of immune checkpoints.

Therefore, it can be inferred that when mTOR is uncontrollably activated due to PTEN oxidation, AMPK is inhibited. DNA repair pathways downstream of AMPK—such as homologous recombination repair, nucleotide excision repair, base excision repair, and mismatch repair—will experience a decrease in maintenance frequency and quality. The genome will consequently experience increased instability. This genomic instability triggers an elevation in P53 levels, and P53 upregulates immune checkpoints, leading to the inhibition of immune clearance.

5.5 Persistent mTOR Signaling Mediates Changes in Downstream Gene Spectrum Expression.

Literature [176] points out that under energy stress conditions, eIF4E mediates systematic translational spectrum rearrangement by differentially binding to cap-proximal sequences.

Therefore, it can be inferred that against the backdrop of persistent mTOR activation signals inhibiting AMPK, cellular ATP will remain continuously insufficient. However, with PTEN being oxidized, mTOR will be prematurely re-activated. That is, before intracellular ATP energy has recovered, mTOR will already promote cellular biosynthetic metabolism again. Due to ATP insufficiency, the duration of this biosynthetic metabolism will not increase significantly. However, each mTOR expression cycle will de novo promote the expression of related genes. In each cycle, eIF4E must dissociate from 4E-BP1 again, but the phosphorylation-dephosphorylation cycle shortens its half-life. Simultaneously, due to different binding sites and affinities, the expression of genes like the transcription factor PAX8 will decrease due to its own structure, while ribosomal proteins like RPS6 may increase in expression due to simpler structures. This represents a change in the downstream gene spectrum expression.

In the context of persistent mTOR mismatched activation caused by PTEN oxidation, this translational rearrangement shifts from a short-term adaptive mechanism to a long-term aging driver.

In this rearrangement, SASP factors, chemokines, acute inflammatory factors, pro-apoptotic factors, DNA damage monitoring genes, hypoxia genes, and amino acid starvation signal molecules will prevail. Meanwhile, tissue-specific transcription factors, cell junctions, hormone receptors, anti-apoptotic factors, growth factors, and oncogenes will decline. Among these, the decrease in anti-apoptotic-related genes and the increase in pro-apoptotic genes do not mean an improvement in the harms of the fourth cause.

When mTOR is persistently expressed in normal cells, the result is the decreased expression of anti-apoptotic genes, increased expression of the DNA damage monitoring gene P53, and increased expression of pro-apoptotic genes. This makes normal cells more prone to entering senescence, while senescent cells are conversely less likely to undergo apoptosis.

5.6 Damage to Telomeres from Elevated P53 Expression Levels and the Vicious Cycle.

Literature [267] points out two points in its theory: First, SIRTs bind to telomeres and rDNA, maintaining the stability of telomeric and rDNA regions. P53 inhibits the expression of the seven SIRT proteins, thereby causing instability in telomeres and nucleolar rDNA. Second, as the telomeric DNA array and/or rDNA array (the clock) shorten, P53 (the primary command) produces a 'concentration gradient' along the time axis... driving programmed expression of gene clusters on chromosomes.

Combining this paper with the preceding text, it can be inferred that when the fourth cause is triggered, human cells, due to frequent and persistent mTOR signals, will have inhibited AMPK activation. DNA repair efficiency decreases, forming genomic instability, and P53 levels increase. Elevated P53 inhibits the expression of the seven SIRT proteins, leading to instability in telomeres and nucleolar rDNA. As the telomeric DNA array and/or rDNA array (clock) shortens, P53 levels further increase. From this point, a vicious cycle forms, possessing self-maintaining and self-reinforcing effects.

5.7 The Field Damage Theory of rDNA Shortening and Recovery Mechanisms.

Literature [269] points out that rRNA constitutes the structural and functional core of ribosomes. ROS can affect RNA in multiple ways [34,35,36,37], including chemical modification of bases and sugar groups, generation of non-basic sites, and strand breaks. Guanine is the most easily oxidized nucleobase and is most fully studied in this regard. One oxidized form of guanine, 8-hydroxyguanine (8-oxoguanine; 8-oxoG), is a ubiquitous oxidative lesion easily detected in cellular nucleic acids. When 8-oxoG is present in mRNA, it interferes with decoding, possibly by forming Hoogsteen pairs with adenine upon rotation around the N-glycosidic bond. Changes in the base-pairing capacity of 8-oxoG can also perturb RNA folding. A recent study revealed diverse outcomes when 8-oxoG was incorporated into model RNA substrates, ranging from stabilization of existing structural motifs to destabilization and rearrangement into new structures. Because ribosomal translation activity depends on many precisely tuned conformational changes and movements within its rRNA framework, oxidation of key bases that maintain correct rRNA structure could impair ribosomal function. Therefore, the need to tolerate some oxidation was likely a factor shaping ribosomal evolution. Many guanines are significantly depleted from mitochondrial rRNA, accompanied by a decrease in overall RNA content.

Literature [270] points out that the muscle regeneration process encompasses four interconnected phases: necrosis, inflammation, satellite cell activation and differentiation, maturation of newly formed myofibrils, and muscle remodeling. During the inflammatory phase, i.e., during muscle injury repair, reactive oxygen species (ROS) are produced in large quantities, mainly present in neutrophils and M2 macrophages. Furthermore, ROS-activated MAPK (mitogen-activated protein kinase), NFκB (nuclear factor kappa B), and AP-1 (activator protein 1) induce protective responses in injured muscle through ROS activation. Additionally, antioxidant enzymes such as superoxide dismutase 2, glutathione peroxidase, and catalase increase in the initial days following injury. Therefore, ROS activate important signaling pathways for muscle repair. However, impaired oxidative stress resolution may lead to secondary damage to uninjured fibers.

Literature [271] indicates that resistance exercise training (RET) can be effectively applied to increase muscle mass and function in older adults aged 65-75 years. However, there is speculation that adults over 85 years may respond less well to the benefits of RET. This study compared the effects of RET on muscle mass and function in healthy older adults aged 65-75 years versus those over 85 years. We treated 17 healthy older adults aged 65-75 years (65-75yr, n=13/4 [female/male]; 68±2 years; 26.9±2.3 kg/m²) and 12 healthy older adults over 85 years (85+ yr, n=7/5 [female/male]; 87±3 years; 26.0±3.6 kg/m²) with 12 weeks of whole-body RET (three times per week). Quadriceps and L3 lumbar muscle cross-sectional area (computed tomography), whole-body lean mass (dual-energy X-ray absorptiometry), strength (one-repetition maximum test), and physical performance (timed up-and-go and short physical performance battery) were assessed before and after 6 and 12 weeks of training. After 12 weeks of RET, quadriceps cross-sectional area increased by 10%±4% and 11%±5% (from 46.5±10.7 to 51.1±12.1 cm², and from 38.9±6.1 to 43.1±8.0 cm²; p<.001; η2 = 0.67); whole-body lean mass increased by 2%±3% and 2%±3% (p=.001; η2=.22); one-repetition maximum leg extension strength increased by 38%±20% and 46%±14% (p<0.001; η2 = 0.77) in the Old 65-75 and Old 85+ groups, respectively. RET responses did not differ between groups (time × group, all p>0.60; all η2 ≤ 0.012). Physical performance on the Short Physical Performance Battery and timed up-and-go both improved (all p < 0.01; η2 ≥ 0.22), with no differences between groups (time × group, p > 0.015; η2 ≤ 0.07). Prolonged RET increases muscle mass, strength, and physical performance in aging populations, with no significant difference between older adults aged 65-75 years and those aged 85+ years.

Literature [272] points out that this study demonstrates resistance training significantly increases muscle stem cell content... In older adults, satellite cell numbers significantly increased after 12 weeks of resistance training. Resistance training significantly increased satellite cell numbers in type II muscle fibers of older adults... This systematic review and meta-analysis showed that resistance training in older adults can significantly increase muscle stem cells.

Based on the four articles above, it can be inferred that the current scope of application for the replicative senescence theory has boundary issues. Replicative senescence is a classic wear-and-tear theory of aging. Within this theoretical framework, there is no concept of recovery, and unidirectional irreversible wear is its core definition of aging. But this is an erroneous inference that overgeneralizes the in vitro passage model to the in vivo context.

Oxidative stress can damage rDNA, leading to loss of rDNA array copies. If one follows the logic of replicative senescence, human exercise would generate free radicals, causing oxidative stress. This oxidative signal drives muscle growth, while these free radicals would simultaneously damage the rDNA array. However, this logical deduction is falsified by resistance training. The empirical evidence showing that individuals engaging in regular, long-term resistance training maintain more muscle mass cannot be explained by this logic. Because if one maintains long-term resistance training, ROS would damage the rDNA array, inhibiting the self-renewal of muscle satellite stem cells. During aging, due to severe loss of rDNA array copies from excessive exercise, muscle satellite stem cells would be unable to maintain their proper numbers, leading to muscle atrophy. But reality is the opposite, indicating that either oxidative stress cannot drive the loss of rDNA array copies, or human stem cells possess a recovery mechanism for the rDNA array.

Given that oxidative stress driving the loss of rDNA array copies has been confirmed, human stem cells must necessarily possess a recovery mechanism for the rDNA array. Otherwise, the beneficial effects of many forms of exercise, such as resistance training, on aging would not exist.

Literature [273] points out that unequal sister chromatid exchange (USCE) allows cells to restore rDNA copy number on one chromatid at the expense of its sister chromatid. This phenomenon occurs specifically in Drosophila male germline stem cells (GSCs)—cells that undergo asymmetric division to produce one self-renewing stem cell and one differentiating daughter cell. In this process, the chromatid that gains rDNA copy number restoration is preferentially retained in the stem cell lineage, while the copy-damaged one segregates into the differentiating daughter cell.

Literature [274] points out that in Saccharomyces cerevisiae, the maintenance of rDNA copy number (CN) depends on competitive occupancy between the Pol I-UAF complex and the Sir2-UAF complex. When CN is high, Pol I-UAF binds to the rDNA promoter, blocking further amplification of copy number by inhibiting transcription-replication coupling negative feedback. When CN decreases due to oxidative stress or recombination, the Sir2-UAF complex relieves the inhibition of the bidirectional E-pro promoter, necessarily initiating intra-array homologous recombination (intra-array HR), driving rDNA gene conversion and amplification to achieve copy number recovery. This "suppress when high, promote when low" bidirectional homeostatic switch enables the rDNA array to possess active counting and self-recovery capabilities, unlike the unidirectional depletion of telomeres.

Literature [275] points out that when rDNA undergoes a double-strand break (DSB), a specialized nucleolar DNA damage response (n-DDR) is activated. Upon activation, rDNA relocates from the nucleolar interior to the nucleolar periphery, forming "nucleolar caps." Within this subnuclear structure, homologous recombination (HR) repair is exclusively performed. During this process, the BLM (Bloom syndrome) helicase plays a crucial role by unwinding the DNA duplex to facilitate recombinational repair—BLM-deficient cells exhibit recombination rates in rDNA exceeding 10%, demonstrating that this enzyme is a core regulatory factor for maintaining genomic stability of the human rDNA array by ensuring its integrity through the HR pathway.

Based on the above literature, it can be inferred that rDNA recovery mechanisms exist in both humans and animals. Combined with the empirical effectiveness of resistance training and the phenomenon of oxidation damaging rDNA, a field theory of dynamic recovery inhibition for rDNA copy number can be proposed. "Field" refers to different interfering factors producing an effect on a single target. The preceding text has already mentioned that genomic instability can inhibit rDNA through P53, and oxidative stress directly damages rDNA, confirming that rDNA copy number loss is multi-source inhibition. Meanwhile, rDNA itself possesses repair mechanisms. The intersection of the two forms a dynamic phenomenon of recovery and loss.

However, this loss is not irreversible. Merely removing inhibitory factors or strengthening recovery factors holds the promise of restoring the normal level of stem cell rDNA arrays.

5.8 Aging Diversity and Central Axis Correlation.

As demonstrated earlier, changes in the antioxidant pattern occur during the fourth cause stage, and this reinforces the pathogenic nodes mentioned earlier, forming the phenomenon of diverse aging-related diseases.

This subsection will explain the central axis changes corresponding to many aging-related diseases under the framework of aging-related central axis changes. However, the scope of this subsection is limited to aging-related frameworks; non-aging-related frameworks may present incompatibility.

5.8.1 Type 2 Diabetes: Decline in Antioxidant Function and Local AMPK/mTOR Signal Imbalance.

In subsection 3.5, the principle behind the origin of insulin resistance was demonstrated: its core is cell membrane oxidation causing decreased membrane fluidity, restricting insulin receptors due to membrane fluidity and failing to complete normal activation and signal transduction. The fourth cause reinforces this process. Among those particularly affected in this stage are individuals with intrinsically weak PGC-1α signaling, weak AMPK signaling, strong mTOR signaling, and strong PPARα signaling. They will be the first to experience enhanced insulin resistance due to increased oxidative stress and decreased cell membrane fluidity. Blood glucose signals stimulate β-cells to increase mTOR to secrete insulin. During this process, if mTOR-driven oxidative stress further pushes the local β-cell NRF2-HO-1-free iron-hydroxyl radical-PTEN oxidation-mTOR promotion-AMPK inhibition pathway, it will reinforce the inhibition of AMPK and NRF1, forming a self-locking dilemma of local cellular metabolic vicious cycle.

Such a metabolic self-locking dilemma will damage β-cells through the ROS pathway, ultimately triggering β-cell dysfunction. Research on the correlation of glycine and cysteine with type 2 diabetes demonstrates that glycine and cysteine indeed have the effect of reversing type 2 diabetes, but do not possess the ability to reverse the local metabolic homeostasis imbalance. Their intervention targets the more fundamental downstream oxidative damage, rather than intervening at the more upstream erroneous metabolic homeostasis.

In literature [276], the improvement effect of glycine and cysteine on type 2 diabetes was empirically validated. When HFD-induced diabetic mice were administered NAC at an effective dose and duration, it significantly improved glucose tolerance and insulin sensitivity and successfully rescued β-cell overcompensation. NAC-treated HFD mice showed normalization of β-cell mass and size, significant improvement in β-cell identity, significant improvement in Pdx-1 nuclear localization, and reduced β-cell oxidative stress marked by 8-OHdG. Importantly, NAC reduced the activation of PaSCs within the islets and inhibited PaSC-induced collagen deposition, thereby preventing HFD-induced fibrosis. This study demonstrates that antioxidant treatment with NAC helps maintain healthy β-cells and a quiescent PaSC population within the islets of HFD-induced diabetic mice, and contributes to a better understanding of the effective dose and timing of antioxidant therapy for human obesity-related diabetes.

5.8.2 Nitric Oxide, Cardiovascular Disease, and Commonalities with Heart Disease.

Subsection 3.4.2 demonstrated the predicament of homocysteine metabolism into cysteine. Subsection 3.1 demonstrated the decline in AKG levels caused by reduced lipid metabolism.

5.8.2.1 Homocysteine-Induced Vascular Endothelial Damage – Atherosclerosis and Heart Disease

Homocysteine has the effect of damaging vascular endothelium [278]. However, if it could be normally metabolized into cysteine, it would not have this damaging effect. The core metabolic homeostasis error is that during the fourth cause stage, nitric oxide becomes oxidized and disabled, further decreasing erythrocyte deformability. The oxygen release function of erythrocytes in liver tissue further declines. Lipid metabolism is further affected by hypoxia, the proportion of lipid metabolism decreases, and AKG levels drop, triggering metabolic accumulation of homocysteine, which damages the cardiovascular system. Simultaneously, due to decreased oxygen release rate, the myocardium will experience occult hypoxia. This forms a situation where non-identical tissues exhibit interrelated pathologies. This metabolic imbalance type corresponds to individuals with weak AMPK signaling, strong mTOR signaling, and weak PGC-1α.

5.8.2.2 Non-Endothelial Damage Myocardial Hypoxic Heart Disease

Individuals with excessive PPARα have lower homocysteine accumulation at the cellular metabolic level and can avoid the metabolic accumulation of homocysteine. However, PPARα itself possesses metabolic pro-oxidative properties, which will exacerbate the oxidative damage of nitric oxide, leading to a decline in oxygen release rate and triggering an occult hypoxic metabolic state in the heart itself.

Literature [279] and [280] confirm the correlation between high-altitude hypoxia and the occurrence of heart disease. On the Qinghai-Tibet Plateau, the prevalence of high-altitude heart disease in immigrant Han children reaches 2.5%, and increases with altitude. Adult high-altitude heart disease is directly related to chronic high-altitude hypoxia, manifesting as significant pulmonary hypertension, right ventricular hypertrophy, and right heart failure. In areas above 3000 meters altitude, the prevalence of hypertension increases by 2% for every 100-meter increase in elevation.

Long-term exposure to high-altitude hypoxic environments induces pulmonary vascular remodeling, leading to pulmonary hypertension (PH), which in extreme cases progresses to right heart failure (RHF). High-altitude exposure exacerbates the risk of decompensation in heart failure patients, resulting in more cardiac events and re-hospitalizations.

5.8.3 Association between AMPK/mTOR Ratio Imbalance and Hypertension.

During sleep, blood flow distribution changes from peripheral to central circulation—this is classic textbook content. Based on this principle, nerve cells have high energy metabolism dependence. In a metabolic background where nitric oxide is oxidatively damaged, the imbalance state jointly formed by weak AMPK signaling and strong mTOR signaling manifests in the pineal gland, which secretes melatonin. Pineal gland melatonin synthesis requires tryptophan hydroxylase (TPH), a high-energy-consuming rate-limiting enzyme (requires NADPH and O₂). This will lead to decreased melatonin secretion, causing difficulty falling asleep, shortened sleep time window, and abnormal blood flow redistribution during sleep, among other negative factors. Due to the oxidation of nitric oxide, the oxygen release capacity of erythrocytes decreases within the same time window. Against the backdrop of a shortened time window, the recovery resources provided will sharply decrease. The internal organs will not receive effective recovery, thus pushing up blood pressure to compensate for occult visceral ischemia.

Literature [277] confirms the association between sleep deprivation and hypertension. During acute sleep deprivation, a significant enhancement of sympathetic nervous system activity can be observed, accompanied by activation of the hypothalamic-pituitary-adrenal (HPA) axis, leading to abnormally elevated cortisol levels. Furthermore, markers of oxidative stress (including NRF2, HO-1, and NQO1 pathways) are upregulated under sleep insufficiency, collectively contributing to increased peripheral vascular resistance and significant increases in both systolic and diastolic blood pressure.

5.8.4 Nitric Oxide and Degenerative Joint and Spine Disease

Subsection 4.5.5 demonstrated the dependence of articular cartilage regeneration on oxygen release rate. Subsection 5.8.2 demonstrated the metabolic homeostasis error of nitric oxide being oxidized and disabled during the fourth cause stage.

In the metabolic context of the fourth cause stage, where nitric oxide's oxidative damage increases and it becomes disabled, individuals with intrinsically weak PGC-1α signaling, weak AMPK signaling, strong mTOR signaling, and strong PPARα signaling will be the first to experience increased oxidative stress, further decreasing erythrocyte deformability. This leads to a further decline in oxygen release rate in joints and spine, forming occult hypoxia in these areas. This hypoxia will exacerbate the flow attenuation of the TCA cycle, reducing the supply of acetyl-CoA, weakening the H3K27ac modification of the COX-2 promoter, and causing PGE2 synthesis capacity to fall below the negative feedback regulation threshold. Consequently, the transcriptional inhibition of 15-PGDH by PGE2 significantly relaxes, leading to a decline in joint and spine repair efficiency. When repair efficiency falls below the daily wear-and-tear rate, it results in the occurrence of degenerative joint and spine diseases.

5.8.5 AMPK/mTOR Ratio Imbalance, Inflammatory Factors – Osteoporosis.

Subsection 2.3.1 demonstrated the mechanism by which weak AMPK signaling leads to reduced inhibition of NF-κB. Subsection 4.8.2 demonstrated the damage of GH deficiency synergizing with cortisol to the bone marrow immune system.

In the fourth cause stage, against the metabolic background of central axis constrictive collapse (weak AMPK signaling, strong mTOR signaling), AMPK's inhibition of NF-κB further weakens. Glucocorticoid levels rise due to increased chronic inflammation levels, jointly inducing adipogenic differentiation of bone marrow mesenchymal stem cells (MSCs). Individuals with weak AMPK signaling will be the first to experience weakened NF-κB inhibition, leading inflammatory factors to drive the transformation of MSCs into adipocytes, forming fatty infiltration of the bone marrow microenvironment by Bone Marrow Adipose Tissue (BMAT).

Inflammatory factors can also drive M1 polarization of macrophages via the NF-κB pathway, secreting matrix metalloproteinases (MMPs) that degrade collagen [259]. Simultaneously, due to weakened AMPK inhibition of NF-κB, RANKL (Receptor Activator of NF-κB Ligand) secretion abnormally increases, while Osteoprotegerin (OPG) expression is suppressed. The imbalance of the RANKL/OPG ratio triggers excessive osteoclast activation, ultimately leading to osteoporosis.

This metabolic imbalance type corresponds to individuals with weak AMPK signaling, strong mTOR signaling, and weak PGC-1α signaling.

5.8.6 Correlation of Fatty Liver and Hyperlipidemia with Metabolic Homeostasis.

Subsection 3.1 demonstrated the mechanism of lipid metabolism decline. PPARα is the master transcriptional regulator of hepatic fatty acid β-oxidation, maintaining the flux of fat metabolism. A decrease in its level vacates spare NADPH resources for PGC-1α to maintain antioxidant function, weakening the situation of nitric oxide being oxidatively disabled due to the fourth cause metabolic background. Therefore, an isolated decline in PPARα signaling is decoupled from the fourth cause. Its metabolic decline can independently complete the phenomena of fatty liver and hyperlipidemia. However, against the metabolic background of the fourth cause, if PGC-1α and PPARα decline simultaneously, the pathway of nitric oxide being oxidatively disabled and the subsequent decrease in oxygen release rate can inhibit the liver's efficiency in fat metabolism. Inhibited lipid metabolism triggers the collapse of PPARα's self-maintenance mechanism, forming a coupled decline in PPARα signaling, leading to fatty liver and hyperlipidemia.

5.8.7 Nitric Oxide – Microcirculatory Disturbance – Increased Cancer Incidence.

Literature [281] points out that through a retrospective cohort study (median follow-up 9 years) of 1042 patients with non-obstructive coronary artery disease (NOCAD), it was confirmed that coronary microvascular dysfunction (CMD, defined as coronary flow reserve ≤2.5) is significantly associated with cancer incidence: CMD patients had a cancer incidence rate of 15.5%, and their cancer-free survival rate was significantly lower than those without CMD (log-rank P = 0.005). Multivariate Cox regression analysis showed that after adjusting for age, sex, hypertension, diabetes, smoking, and renal function, CMD was an independent predictor of cancer (hazard ratio 1.40, 95% confidence interval 1.09–2.04, P = 0.04). This study only established a clinical correlation without elucidating the molecular mechanism. Literature [282] points out the mechanism: when local microcirculatory disturbance (nitric oxide disability leading to decreased erythrocyte deformability) triggers structural hypoxia, cells are forced to initiate glycolytic metabolism. The continuous siphoning effect of glycolysis on the Pentose Phosphate Pathway (PPP) substrate glucose-6-phosphate (G6P) leads to decreased NADPH levels. The decline in NADPH triggers a shift in hyaluronic acid (HA) molecular weight from high molecular weight (anti-inflammatory) to low molecular weight (pro-inflammatory) state, activating the TLR2/4-NF-κB signal and inducing the expression of inflammatory factors like IL-1β and TNF-α. Under continuous hypoxia and inflammatory pressure, cells acquire advantageous mutations in the unfolded protein response (UPR) through natural selection, ultimately heading towards hypoxic carcinogenesis.

Therefore, in the fourth cause stage, nitric oxide oxidative disability → decreased erythrocyte deformability → collapse of microcirculatory oxygen release rate → tissue occult hypoxia is the metabolic bridge connecting CMD and cancer. Hypoxia induces HIF-1α stabilization, driving the glycolysis-lactate-inflammation cascade, ultimately forming the pathological loop of "hypoxic carcinogenesis."

5.8.8 Sodium-Related Alzheimer's Disease Due to Decreased Energy Metabolism.

Subsection 2.7 demonstrated that sodium-potassium pump dysfunction reversely inhibits lymphatic drainage. The efflux of cerebrospinal fluid (CSF) is achieved through the glymphatic pathway. When intracranial neurons or glial cells fall into energy metabolism disorder due to central axis imbalance—such as weak AMPK signaling causing energy metabolism decline, or weak PGC-1 signaling causing oxidative stress-induced mitochondrial damage and mitochondrial regeneration dilemma—the sodium-potassium pump suffers from insufficient energy supply. This leads to a situation where sodium ions reversely inhibit the glymphatic pathway for CSF efflux.

The glymphatic pathway for CSF efflux is the core mechanism for clearing misfolded proteins from the brain. Its inhibition can induce the onset of Alzheimer's disease.

Literature [283] points out that in AD patients, [Na] and Na/K ratio are elevated in CSF and brain tissue.

Na/K ratio is often used as an indicator of cardiovascular disease risk, including hypertension. Therefore, we assessed Na and K levels in the prefrontal cortex, thalamus, and CSF of Alzheimer's disease patients (n=67) and controls (n=30). [Na] in the prefrontal cortex was similar in AD patients and controls, while [K] was lower in AD patients compared to those without hypertension (HTN) (Fig 1A, B). Despite no significant difference in [Na], the Na/K ratio in the prefrontal cortex was significantly higher in AD patients regardless of HTN status. In thalamic tissue, [Na] was significantly higher in the hypertensive AD group compared to hypertensive controls, and generally higher in normotensive AD group, though this difference was not statistically significant. [K] was similar across all groups, resulting in a significantly higher Na/K ratio in the hypertensive AD group compared to hypertensive controls. In CSF, compared to controls, [Na] was significantly higher and [K] significantly lower in AD patients, irrespective of HTN status; thus, the Na/K ratio was significantly higher in AD patients compared to controls.

In the frontal cortex and thalamus, as well as within the CSF, [Na] and Na/K ratio were consistently and positively correlated with Braak stage. Neither frontal cortex nor thalamic [K] correlated with Braak stage, whereas [K] in CSF was negatively correlated with Braak stage. [Na], [K], and Na/K ratio at different Braak stages (0–VI) are displayed via bar graphs, showing a gradual increase in Na and Na/K ratio as Braak stage progresses from 0 to VI. Taken together, [Na] and Na/K ratio in CSF and the examined brain tissues are positively correlated with the severity of AD as determined by Braak stage.

This research finding proves that indeed, a phenomenon of insufficient sodium-potassium pump energy supply occurs in the brains of Alzheimer's disease patients. Simultaneously, this paper further demonstrates the positive correlation between Alzheimer's disease patients and sodium, providing empirical support for subsection 5.8.8.

Against the background of the fourth cause comprehensively elevating the body's oxidative stress baseline, PTEN is oxidatively activated, leading to sustained and frequent initiation of mTOR signaling, and the activation window for AMPK is significantly compressed. In this metabolic pattern, individuals with the central axis subtype characterized by decreased AMPK signaling and decreased PGC-1α signaling in the brain will develop Alzheimer's disease.

Conclusion: Although subsection 5.8 has not exhaustively covered the full spectrum of aging-related diseases, using the above representative pathological models of cardiovascular, metabolic, skeletal, and neoplastic diseases as examples, it has fully demonstrated the dialectical explanatory power of the metabolic flux homeostasis theory for both aging diversity (differential manifestation across multiple organs) and convergence (collapse of the oxidative stress baseline in the fourth cause as the common convergence node). Based on different individuals, different organs, and the innate differences in genetic gene expression superimposed with acquired homeostatic shaping, different central axis homeostatic preferences (specific combinations of AMPK/mTOR/PGC-1α/PPARα imbalances) are formed. Under the same metabolic background of the fourth cause, they manifest pathogenic pathways that are phenotypically diverse yet mechanistically isomorphic, confirming that aging is a continuous phase transition of metabolic homeostasis hierarchical collapse, rather than a simple superposition of discrete diseases.

6 The Fifth Cause of Aging: Inflammatory Factors Hijack the Glucocorticoid Axis, Signal Desensitization Reduces Regulatory Effects, Amplifying Immunosuppressive Negative Effects.

The increase in senescent cells driven by the fourth cause promotes the elevation of chronic inflammation levels. The fifth cause will be a stage dominated by inflammatory factors. This stage will expand the severity of damage through the SLAM family-IP3 pathway, synchronously affecting stem cell self-renewal, antioxidant functions, hormone secretion, and other pathways to promote the aging process.

6.1 Collapse of Senescent Cell Clearance: Failure of the Glucocorticoid-Senescent Cell Apoptosis Axis

Literature [114] points out that ketone bodies can inhibit HDAC. Literature [115] indicates that inhibiting HDAC enhances the transcription of the glucocorticoid receptor (GR). Literature [116] points out that in thymocytes and lymphocytes, glucocorticoids strongly induce apoptosis via the mitochondrial pathway and the death receptor pathway. Literature [117] indicates that cortisol can adjust the competitive balance between pro-survival and pro-apoptotic factors.

Therefore, it can be inferred that cortisol can initiate a reverse regulatory effect on mTOR when mTOR inhibits apoptosis. However, literature [118] points out that the p65 (RelA) component of NF-κB and the glucocorticoid receptor (GR) mutually inhibit each other's ability to activate transcription.

This constitutes a decreased sensitivity of senescent cells to the negative regulatory hormone for mTOR, thereby causing both cortisol's inhibition of inflammatory factor secretion by senescent cells and its inhibition of mTOR activation to decrease. Simultaneously, literature [119] points out that a high inflammatory factor environment also upregulates key anti-apoptotic proteins like c-FLIP and Bcl-2 through the TNFR2-TRAF2-NF-κB axis and the parallel PI3K-Akt axis. Therefore, it can be inferred that the increase in senescent cells caused by the fourth cause simultaneously inhibits the glucocorticoid-mediated mitochondrial apoptotic pathway and the TNFR1-mediated death receptor apoptotic pathway through inflammatory factor mediation, preventing senescent cell apoptosis from multiple pathways and exacerbating the rate of increase in senescent cell accumulation.

6.2 The Inhibitory Effect of Elevated Glucocorticoid Levels on Immunity and Metabolism

Literature [238] points out that glucocorticoids have the effect of inducing apoptosis in immature thymocytes and eosinophils. Literature [239] points out the suppressive effect of glucocorticoids on various immune cells.

Combined with the hijacking and inhibition of GR caused by the drastic increase in inflammatory factor concentration due to senescent cell accumulation mentioned earlier in Section 6.1, it can be inferred that the body will further increase glucocorticoid concentration due to chronic inflammation, forming inhibition on immune cells and further promoting immune cell exhaustion.

6.3 Glucocorticoid Axis Hijacked by Inflammatory Factors, Sustained Activation of the SLAMF Family-IP3 Pathway by Inflammatory Factors, Triggering Calcium Oscillation Rhythm Collapse.

The SLAM family can be induced and upregulated in various cells by inflammatory factors via the NF-κB pathway. Literature [28] points out that inflammatory factors can increase SLAMF7 expression via the NF-κB pathway. Literature [29] indicates a mechanism of ectopic expression for SLAMF1. Literature [240] points out that the SLAMF family is expressed in multiple immune cells and responds to induction by inflammatory factors TNF-α/IL-1β through the NF-κB pathway. Literature [241] indicates that SLAMF3 is expressed in hepatocytes. Literature [13] points out that SLAMF1 is expressed in hematopoietic stem cells (HSCs), and that removing HSCs with high SLAMF1 can reverse the aging phenotype. Literature [30] points out that SLAMF1 recruits PLCγ via ITSM, and PLCγ requires its PH domain to bind PIP3 for membrane targeting to achieve calcium release. Literature [31] points out that calcium oscillations in mesenchymal stem cells (MSCs) control cell cycle progression, determining whether cells proceed to proliferation or differentiation. Literature [242] points out the relationship between calcium release and mitochondrial flashes. Literature [243], a review, provides a more systematic description of the phenomenon from IP3 to mitochondrial flashes. Literature [244] points out that mitochondrial flashes can reshape the epigenome. Literature [245] points out the relationship between epigenetic methylation and the release mechanism of endogenous retroviruses.

Therefore, it can be inferred that under the sustained backdrop of chronic inflammation, chronic inflammation induces increased expression of a single SLAMF family gene in multiple cells, achieving sustained calcium release signals through the IP3 pathway. This forms an erroneous calcium metabolic homeostasis, causing stem cells to be more inclined towards differentiation rather than self-renewal, leading to stem cell aging. Simultaneously, due to excessive calcium release, the efficiency of refilling the depleted calcium stores decreases, leading to a decrease in the frequency of mitochondrial flashes. Since mitochondrial flashes can reshape the epigenome, this pathway also leads to epigenetic aging of stem cells and conventional somatic cells.

The decline in epigenetic homeostasis triggers the release of endogenous retroviruses (ERVs) previously suppressed by the epigenome. This will lead to ERVs triggering inflammation, and inflammation will again upregulate the expression of the SLAMF family. This forms an erroneous cycle, possessing self-reinforcing and self-maintaining metabolic homeostasis.

Concurrently, the depolarization pathway and the SLAMF family pathway are convergent. Depolarization inputs calcium into the cytoplasm, and the SLAMF family-IP3 pathway similarly inputs calcium into the cytoplasm. The core of both is inputting calcium into the cytoplasm. To avoid calcium-induced cell death, cells pump calcium out via the sodium-calcium exchanger. Therefore, the depolarization aging pathway cannot form a negative regulatory effect on the erroneous calcium release.

7 The Sixth Cause of Aging: Senescent Cell Accumulation and Reverse Reinforcement of Damage Pathways.

Senescent cell accumulation is driven jointly by the preceding five causes. The iNKT immune cell clearance pathway fails due to declining NAD+ levels. NK and T cell clearance fails due to decreased ketone body proportion, increased lactate proportion, and upregulation of immune checkpoints. The sustained elevation of mTOR due to PTEN oxidation causes the self-apoptosis pathway of senescent cells to fail. Senescent cells themselves secrete inflammatory factors, which can, in turn, reinforce the previously collapsed homeostatic environment by inhibiting mitochondrial functionality and NAMPT-mediated NAD+ regeneration, and through the SLAMF family pathway. This forms a vicious cycle, making it the ultimate driver of aging.

Simultaneously, through the sustained release of inflammatory factors, senescent cells can be viewed as the most fundamental anchor of the aging metabolic homeostasis. As long as the number of senescent cells or their secreted SASP cannot be effectively reduced, the human body should not possess the possibility of reverse homeostatic restoration.

8.1 Gender Differences and Hormonal Associations.

Literature [261] points out that both estrogen receptors ERα and ERβ can promote growth hormone secretion. Literature [43] indicates the correlation between obese patients and decreased growth hormone. Literature [42] points out gender differences in fat distribution: male fat tends to accumulate in the abdomen, while female fat tends to accumulate in the legs and subcutaneously. Literature [44] indicates the correlation between fat and inflammatory factor secretion. Literature [45] points out the effect of adiponectin on skin function. Literature [47] points out the phenomenon of cortisol promoting lipolysis. Literature [48] points out that cytokines promote lipolysis in 3T3-L1 adipocytes by inducing NADPH oxidase 3 expression and superoxide production. Literature [46] points out that breast development requires ERα signaling. Literature [262] points out the phenomenon of fat converting into estrogen, and how estrogen exerts its biological functions by interacting with its receptors (ER). These receptors can be either nuclear or membrane-bound. The main nuclear forms are two: α and β, which differ in tissue expression and function. Although ERα has a stronger physiological role in females, ERβ activity is similar in males and females. Upon ligand binding, ER undergoes a conformational change, allowing heterodimer formation and interaction with the estrogen response element (ERE) in target gene promoters. Literature [263] points out the phenomenon of male pubertal gynecomastia, affecting up to 50% of adolescents of the appropriate age. Literature [264] indicates that ER receptors have been shown to directly interact with Peroxisome Proliferator-Activated Receptor gamma (PPARγ), the main driver of lipid storage and adipogenesis, thereby blocking its transcriptional activity. Literature [265] points out the effects of pulsatile versus continuous estradiol treatment on two key aspects of estradiol action: gene expression and cell proliferation. Cells were stimulated with estradiol in 1-hour pulses or continuously for 24 hours, with the concentration × time exposure being identical for both conditions. In MCF7 cells, the transcriptional activity of a transiently transfected responsive estrogen response element luciferase reporter construct by the estrogen receptor (ER) was significant (approximately 10-fold). Literature [266] points out that E2 induces short-term translation of ERβ mRNA (2 and 4 hours post-stimulation) followed by a late (24 hours post-stimulation) enhancement of transcription. Both processes require E2-induced sustained and palmitoylation-dependent p38/MAPK activation.

Based on the above literature, the following inference can be made: during human puberty, adolescents, due to abundant subcutaneous fat, have a higher local conversion efficiency of estrogen. This conversion efficiency can maintain a local high signal without globally stimulating the negative feedback of ERβ signaling. Estrogen maintains the adolescent's skin condition through ERα signaling. Pubertal gynecomastia can self-resolve and disappear, indicating that ERα signaling declines in the later stages of development. This pathway may be due to inflammatory factors driving lipolysis, leading to the loss of subcutaneous fat, resulting in a decline in the local conversion rate of androgens to estrogen.

Androgens induce fat to accumulate in the abdomen, again affecting the efficiency of subcutaneous fat in converting androgens to estrogen and secreting adiponectin. Abdominal fat accumulation further increases inflammatory factor levels, which in turn promotes glucocorticoid secretion. Glucocorticoids also have the function of promoting lipolysis and abdominal accumulation, collectively forming the erroneous metabolic state of stable abdominal obesity. Simultaneously, the estrogen secreted by abdominal obesity itself is non-pulsatile. This pathway, due to its duration, reinforces ERβ signaling, forming an inhibition of ERα signaling by ERβ signaling.

The decline in local estrogen conversion rate may be the first node where metabolic homeostasis collapse occurs earlier in males. This homeostatic collapse is the decline of beneficial subcutaneous estrogen conversion. Due to physiological structural differences between males and females, ERα signaling is easily disrupted by abnormalities in one's own fat homeostasis, forming an erroneous hormonal secretion state of decreased ERα signaling and increased ERβ signaling.

As abdominal fat continues to accumulate, it will suppress growth hormone. Compared to estrogen's effect in females of promoting growth hormone secretion, this pathway exhibits a clear difference in the timing of homeostatic collapse. The second cause in females, because estrogen promotes growth hormone secretion, is weaker in its malignancy compared to males of the same age. During the progression from the third cause to the fourth cause, estrogen maintains higher growth hormone levels than in males. Even in the early fourth cause, estrogen can still maintain the promotion of growth hormone. These factors collectively become key reasons for the difference in average lifespan between males and females.

9 Self-Locking Mechanism of Aging Pathways: Interlocking Cascade Amplification

The core of aging is the collapse of metabolic homeostasis, which will form an erroneous homeostatic maintenance. This is the core self-locking mechanism of this paper. Erroneous homeostatic maintenance—the self-locking mechanism—is the main factor behind the current irreversibility of aging. Single-pathway drug regulation cannot break through the homeostatic self-locking.

The first self-locking mechanism originates from the central axis imbalance. The central axis itself possesses self-maintenance mechanisms that can persistently maintain an erroneous homeostasis, biasing it towards the aging pathway it maintains. Through non-homeostatic damage convergent pathways like inflammatory factors, decreased erythrocyte oxygen release-induced hypoxia, and multi-causal oxidative stress, it dominates the maintenance of the erroneous metabolic state of mitochondrial functional decline. The decline in CoQ10 levels (second cause) further impairs mitochondrial functionality, leading to a situation where the central axis can be restored, but mitochondrial energy metabolism remains decreased. This means that restoring the metabolic homeostasis of the central axis cannot effectively reverse aging.

The second self-locking mechanism comes from the decline in T3-carnitine synthesis triggered by decreased growth hormone levels. This pathway fundamentally causes the metabolic error of glycolipid metabolic disorder. Even by restoring the central axis and supplementing CoQ10, normal energy metabolism cannot be restored. Glycolipid metabolic disorder is persistently maintained by the decline in carnitine levels.

The third self-locking mechanism is the inhibition of NRF1 expression formed by the increased frequency of NRF2 expression due to oxidative stress, excessively binding the ARE element. This pathway dictates that even if the central axis is restored, CoQ10 is supplemented, and drugs promote NRF1 expression, as long as the state of frequent NRF2 expression is maintained due to oxidative stress, NRF1 expression will decline, mitochondrial quantity will synchronously decrease, and the pituitary gland will still be limited by the problem of insufficient ATP within the same time window.

The fourth self-locking mechanism is the accumulation of senescent cells secreting SASP. The SLAMF family-driven decline in mitochondrial flashes affects epigenetic homeostasis and stem cell self-renewal. The disruption of epigenetic homeostasis triggers the expression of endogenous retroviruses, causing inflammation, which in turn promotes SLAMF family expression. Simultaneously, inflammation can also promote mitochondrial functional decline. This means that even if the central axis is restored, CoQ10 is supplemented, NRF1 expression is enhanced by drugs, and ketone body levels are increased through fasting to improve glycolipid metabolic disorder, as long as senescent cells are not cleared and the inflammation triggered by the first three causes does not cease, this pathway cannot be reversed or corrected.

The emergence of self-locking mechanisms describes the key nodes and obstacles in the process of aging reversal through changes in metabolic homeostasis, thereby enabling a clearer understanding of aging, decoding aging, and reversing aging.

Evolution Model of Dominant Aging Factors, i.e., the Aging Chronological Model.

Latent Phase (Adolescence): The "first cause" of aging has already been initiated. Its early manifestation may be the dysregulation of the "four axes," causing mitochondrial functional decline through one of the eighty non-homeostatic pathways, for example, triggering occult tissue hypoxia, thereby decreasing mitochondrial ATP output.

However, this stage is strongly compensated by extremely vigorous growth hormone secretion. The exceptionally high capacity for mitochondrial biogenesis and quality maintenance masks the decline in mitochondrial functionality, temporarily preventing the system from collapsing downstream. This represents the earliest form of aging: sub-health.

Young Adulthood (Approx. 18-25 years): The plateau period of growth hormone ends and it begins to decline. Glycolipid metabolic disorder triggered by sub-health starts to emerge. This stage is primarily driven by aging caused by central axis imbalance sub-health, i.e., the first cause, mitochondrial functional decline. This stage continues until around the age of 25, after which it transitions into aging driven by glycolipid metabolic disorder. The previous driver of sub-health aging, mitochondrial functional decline, becomes a background aging driver and is no longer the primary aging driver.

Prime Adulthood (Approx. 25-34 years): This stage is the primary phase where glycolipid metabolic network disorder drives aging. The key aging characteristics of this stage include the emergence of antioxidant function decline caused by decreased lipid metabolism network, an increase in the duration of oxidized VE state, and the first acceleration of senescent cell accumulation. Simultaneously, growth hormone undergoes a slow decline, but it has not yet become a primary aging driver. NRF1 expression levels decrease, and CoQ10 levels decline. This aging driver reaches its limit around age 34, subsequently falling into the next imbalance: aging driven by declining growth hormone levels.

Middle Age (Approx. 34-45 years): In this stage, the decline in growth hormone becomes the primary aging factor. The key transition node occurs when the growth hormone pulse fails to reach the functional threshold required for growth hormone receptor conformational change. The resulting decline in NRF1 expression becomes the main factor driving the self-maintenance of the growth hormone decline. NRF2 expression levels will begin to increase, but the antioxidant network has not yet collapsed. The main features are a natural decline in muscle mass. Inflammation levels have not significantly increased due to glucocorticoid inhibition, but the efficiency of immune cells in clearing senescent cells decreases due to glucocorticoid-mediated immunosuppression. Senescent cell accumulation accelerates again, forming a vicious cycle where senescent cells secrete inflammatory factors, and inflammatory factors drive glucocorticoid secretion.

Middle Age (Approx. 45-60 years): Sustained metabolic pressure causes NRF2's compensatory antioxidant mechanism to reach its limit. The collapse of the antioxidant network becomes apparent, with a typical marker being an increase in the proportion of oxidized Vitamin E, which reversely inhibits CoQ10 synthesis, further decreasing growth hormone levels. Simultaneously, the antioxidant network, like a snapped spring, forms a state where chronic oxidative stress inhibits the recovery of antioxidant function. By oxidizing PTEN and enhancing mTOR activity, the rate of senescent cell accumulation suddenly increases, differing from previous rates.

Against the backdrop of GH-IGF-1 axis decline, the rapidly increasing senescent cells and the soaring inflammatory factors due to their concentration jointly drive down mitochondrial ATP output. This decline will trigger a cliff-like drop in gonadal hormone secretion levels. This drop will cause a second decrease in energy metabolism, i.e., another decline in mitochondrial ATP output. These two steps of decline in baseline mitochondrial ATP output will cause the calcium pump's energy demands to go unmet. Mitochondrial flashes depend on the calcium pump to transport calcium ions into the endoplasmic reticulum. This dual decline in baseline mitochondrial ATP output will lead to decreased efficiency in refilling calcium stores. The SLAMF pathway will become a secondary factor in aging at this point. The mechanism by which stem cells compensate for diversity through quantity will, under the influence of the SLAMF-IP3 pathway, gradually move towards a collapse in numbers, causing a drastic decline in tissue repair capacity.

Old Age (Approx. 60-70 years): The inflammatory-glucocorticoid axis (fifth cause) is continuously hijacked by inflammatory factors. The stem cell pool continues to be exhausted as the SLAMF family pathway affects calcium homeostasis, preventing self-renewal. The system falls into a vicious cycle of "inflammatory factors-inflammatory factors." The rate of senescent cell accumulation continues to increase until the stage where senescent cells become the primary driver of aging, driving inflammation, which in turn drives more inflammation.

Senescence Phase (Approx. 70-105 years): Aging in this stage is primarily driven by senescent cells. Senescent cells are the main driver at this stage, capable of influencing the other five causes in reverse by secreting inflammatory factors, thus driving aging.

Terminal Phase (Approx. 105+ years): The aging process halts. At this age, the increase in mortality risk due to aging ceases. The core mechanism behind the cessation of this increasing mortality risk is that all positive maintenance pathways in the human body—including antioxidant, anti-inflammatory, and energy generation functions—have collapsed to an extreme point. The body can no longer collapse towards a further imbalanced homeostatic state, analogous to the true vacuum state in vacuum decay.

11 Discussion

This hypothesis, through my process of tracing back from initial observations of high mTOR causing senescent cell accumulation, step-by-step back to growth hormone, the necessity of peak ATP levels within the same time window for the extremely short secretion window of growth hormone, and then reaching the construction of the higher-level central axis theory, ultimately resulted in the current version of the theory.

11.1 The current mainstream understanding is that AMPK is good, but the theory states that excessive AMPK expression is bad. Why?

In ketogenic diet research, one study result showed that the ketogenic diet promotes senescent cell generation. If AMPK is good, why would ketone bodies, whose primary function is to promote AMPK, produce a contrary result? The answer mainly lies in the difference between the oxidized and reduced states of VE. If a cell maintains a high proportion of reduced VE, then BAX will be inhibited by reduced VE. The AMPK-P53 pathway driven by ketone bodies cannot effectively drive BAX expression, preventing the cell from effectively entering the apoptosis program and keeping it more focused within the repair window. However, if the proportion of oxidized VE increases, cell membrane fluidity decreases. Promoting the AMPK pathway then easily enables the P53-BAX pathway downstream to take effect, initiating the cell into the apoptosis program. But because oxidized VE leads to decreased cell membrane fluidity and a stiffer membrane, the pore formation driven by this apoptosis program cannot effectively kill the cell. This creates a state where promoting AMPK is paradoxically harmful and pro-aging.

11.2 Why should we first verify the hypoxic non-steady state?

The hypoxic non-steady state is easier to verify in reality. Metabolic homeostasis imbalance driving mitochondrial functional decline is the key convergence node of the theory. If it cannot be verified, the whole theory's driving factors would be left hanging. The difficulty in verifying the central axis lies in the multitude of non-steady states, but changes in their strength combinations ultimately converge downwards onto eight main factors following roughly convergent paths. Therefore, microcirculatory disturbance caused by structural ischemia and hypoxia has a universal tendency in reality. However, this verification cannot be done too late; it must be conducted on young people. This is because middle-aged and elderly individuals may, due to increased levels of angiogenic factors, have microcirculatory disturbance become a permanent steady state unrelated to central axis metabolic imbalance.

11.3 If intervention were to be undertaken, how should it be carried out according to the theoretical pathway?

Ferulic acid: This drug can directly bypass the microcirculatory disturbance caused by central axis imbalance and has a strong improving effect on the entire branch pathway of the metabolic switch, i.e., improving the stem cell aging pathway caused by sustained hypoxia. Oxygen inhalation promotes nitric oxide synthesis, promotes the NAD+/NADH cycle, promotes the FAD/FADH2 cycle, clears lactate to break the self-locking pathway formed by lactate.

Simultaneously, using NRF1 activators like PQQ to restore mitochondrial biogenesis, combined with spermidine to restore mitophagy, and Coenzyme Q10 to strengthen mitochondrial energy metabolism, enhances mitochondrial energy output, reduces the proportion of glycolytic metabolism in normal cells, suppresses blood lactate levels, and, together with ferulic acid, shuts down the impact of the metabolic switch's downstream pathways on aging. This restores the maximum efficiency of erythrocyte oxygen transport within the same time window.

Regarding anti-inflammatory pathways, ginseng extract can be used to take the glucocorticoid anti-inflammatory pathway. However, because this anti-inflammatory pathway is activated by ginseng extract, it does not affect the immune system. When inflammation levels decrease, glucocorticoid levels subside, the conversion ratio of T4 to T3 increases, and the ratio of conversion to rT3 decreases, facilitating the recovery of the T3 anti-inflammatory axis. Omega-3 fatty acids can functionally mimic the T3 anti-inflammatory mechanism. At this step, VE must be supplemented; otherwise, it can trigger an increase in cell membrane lipid peroxidation, as mentioned in related literature [284].

VD supplementation can mimic the anti-inflammatory mechanism of T3.

Growth hormone relies on signaling and energy metabolism within the same time window. Based on the intervention strategy of the preceding drugs, by this point, energy metabolism has been restored, inflammation levels have decreased, and increased NRF1 expression improves the body's antioxidant function. The metabolic background now supports the recovery of growth hormone pulsatility. At this time, high-intensity intermittent exercise should be used to increase daytime growth hormone secretion. At night, a combination of lysine and arginine promotes growth hormone secretion.

This pathway cannot use direct injection of growth hormone as a replacement means; it must center on restoring the body's normal biological rhythm. Exogenous growth hormone injection can disrupt the sensitivity of human growth hormone receptors.

Recovery of the antioxidant network and clearance of senescent cells:

Supplement glycine and cysteine, combined with VC shock to replace oxidized VC in the body, to complete the rebuilding of the antioxidant network. Simultaneously, the combination of cysteine and glycine can clear senescent cells. For NAD+ supplementation, niacin can be used. In the metabolic background where inflammation levels have decreased, NAMPT is no longer inhibited by inflammatory factors, negating the need for more expensive NR and NMN. Concurrently, the increase in NAD+ levels will promote the activation of iNKT immune cells, increasing their probability of clearing senescent cells.

Fasting: This is a mandatory component of the theory. The ketone bodies it generates can, together with ginseng extract, strengthen the sodium-potassium pump. AKG can promote epigenetic demethylation. The enhancement of fat metabolism promotes the TCA cycle, increasing acetyl-CoA output, achieving the reversal of epigenetic drift. Simultaneously, it can enhance autophagy, compensating for the missing T3 autophagy signal, relieving the stress response of lysosomes, and improving the aging pathway of stem cell lysosomes. By lowering insulin levels, it inhibits the stem cell aging pathway of arachidonic acid. Ketone bodies, by inhibiting P53 in senescent cells, can inhibit the expression of immune checkpoints on senescent cells, increasing the probability of their clearance by NK and T cells.

Adjusting central axis metabolic homeostasis imbalance is difficult. Restoring it through cold stimulation is one path, but the elderly cannot easily bear its risks. Fasting can reverse the problem of decreased fat metabolism proportion. Combined with ferulic acid, this effectively bypasses the difficulty of restoring the first cause.

11.4 Why are there relatively many drugs that functionally mimic the T3 anti-inflammatory pathway?

The abundance of T3-mimicking drugs is mainly due to VD being limited by its own metabolic flux. Although its anti-inflammatory pathway most closely matches T3's mechanism, its hormonal nature creates toxicity when its flux is increased. Therefore, to replicate T3's anti-inflammatory mechanism, one must approach it from the perspective of multi-pathway, weak modulation, avoiding single-pathway toxicity.

When the body's T3 levels recover and achieve a positive cycle homeostasis with growth hormone itself, most drugs that mimic the T3 anti-inflammatory mechanism and functionality can be withdrawn. This drug modulation pathway is not intended to have drugs completely simulate the body's rhythm—nor can drugs perfectly simulate the body's rhythm—but to provide support for the recovery of the body's rhythm, forming a reverse cascade restoration of metabolic homeostasis.

11.5 Senescent Cell Clearance Plan.

Through pretreatment to enhance the body's antioxidant performance, use glycine + cysteine to reverse the phenomenon of accelerated senescent cell accumulation realized through the PTEN-mTOR pathway. Simultaneously supplement VC + VE + algal oil to restore cell membrane fluidity, creating the necessary conditions suitable for apoptosis. This process requires 4-8 weeks. Finally, promote the AMPK pathway through fasting, combined with AMPK activators, to further elevate the level of the AMPK pathway. Then use protocatechuic acid to lower anti-apoptotic proteins, supplement NAD+ boosters to increase NAD+ levels, allowing senescent cells to absorb NAD+ and form a high NAD+ state. This induces senescent cells to metabolize ketone bodies for energy, and through the promotion of the AMPK-P53 pathway, re-initiates the apoptotic program in senescent cells.

This pathway holds the promise of completing senescent cell apoptosis by restarting their intrinsic apoptosis program.

11.6 Senescent Cell Clearance Plan via the Immune Pathway.

Immune clearance never stops during aging; it merely becomes less efficient. Therefore, enhancing immunity through drugs holds the potential to clear senescent cells. This pathway can be achieved by supplementing NAD+ boosters, B6, AMPK activators, VC, combined with fasting to obtain ketone bodies. Ketone bodies, through modification pathways that inhibit P53 and lower immune checkpoints, can achieve enhanced immune clearance of senescent cells.

11.7 Are the self-locking mechanisms in the theory all of them?

They are not all the self-locking mechanisms. They are only a few key self-locking mechanisms deduced rationally based on the current level of knowledge of the author. Potential self-locking mechanisms have not been written into it. For example, genomic instability - increased P53 - increased immune checkpoints, forming an effect where senescent cells have higher immune checkpoints during apoptosis resistance, creating an effect of resisting immune clearance. However, this pathway can be breached by iNKT cells, so it was not mentioned among the four major self-locking mechanisms. This implies that the human body may have more potential self-locking mechanisms, restricting the body from breaking through the aging homeostasis and restoring youthful homeostasis through multiple pathways.

11.8 Academic Statement on the Compatibility of this Theory with Genomics

This hypothesis is fully compatible with genomics: it posits that aging rate depends on the dynamic interaction between genetic set points and metabolic flux homeostasis. Specifically, the coding genes of the four central axis pathways (PPARα, AMPK, PGC-1α, mTOR) and their regulatory region polymorphisms innately determine the activation threshold and self-maintenance gain of each pathway in an individual, forming a unique "homeostatic preference." Genetic backgrounds such as G6PD activity and mitochondrial DNA haplogroups modulate NADPH regeneration efficiency and oxidative stress tolerance thresholds. Extreme monogenic genetic diseases (such as Werner syndrome) are not counter-examples beyond the theory's scope but represent "fast-track passage"—where dysfunction of DNA repair genes causes the six-factor cascade to complete in a few years the phase transitions that normally take decades in aging. This is merely a phenomenon of mechanism isomorphism with compressed timing. Therefore, from physiological aging to pathological premature aging constitutes a continuous phase transition spectrum, to which this theory applies for the full spectrum of explanations.

11.9 Clarification on the Theory's Applicability Limited to Humans, and the Need for Targeted Metabolic Flux Modifications for Rodent Studies

When conducting rodent studies, targeted modifications for rodent-specific metabolic flux are needed. For example, humans cannot self-synthesize VC, but rodents can. Inhibiting growth hormone in rodents can extend lifespan. However, inhibiting growth hormone in humans leads to premature aging phenomena, such as the skin premature aging observed in Laron syndrome patients. This is because IGF-1 signaling is responsible for promoting collagen production by fibroblasts. Related literature [285] empirically demonstrates the skin premature aging phenomenon in Laron syndrome patients. Due to insufficient muscle development, milestones for walking and other gross motor skills are delayed. Hands and feet are small (acromicria). Hip dysplasia, especially avascular necrosis of the femoral head, is reported in up to 25% of patients. The skin is thin and finely textured, with premature aging wrinkles.

It is speculated that this is because rodents need to meet the demands of excessively rapid development, leading to excessively high growth hormone levels. When development reaches a threshold, it will directly drive phenomena akin to the fourth cause in humans. Growth hormone drives up mTOR levels, inhibiting AMPK, initiating an aging phenomenon starting from the fourth cause. Simply put, if we reorganize its aging metabolic flux, the process should be: a phenomenon akin to the fourth cause is initiated by growth hormone, the rate of senescent cell accumulation increases, inflammatory factors form self-perpetuating cycles affecting cellular calcium homeostasis, calcium homeostasis triggers epigenetic disorder, epigenetic disorder inhibits NRF1 and VC synthesis, leading to antioxidant network collapse. The entire initiation process can be said to be largely opposite to that in humans. However, this initiation process can explain why different species have different aging efficiencies.

If humans have multi-level networks that complement each other and exhibit homeostatic self-locking, rodents have a single aging pathway without an effective braking mechanism, plunging straight towards death. This also explains why many anti-aging therapies show good results in mice but exhibit reduced efficacy when translated to humans—because the metabolic backgrounds of aging they face are completely different.

11.10 Clarification on the Non-Applicability of Synchronous Flowering in Moso Bamboo Clones to Humans

Literature [286] points out that cloned moso bamboo asexual lines flower and die synchronously across geographies (60-120 year cycles). However, the scope of this theory cannot be fully replicated in humans. Literature [287] empirically demonstrates that the degree of difference in DNA methylation within monozygotic twin pairs is equivalent to the degree of difference between randomly paired unrelated individuals, indicating that even with identical genetic backgrounds, individual epigenetic clocks will move towards asynchrony.

Therefore, it can be demonstrated that the physiological mechanism of synchronous flowering and death across geographies as seen in moso bamboo asexual lines does not exist in humans.

Research Limitations and Future Outlook

The limitation of the current theory lies in the lack of decisive evidence to prove central axis imbalance. The hypoxic-ischemic model is a key phase for verifying aging homeostatic imbalance. However, because microcirculatory disturbance, according to the theory, becomes fixed with age, the subjects for inflammation measurement must be under 18 or just turned 18 years old to ensure measurement accuracy.

Measurement pathway: The benchmark is to measure whether erythrocyte deformability in the blood has decreased. If decreased erythrocyte deformability is observed, then central axis imbalance is an early factor in aging, and the central axis theory is confirmed. Otherwise, if no decrease in erythrocyte deformability is observed, central axis imbalance is not an early factor, i.e., the central axis theory is falsified.

Secondly, measure whether adolescents with microcirculatory disturbance exhibit increased senescent cells in the areas of microcirculatory disturbance and whether the level of inflammatory factors released due to their own hypoxia can, in the 18-25 age range, at the end of the growth hormone compensation stage, trigger mitochondrial functional decline through inflammatory factor levels. If mitochondrial functional decline occurs, it is confirmed; otherwise, the theory that mitochondrial functional decline is the key convergence node for multiple aging factors is falsified.

Simultaneously, this theory inevitably incorporates numerous mouse-related gene studies, which will lead to instability in the foundations of the current theory. This is an unavoidable predicament due to the limitations of current research.

References

[1] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6;153(6):1194-217. doi: 10.1016/j.cell.2013.05.039. PMID: 23746838; PMCID: PMC3836174.

[2] Zong, Y., Li, H., Liao, P. et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 124 (2024). https://doi.org/10.1038/s41392-024-01839-8

[3] Wenz T. Mitochondria and PGC-1α in Aging and Age-Associated Diseases. J Aging Res. 2011;2011:810619. doi: 10.4061/2011/810619. Epub 2011 May 5. PMID: 21629705; PMCID: PMC3100651.

[4] Gureev AP, Shaforostova EA and Popov VN (2019) Regulation of Mitochondrial Biogenesis as a Way for Active Longevity: Interaction Between the Nrf2 and PGC-1α Signaling Pathways. Front. Genet. 10:435. doi: 10.3389/fgene.2019.00435

[5] Chung KW, Lee EK, Lee MK, Oh GT, Yu BP, Chung HY. Impairment of PPARα and the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging. J Am Soc Nephrol. 2018 Apr;29(4):1223-1237. doi: 10.1681/ASN.2017070802. Epub 2018 Feb 12. PMID: 29440279; PMCID: PMC5875952.

[6] Wang, Y., Deng, P., Liu, Y. et al. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nat Commun 11, 5596 (2020). https://doi.org/10.1038/s41467-020-19360-1

[7] Tian Q, Liu X, Du M. Alpha-ketoglutarate for adipose tissue rejuvenation. Aging (Albany NY). 2020 Jul 29;12(14):13845-13846. doi: 10.18632/aging.103853. Epub 2020 Jul 29. PMID: 32756003; PMCID: PMC7425480.

[8] Chini CCS, Peclat TR, Warner GM, Kashyap S, Espindola-Netto JM, de Oliveira GC, Gomez LS, Hogan KA, Tarragó MG, Puranik AS, Agorrody G, Thompson KL, Dang K, Clarke S, Childs BG, Kanamori KS, Witte MA, Vidal P, Kirkland AL, De Cecco M, Chellappa K, McReynolds MR, Jankowski C, Tchkonia T, Kirkland JL, Sedivy JM, van Deursen JM, Baker DJ, van Schooten W, Rabinowitz JD, Baur JA, Chini EN. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat Metab. 2020 Nov;2(11):1284-1304. doi: 10.1038/s42255-020-00298-z. Epub 2020 Nov 16. PMID: 33199925; PMCID: PMC8752031.

[9] Liu K, Li F, Sun Q, Lin N, Han H, You K, Tian F, Mao Z, Li T, Tong T, Geng M, Zhao Y, Gu W, Zhao W. p53 β-hydroxybutyrylation attenuates p53 activity. Cell Death Dis. 2019 Mar 11;10(3):243. doi: 10.1038/s41419-019-1463-y. PMID: 30858356; PMCID: PMC6411878.

[10] Gulen, M.F., Samson, N., Keller, A. et al. cGAS–STING drives ageing-related inflammation and neurodegeneration. Nature 620, 374–380 (2023). https://doi.org/10.1038/s41586-023-06373-1

[11] Jiménez-Loygorri, J.I., Villarejo-Zori, B., Viedma-Poyatos, Á. et al. Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging. Nat Commun 15, 830 (2024). https://doi.org/10.1038/s41467-024-45044-1

[12] Beerman I, Bhattacharya D, Zandi S, Sigvardsson M, Weissman IL, Bryder D, Rossi DJ. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5465-70. doi: 10.1073/pnas.1000834107. Epub 2010 Mar 18. PMID: 20304793; PMCID: PMC2851806.

[13] Wang, Y., Zhang, W., Zhang, C. et al. Reducing functionally defective old HSCs alleviates aging-related phenotypes in old recipient mice. Cell Res 35, 45–58 (2025). https://doi.org/10.1038/s41422-024-01057-5

[14] Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008 Apr 25;30(2):214-26. doi: 10.1016/j.molcel.2008.03.003. PMID: 18439900; PMCID: PMC2674027.

[15] Ling NXY, Kaczmarek A, Hoque A, Davie E, Ngoei KRW, Morrison KR, Smiles WJ, Forte GM, Wang T, Lie S, Dite TA, Langendorf CG, Scott JW, Oakhill JS, Petersen J. mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress. Nat Metab. 2020 Jan;2(1):41-49. doi: 10.1038/s42255-019-0157-1. Epub 2020 Jan 20. PMID: 31993556; PMCID: PMC6986917.

[16] Williams A, Bissinger R, Shamaa H, Patel S, Bourne L, Artunc F, Qadri SM. Pathophysiology of Red Blood Cell Dysfunction in Diabetes and Its Complications. Pathophysiology. 2023 Aug 2;30(3):327-345. doi: 10.3390/pathophysiology30030026. PMID: 37606388; PMCID: PMC10443300.

[17] Ebenuwa I, Violet PC, Tu H, Lee C, Munyan N, Wang Y, Niyyati M, Patra K, Wilkins KJ, Parrow N, Levine M. Altered RBC deformability in diabetes: clinical characteristics and RBC pathophysiology. Cardiovasc Diabetol. 2024 Oct 18;23(1):370. doi: 10.1186/s12933-024-02453-2. PMID: 39425096; PMCID: PMC11490132.

[18] Gnaiger E, Méndez G, Hand SC. High phosphorylation efficiency and depression of uncoupled respiration in mitochondria under hypoxia. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11080-5. doi: 10.1073/pnas.97.20.11080. PMID: 11005877; PMCID: PMC27151.

[19] Hartley MJ, Gounder P, Oliphant H. Spontaneous periocular ecchymosis: a major review. Orbit. 2023 Apr;42(2):124-129. doi: 10.1080/01676830.2022.2142944. Epub 2022 Nov 14. PMID: 36374198.

[20] Fedosov DA, Caswell B, Karniadakis GE. A multiscale red blood cell model with accurate mechanics, rheology, and dynamics. Biophys J. 2010 May 19;98(10):2215-25. doi: 10.1016/j.bpj.2010.02.002. PMID: 20483330; PMCID: PMC2872218.

[21] Musielak M. Red blood cell-deformability measurement: review of techniques. Clin Hemorheol Microcirc. 2009;42(1):47-64. doi: 10.3233/CH-2009-1187. PMID: 19363240.

[22] Sánchez-Castillo, A.; Vooijs, M.; Kampen, K.R. Linking Serine/Glycine Metabolism to Radiotherapy Resistance. Cancers 2021, 13, 1191. https://doi.org/10.3390/cancers13061191

[23] Berry DC, O'Byrne SM, Vreeland AC, Blaner WS, Noy N. Cross talk between signaling and vitamin A transport by the retinol-binding protein receptor STRA6. Mol Cell Biol. 2012 Aug;32(15):3164-75. doi: 10.1128/MCB.00505-12. Epub 2012 Jun 4. PMID: 22665496; PMCID: PMC3434520.

[24] Berry DC, Levi L, Noy N. Holo-retinol-binding protein and its receptor STRA6 drive oncogenic transformation. Cancer Res. 2014 Nov 1;74(21):6341-51. doi: 10.1158/0008-5472.CAN-14-1052. Epub 2014 Sep 18. PMID: 25237067; PMCID: PMC4216741.

[25] Berry DC, Jin H, Majumdar A, Noy N. Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4340-5. doi: 10.1073/pnas.1011115108. Epub 2011 Feb 23. PMID: 21368206; PMCID: PMC3060239.

[26] Weiman He, Zhen Cheng, Zijun Huo, Bo Lin, Xuejie Wang, Yijia Sun, Shuang Yu, Siting Cao, Junyu Xue, Rengyun Liu, Weiming Lv, Yanbing Li, Shubin Hong, Haipeng Xiao, STRA6 Promotes Thyroid Carcinoma Progression via Activation of the ILK/AKT/mTOR Axis in Cells and Female Nude Mice, Endocrinology, Volume 164, Issue 3, March 2023, bqac215, https://doi.org/10.1210/endocr/bqac215

[27] Noy N. Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr. 2010 Aug 21;30:201-17. doi: 10.1146/annurev.nutr.28.061807.155509. PMID: 20415582.

[28] Choe, U., Pham, Q., Kim, Y.S. et al. Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages. Sci Rep 13, 11007 (2023). https://doi.org/10.1038/s41598-023-37040-0

[29] Farhangnia P, Ghomi SM, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi AA. SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. 2023 May 11;14:1174138. doi: 10.3389/fimmu.2023.1174138. PMID: 37251372; PMCID: PMC10213746.

[30] Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998 Jan 15;17(2):414-22. doi: 10.1093/emboj/17.2.414. PMID: 9430633; PMCID: PMC1170392.

[31] Vallet LA, Sánchez-Petidier M, Fernandes R, Naumova N, Merla C, Consales C, Innamorati G, André FM, Mir LM. Calcium oscillations in mesenchymal stem cells, a control on cell cycle progression to influence cell fate towards proliferation or differentiation? Stem Cell Res Ther. 2025 Aug 21;16(1):446. doi: 10.1186/s13287-025-04454-8. PMID: 40841986; PMCID: PMC12369127.

[32] Webb TJ, Carey GB, East JE, Sun W, Bollino DR, Kimball AS, Brutkiewicz RR. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses. Pathog Dis. 2016 Aug;74(6):ftw055. doi: 10.1093/femspd/ftw055. Epub 2016 Jun 12. PMID: 27297969; PMCID: PMC5985505.

[33] Anisimova AS, Alexandrov AI, Makarova NE, Gladyshev VNDmitriev SE, . Protein synthesis and quality control in aging. Aging (Albany NY). 2018 Dec 18; 10:4269-4288 . https://doi.org/10.18632/aging.101721

[34] Then AA, Goenawan H, Lesmana R, Christoper A, Sylviana N, Gunadi JW. Exploring the potential regulation of DUOX in thyroid hormoneautophagy signaling via IGF1 in the skeletal muscle (Review). Biomed Rep. 2024 Dec 24;22(3):39. doi: 10.3892/br.2024.1917. PMID: 39781041; PMCID: PMC11704872.

[35] Yau WW, Singh BK, Lesmana R, Zhou J, Sinha RA, Wong KA, Wu Y, Bay BH, Sugii S, Sun L, Yen PM. Thyroid hormone (T) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy. Autophagy. 2019 Jan;15(1):131-150. doi: 10.1080/15548627.2018.1511263. Epub 2018 Sep 13. PMID: 30209975; PMCID: PMC6287687.3

[36] Audesse AJ, Dhakal S, Hassell LA, Gardell Z, Nemtsova Y, Webb AE. FOXO3 directly regulates an autophagy network to functionally regulate proteostasis in adult neural stem cells. PLoS Genet. 2019 Apr 11;15(4):e1008097. doi: 10.1371/journal.pgen.1008097. PMID: 30973875; PMCID: PMC6478346.

[37] Ronny Lesmana, Rohit A. Sinha, Brijesh K. Singh, Jin Zhou, Kenji Ohba, Yajun Wu, Winifred WY. Yau, Boon-Huat Bay, Paul M. Yen, Thyroid Hormone Stimulation of Autophagy Is Essential for Mitochondrial Biogenesis and Activity in Skeletal Muscle, Endocrinology, Volume 157, Issue 1, 1 January 2016, Pages 23–38, https://doi.org/10.1210/en.2015-1632

[38] Kim JH, Choi TG, Park S, Yun HR, Nguyen NNY, Jo YH, Jang M, Kim J, Kim J, Kang I, Ha J, Murphy MP, Tang DG, Kim SS. Mitochondrial ROS-derived PTEN oxidation activates PI3K pathway for mTOR-induced myogenic autophagy. Cell Death Differ.2018Nov;25(11):1921-1937.doi: 10.1038/s41418-018-0165-9. Epub 2018 Jul 24. PMID: 30042494; PMCID: PMC6219511.

[39] Jung, S.H., Hwang, H.J., Kang, D. et al. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene 38, 1639–1650 (2019). https://doi.org/10.1038/s41388-018-0521-8

[40] Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, Andrews DW. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018 Sep;19(9):e45235. doi: 10.15252/embr.201745235. Epub 2018 Jul 9. PMID: 29987135; PMCID: PMC6123645.

[41] Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity. Front Immunol. 2020 Nov 30;11:597959. doi: 10.3389/fimmu.2020.597959. PMID: 33329591; PMCID: PMC7734206.

[42] Shi H, Clegg DJ. Sex differences in the regulation of body weight. Physiol Behav. 2009 May 25;97(2):199-204. doi: 10.1016/j.physbeh.2009.02.017. Epub 2009 Feb 27. PMID: 19250944; PMCID: PMC4507503.

[43] Ozata M, Dieguez C, Casanueva FF. The inhibition of growth hormone secretion presented in obesity is not mediated by the high leptin levels: a study in human leptin deficiency patients. J Clin Endocrinol Metab. 2003 Jan;88(1):312-6. doi: 10.1210/jc.2002-020122. PMID: 12519870.

[44] Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020. Epub 2020 Dec 23. PMID: 33356944; PMCID: PMC8294624.

[45] Oh J, Lee Y, Oh SW, Li T, Shin J, Park SH, Lee J. The Role of Adiponectin in the Skin. Biomol Ther (Seoul). 2022 May 1;30(3):221-231. doi: 10.4062/biomolther.2021.089. PMID: 34615771; PMCID: PMC9047493.

[46] Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2196-201. doi: 10.1073/pnas.0510974103. Epub 2006 Feb 1. PMID: 16452162; PMCID: PMC1413744.

[47] Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE, Møller N. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E172-7. doi: 10.1152/ajpendo.00544.2001. PMID: 12067858.

[48] Issa N, Lachance G, Bellmann K, Laplante M, Stadler K, Marette A. Cytokines promote lipolysis in 3T3-L1 adipocytes through induction of NADPH oxidase 3 expression and superoxide production. J Lipid Res. 2018 Dec;59(12):2321-2328. doi: 10.1194/jlr.M086504. Epub 2018 Oct 12. PMID: 30317185; PMCID: PMC6277153.

[49] Alotiby A. Immunology of Stress: A Review Article. J Clin Med. 2024 Oct 25;13(21):6394. doi: 10.3390/jcm13216394. PMID: 39518533; PMCID: PMC11546738.

[50] Li, X., Li, C., Zhang, W. et al. Inflammation and aging: signaling pathways and intervention therapies. Sig Transduct Target Ther 8, 239 (2023). https://doi.org/10.1038/s41392-023-01502-8

[51] Ren LL, Miao H, Wang YN, Liu F, Li P, Zhao YY. TGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis. Aging Dis. 2023 Oct 1;14(5):1633-1650. doi: 10.14336/AD.2023.0222. PMID: 37196129; PMCID: PMC10529747.

[52] Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32:51-82. doi: 10.1146/annurev-immunol-032713-120257. Epub 2013 Dec 2. PMID: 24313777; PMCID: PMC4010192.

[53] Huang P, Chen G, Jin W, Mao K, Wan H, He Y. Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. Int J Mol Sci. 2022 Jun 30;23(13):7292. doi: 10.3390/ijms23137292. PMID: 35806303; PMCID: PMC9266317.

[54] Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, Schoonjans K, Schreiber V, Sauve AA, Menissier-de Murcia J, Auwerx J. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011 Apr 6;13(4):461-468. doi: 10.1016/j.cmet.2011.03.004. PMID: 21459330; PMCID: PMC3086520.

[55] Li R, Ding C, Zhang J, Xie M, Park D, Ding Y, Chen G, Zhang G, Gilbert-Ross M, Zhou W, Marcus AI, Sun SY, Chen ZG, Sica GL, Ramalingam SS, Magis AT, Fu H, Khuri FR, Curran WJ, Owonikoko TK, Shin DM, Zhou J, Deng X. Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Res. 2017 Jun 1;77(11):3001-3012. doi: 10.1158/0008-5472.CAN-16-2356. Epub 2017 Apr 5. PMID: 28381544; PMCID: PMC5503158.

[56] Bae HR, Kim DH, Park MH, Lee B, Kim MJ, Lee EK, Chung KW, Kim SM, Im DS, Chung HY. β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget. 2016 Oct 11;7(41):66444-66454. doi: 10.18632/oncotarget.12119. PMID: 27661104; PMCID: PMC5341812.

[57] Liu, K., Li, F., Sun, Q. et al. p53 β-hydroxybutyrylation attenuates p53 activity. Cell Death Dis 10, 243 (2019). https://doi.org/10.1038/s41419-019-1463-y

[58] Newman JC, Verdin E. β-Hydroxybutyrate: A Signaling Metabolite. Annu Rev Nutr. 2017 Aug 21;37:51-76. doi: 10.1146/annurev-nutr-071816-064916. PMID: 28826372; PMCID: PMC6640868.

[59] Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000 Mar;20(5):1868-76. doi: 10.1128/MCB.20.5.1868-1876.2000. PMID: 10669761; PMCID: PMC85369.

[60] Sozio MS, Lu C, Zeng Y, Liangpunsakul S, Crabb DW. Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4):G739-47. doi: 10.1152/ajpgi.00432.2010. Epub 2011 Jun 23. PMID: 21700905; PMCID: PMC3191559.

[61] Abu Shelbayeh O, Arroum T, Morris S, Busch KB. PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response. Antioxidants (Basel). 2023 May 10;12(5):1075. doi: 10.3390/antiox12051075. PMID: 37237941; PMCID: PMC10215733.

[62] Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem. 2008 Nov 28;283(48):33554-62. doi: 10.1074/jbc.M804597200. Epub 2008 Sep 30. PMID: 18826952; PMCID: PMC2662273.

[63] Wufuer, R.; Fan, Z.; Liu, K.; Zhang, Y. Differential Yet Integral Contributions of Nrf1 and Nrf2 in the Human HepG2 Cells on Antioxidant Cytoprotective Response against Tert-Butylhydroquinone as a Pro-Oxidative Stressor. Antioxidants 2021, 10, 1610. https://doi.org/10.3390/antiox10101610

[64] Manful, C.F.; Fordjour, E.; Ikumoinein, E.; Abbey, L.; Thomas, R. Therapeutic Strategies Targeting Oxidative Stress and Inflammation: A Narrative Review. BioChem 2025, 5, 35. https://doi.org/10.3390/biochem5040035

[65] Dodson M, Anandhan A, Zhang DD and Madhavan L (2021) An NRF2 Perspective on Stem Cells and Ageing. Front. Aging 2:690686. doi: 10.3389/fragi.2021.690686

[66] Krishnamurthy HK, Pereira M, Rajavelu I, Jayaraman V, Krishna K, Wang T, Bei K and Rajasekaran JJ (2024) Oxidative stress: fundamentals and advances in quantification techniques. Front. Chem. 12:1470458. doi: 10.3389/fchem.2024.1470458

[67] Tumilaar, S., Hardianto, A., Dohi, H., & Kurnia, D. (2024). A Comprehensive Review of Free Radicals, Oxidative Stress, and Antioxidants: Overview, Clinical Applications, Global Perspectives, Future Directions, and Mechanisms of Antioxidant Activity of Flavonoid Compounds. Journal of Chemistry. https://doi.org/10.1155/2024/5594386.

[68] Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1066-1077. doi: 10.1016/j.bbadis.2016.11.010. Epub 2016 Nov 9. PMID: 27836629; PMCID: PMC5423868.

[69] La P, Oved JH, Ghiaccio V, Rivella S. Mitochondria Biogenesis Modulates Iron-Sulfur Cluster Synthesis to Increase Cellular Iron Uptake. DNA Cell Biol. 2020 May;39(5):756-765. doi: 10.1089/dna.2019.5123. Epub 2020 Apr 13. PMID: 32282232; PMCID: PMC7232706.

[70] Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr. 2011 Jan;48(1):26-32. doi: 10.3164/jcbn.11-005FR. Epub 2010 Dec 29. PMID: 21297908; PMCID: PMC3022059.

[71] Khor SC, Abdul Karim N, Ngah WZ, Yusof YA, Makpol S. Vitamin E in sarcopenia: current evidences on its role in prevention and treatment. Oxid Med Cell Longev. 2014;2014:914853. doi: 10.1155/2014/914853. Epub 2014 Jul 6. PMID: 25097722; PMCID: PMC4109111.

[72] Stocker A, Baumann U. Supernatant protein factor in complex with RRR-alpha-tocopherylquinone: a link between oxidized Vitamin E and cholesterol biosynthesis. J Mol Biol. 2003 Sep 26;332(4):759-65. doi: 10.1016/s0022-2836(03)00924-0. PMID: 12972248.

[73] Duan, Y., Gong, K., Xu, S. et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Sig Transduct Target Ther 7, 265 (2022). https://doi.org/10.1038/s41392-022-01125-5

[74] Stocker A. Molecular mechanisms of vitamin E transport. Ann N Y Acad Sci. 2004 Dec;1031:44-59. doi: 10.1196/annals.1331.005. PMID: 15753133.

[75] Tricarico PM, Crovella S, Celsi F. Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link. Int J Mol Sci. 2015 Jul 15;16(7):16067-84. doi: 10.3390/ijms160716067. PMID: 26184189; PMCID: PMC4519939.

[76] Aaseth J, Alexander J, Alehagen U. Coenzyme Q supplementation - In ageing and disease. Mech Ageing Dev. 2021 Jul;197:111521. doi: 10.1016/j.mad.2021.111521. Epub 2021 Jun 12. PMID: 34129891.10

[77] Budzinska, A.; Jarmuszkiewicz, W. The Cellular and Mitochondrial Consequences of Mevalonate Pathway Inhibition by Nitrogen-Containing Bisphosphonates: A Narrative Review. Pharmaceuticals 2025, 18, 1029. https://doi.org/10.3390/ph18071029

[78] Zhang Y, Park J, Han SJ, Yang SY, Yoon HJ, Park I, Woo HA, Lee SR. Redox regulation of tumor suppressor PTEN in cell signaling. Redox Biol. 2020 Jul;34:101553. doi: 10.1016/j.redox.2020.101553. Epub 2020 May 3. PMID: 32413744; PMCID: PMC7226887.

[79] Poudel SB, Dixit M, Neginskaya M, Nagaraj K, Pavlov E, Werner H, Yakar S. Effects of GH/IGF on the Aging Mitochondria. Cells. 2020 Jun 2;9(6):1384. doi: 10.3390/cells9061384. PMID: 32498386; PMCID: PMC7349719.

[80] Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Front Endocrinol (Lausanne). 2018 Feb 13;9:35. doi: 10.3389/fendo.2018.00035. PMID: 29487568; PMCID: PMC5816795.

[81] Kucharska, A.M.; Witkowska-Sędek, E.; Rumińska, M.; Pyrżak, B. Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients. J. Clin. Med. 2021, 10, 5354. https://doi.org/10.3390/jcm10225354

[82] Sabatino L, Vassalle C, Del Seppia C, Iervasi G. Deiodinases and the Three Types of Thyroid Hormone Deiodination Reactions. Endocrinol Metab (Seoul). 2021 Oct;36(5):952-964. doi: 10.3803/EnM.2021.1198. Epub 2021 Oct 21. PMID: 34674502; PMCID: PMC8566136.

[83] Wong TH, Chen TY, Tseng KY, Chen ZY, Chen CH, Lin FH, Wu HM, Lin S. Decorin inhibits the insulin-like growth factor I signaling in bone marrow mesenchymal stem cells of aged humans. Aging (Albany NY). 2020 Nov 26;13(1):578-597. doi: 10.18632/aging.202166. Epub 2020 Nov 26. PMID: 33257596; PMCID: PMC7835024.

[84] Nara H, Watanabe R. Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism. Int J Mol Sci. 2021 Sep 13;22(18):9889. doi: 10.3390/ijms22189889. PMID: 34576053; PMCID: PMC8471880.

[85] Forhead AJ, Curtis K, Kaptein E, Visser TJ, Fowden AL. Developmental control of iodothyronine deiodinases by cortisol in the ovine fetus and placenta near term. Endocrinology. 2006 Dec;147(12):5988-94. doi: 10.1210/en.2006-0712. Epub 2006 Sep 7. PMID: 16959839.

[86] Pekala J, Patkowska-Sokoła B, Bodkowski R, Jamroz D, Nowakowski P, Lochyński S, Librowski T. L-carnitine--metabolic functions and meaning in humans life. Curr Drug Metab. 2011 Sep;12(7):667-78. doi: 10.2174/138920011796504536. PMID: 21561431.

[87] Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015 Nov 20;36(1):e00281. doi: 10.1042/BSR20150240. PMID: 26589966; PMCID: PMC4718505.

[88] Sidossis LS, Wolfe RR. Glucose and insulin-induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am J Physiol. 1996 Apr;270(4 Pt 1):E733-8. doi: 10.1152/ajpendo.1996.270.4.E733. PMID: 8928782.

[89] Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019 Jul;44(1):3-15. doi: 10.3892/ijmm.2019.4188. Epub 2019 May 8. PMID: 31115493; PMCID: PMC6559295.

[90] Maalouf M, Sullivan PG, Davis L, Kim DY, Rho JM. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007 Mar 2;145(1):256-64. doi: 10.1016/j.neuroscience.2006.11.065. Epub 2007 Jan 18. PMID: 17240074; PMCID: PMC1865572.

[91] Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017 Feb 7;25(2):262-284. doi: 10.1016/j.cmet.2016.12.022. PMID: 28178565; PMCID: PMC5313038.

[92] Jensen MD. Adipose tissue and fatty acid metabolism in humans. J R Soc Med. 2002;95 Suppl 42(Suppl 42):3-7. PMID: 12216324; PMCID: PMC1308942.

[93] Guo C, Sun L, Chen X, Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. 2013 Jul 25;8(21):2003-14. doi: 10.3969/j.issn.1673-5374.2013.21.009. PMID: 25206509; PMCID: PMC4145906.

[94] Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci (Landmark Ed). 2009 Jan 1;14(4):1403-13. doi: 10.2741/3315. PMID: 19273137; PMCID: PMC2661616.

[95] Rungratanawanich, W., Qu, Y., Wang, X. et al. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 53, 168–188 (2021). https://doi.org/10.1038/s12276-021-00561-7

[96] Sozio MS, Lu C, Zeng Y, Liangpunsakul S, Crabb DW. Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4):G739-47. doi: 10.1152/ajpgi.00432.2010. Epub 2011 Jun 23. PMID: 21700905; PMCID: PMC3191559.

[97] Rabinovitch RC, Samborska B, Faubert B, Ma EH, Gravel SP, Andrzejewski S, Raissi TC, Pause A, St-Pierre J, Jones RG. AMPK Maintains Cellular Metabolic Homeostasis through Regulation of Mitochondrial Reactive Oxygen Species. Cell Rep. 2017 Oct 3;21(1):1-9. doi: 10.1016/j.celrep.2017.09.026. PMID: 28978464.

[98] Wang Y, Li Q, Zhang Z, Peng K, Zhang DM, Yang Q, Passerini AG, Simon SI, Sun C. mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling. Commun Biol. 2022 Jul 22;5(1):726. doi: 10.1038/s42003-022-03653-w. PMID: 35869262; PMCID: PMC9307829.

[99] Ming XF, Montani JP, Yang Z. Perspectives of Targeting mTORC1-S6K1 in Cardiovascular Aging. Front Physiol. 2012 Jan 25;3:5. doi: 10.3389/fphys.2012.00005. PMID: 22291661; PMCID: PMC3265748.

[100] Liu W, Ji Y, Zhang B, Chu H, Yin C, Xiao Y. Stat5a promotes brown adipocyte differentiation and thermogenic program through binding and transactivating the Kdm6a promoter. Cell Cycle. 2020 Apr;19(8):895-905. doi: 10.1080/15384101.2020.1731644. Epub 2020 Mar 24. PMID: 32207362; PMCID: PMC7217358.

[101] Devesa, P., Agasse, F., Xapelli, S. et al. Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice. BMC Neurosci 15, 100 (2014). https://doi.org/10.1186/1471-2202-15-100

[102] Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic Effects of Glucocorticoids: An Updated View. Trends Pharmacol Sci. 2019 Jan;40(1):38-49. doi: 10.1016/j.tips.2018.11.002. Epub 2018 Nov 26. PMID: 30497693; PMCID: PMC7106476.

[103] Jones RB, Silva AD, Ankenbauer KE, Britain CM, Chakraborty A, Brown JA, Ballinger SW, Bellis SL. Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism. Glycobiology. 2023 Oct 6;33(8):626-636. doi: 10.1093/glycob/cwad051. PMID: 37364046; PMCID: PMC10560082.

[104] Krick S, Helton ES, Easter M, Bollenbecker S, Denson R, Zaharias R, Cochran P, Vang S, Harris E, Wells JM, Barnes JW. ST6GAL1 and α2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease. Front Immunol. 2021 Jul 5;12:693149. doi: 10.3389/fimmu.2021.693149. PMID: 34290711; PMCID: PMC8287524.

[105] Lasa M, Contreras-Jurado C. Thyroid hormones act as modulators of inflammation through their nuclear receptors. Front Endocrinol (Lausanne). 2022 Aug 8;13:937099. doi: 10.3389/fendo.2022.937099. PMID: 36004343; PMCID: PMC9393327.

[106] Galdieri L, Vancura A. Acetyl-CoA carboxylase regulates global histone acetylation. J Biol Chem. 2012 Jul 6;287(28):23865-76. doi: 10.1074/jbc.M112.380519. Epub 2012 May 11. PMID: 22580297; PMCID: PMC3390662.

[107] Chu YW, Schmitz S, Choudhury B, Telford W, Kapoor V, Garfield S, Howe D, Gress RE. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood. 2008 Oct 1;112(7):2836-46. doi: 10.1182/blood-2008-04-149435. Epub 2008 Jul 24. PMID: 18658030; PMCID: PMC2556619.

[108] Misra M, Bredella MA, Tsai P, Mendes N, Miller KK, Klibanski A. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E385-92. doi: 10.1152/ajpendo.00052.2008. Epub 2008 Jun 10. PMID: 18544645; PMCID: PMC2519763.

[109] Harrington KA, Kennedy DS, Tang B, Hickie C, Phelan E, Torreggiani W, Halpenny D. Computed tomographic evaluation of the thymus-does obesity affect thymic fatty involution in a healthy young adult population? Br J Radiol. 2018 Sep;91(1089):20170609. doi: 10.1259/bjr.20170609. Epub 2018 Mar 7. PMID: 29356558; PMCID: PMC6223166.

[110] Sandstedt, M., Chung, R., Skoglund, C. et al. Complete fatty degeneration of thymus associates with male sex, obesity and loss of circulating naïve CD8 T cells in a Swedish middle-aged population. Immun Ageing 20, 45 (2023). https://doi.org/10.1186/s12979-023-00371-7+

[111] Devlin MJ, Rosen CJ. The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol. 2015 Feb;3(2):141-7. doi: 10.1016/S2213-8587(14)70007-5. Epub 2014 Feb 19. PMID: 24731667; PMCID: PMC4138282.

[112] Marinelli Busilacchi E, Morsia E, Poloni A. Bone Marrow Adipose Tissue. Cells. 2024 Apr 23;13(9):724. doi: 10.3390/cells13090724. PMID: 38727260; PMCID: PMC11083575.

[113] Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013 Jun;9(6):366-376. doi: 10.1038/nrendo.2013.67. Epub 2013 Apr 16. PMID: 23591370; PMCID: PMC4074016.

[114] Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11;339(6116):211-4. doi: 10.1126/science.1227166. Epub 2012 Dec 6. PMID: 23223453; PMCID: PMC3735349.

[115] Zhou L, Roth M, Papakonstantinou E, Tamm M, Stolz D. Expression of glucocorticoid receptor and HDACs in airway smooth muscle cells is associated with response to steroids in COPD. Respir Res. 2024 May 29;25(1):227. doi: 10.1186/s12931-024-02769-3. PMID: 38812021; PMCID: PMC11137987.

[116] Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells. 2013 Mar 26;2(2):202-23. doi: 10.3390/cells2020202. PMID: 24709697; PMCID: PMC3972684.

[117] Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002 Jan;9(1):6-19. doi: 10.1038/sj.cdd.4400969. PMID: 11803370.

[118] Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gerritsen ME, Collins T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem. 1998 Nov 6;273(45):29291-4. doi: 10.1074/jbc.273.45.29291. PMID: 9792627.

[119] Medler J, Kucka K, Wajant H. Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy. Cancers (Basel). 2022 May 25;14(11):2603. doi: 10.3390/cancers14112603. PMID: 35681583; PMCID: PMC9179537.

[120] Park CY, Han SN. The Role of Vitamin D in Adipose Tissue Biology: Adipocyte Differentiation, Energy Metabolism, and Inflammation. J Lipid Atheroscler. 2021 May;10(2):130-144. doi: 10.12997/jla.2021.10.2.130. Epub 2021 Mar 16. PMID: 34095008; PMCID: PMC8159757.

[121] Payet T, Astier J, Bournot L, Sicard F, Robert S, Lacroix R, Wabitsch M, Landrier JF, Mounien L. Vitamin D modulates the content of inflammatory microRNAs in extracellular vesicles from human adipocyte cells in inflammatory context. Biofactors. 2025 Jan-Feb;51(1):e70003. doi: 10.1002/biof.70003. PMID: 39887543; PMCID: PMC11779547.

[122] Hii CS, Ferrante A. The Non-Genomic Actions of Vitamin D. Nutrients. 2016 Mar 2;8(3):135. doi: 10.3390/nu8030135. PMID: 26950144; PMCID: PMC4808864.

[123] Lacombe J, Guo K, Bonneau J, Faubert D, Gioanni F, Vivoli A, Muir SM, Hezzaz S, Poitout V, Ferron M. Vitamin K-dependent carboxylation regulates Ca2+ flux and adaptation to metabolic stress in β cells. Cell Rep. 2023 May 30;42(5):112500. doi: 10.1016/j.celrep.2023.112500. Epub 2023 May 11. PMID: 37171959; PMCID: PMC10305719.

[124] Mejía-Ramírez E, Picazo PI, Walter B, Montserrat-Vazquez S, Affuso F, Wieser S, Pezzano F, Reymond L, Castillo-Robles J, Matteini F, Mularoni L, Maciá D, Raya Á, Ruprecht V, Zheng Y, Petrone P, Florian MC. Targeting RhoA nuclear mechanoactivity rejuvenates aged hematopoietic stem cells. Nat Aging. 2025 Nov 24. doi: 10.1038/s43587-025-01014-w. Epub ahead of print. PMID: 41286464.

[125] Wang GJ, Tian Y, Zhang HY. [Research Progress of Fatty Acid Desaturase 2 Gene in Glycolipid Metabolism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Feb;44(1):158-163. Chinese. doi: 10.3881/j.issn.1000-503X.14235. PMID: 35300779.

[126] Arif T, Qiu J, Khademian H, Lohithakshan A, Menon A, Menon V, Slavinsky M, Batignes M, Lin M, Sebra R, Beaumont KG, Benson DL, Tzavaras N, Ménager MM, Ghaffari S. Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells. Cell Stem Cell. 2025 Nov 24:S1934-5909(25)00405-9. doi: 10.1016/j.stem.2025.10.012. Epub ahead of print. PMID: 41289991.

[127] Singla M, Wang YX, Monti E, Bedi Y, Agarwal P, Su S, Ancel S, Hermsmeier M, Devisetti N, Pandey A, Bakooshli MA, Palla AR, Goodman S, Blau HM, Bhutani N. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2025 Nov 27:eadx6649. doi: 10.1126/science.adx6649. Epub ahead of print. PMID: 41308124.

[128] Trefely S, Lovell CD, Snyder NW, Wellen KE. Compartmentalised acyl-CoA metabolism and roles in chromatin regulation. Mol Metab. 2020 Aug;38:100941. doi: 10.1016/j.molmet.2020.01.005. Epub 2020 Feb 14. PMID: 32199817; PMCID: PMC7300382.

[129] Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009 May 22;324(5930):1076-80. doi: 10.1126/science.1164097. PMID: 19461003; PMCID: PMC2746744.

[130] Maroudas A. Transport of solutes through cartilage: permeability to large molecules. J Anat. 1976 Nov;122(Pt 2):335-47. PMID: 1002608; PMCID: PMC1231906.

[131] Luis Batista, Franklin Zhong, Sharon A Savage, Steven Artandi; TIN2 Mutations In Dyskeratosis Congenita Cause Telomere Shortening In Induced Pluripotent Stem Cells Through Potent Dominant Negative Inhibition Of Telomerase. Blood 2013; 122 (21): 590. doi: https://doi.org/10.1182/blood.V122.21.590.590

[132] Kim SH, Kaminker P, Campisi J. TIN2, a new regulator of telomere length in human cells. Nat Genet. 1999 Dec;23(4):405-12. doi: 10.1038/70508. PMID: 10581025; PMCID: PMC4940194.

[133] Li M, Wang Z, Tao J, Jiang H, Yang H, Guo D, Zhao H, He X, Luo S, Jiang X, Yuan L, Xiao L, He H, Yu R, Fang J, Liang T, Mao Z, Xu D, Lu Z. Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression. Nat Chem Biol. 2024 Nov;20(11):1505-1513. doi: 10.1038/s41589-024-01597-2. Epub 2024 Mar 27. Erratum in: Nat Chem Biol. 2024 Nov;20(11):1547. doi: 10.1038/s41589-024-01623-3. PMID: 38538923.

[134] Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62. doi: 10.1038/nrm3311. PMID: 22436748; PMCID: PMC5726489.

[135] Chen CH, Kiyan V, Zhylkibayev AA, Kazyken D, Bulgakova O, Page KE, Bersimbaev RI, Spooner E, Sarbassov DD. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. J Biol Chem. 2013 Sep 20;288(38):27019-27030. doi: 10.1074/jbc.M113.498055. Epub 2013 Aug 8. PMID: 23928304; PMCID: PMC3779703.

[136] Nieves-Cintrón M, Syed AU, Nystoriak MA, Navedo MF. Regulation of voltage-gated potassium channels in vascular smooth muscle during hypertension and metabolic disorders. Microcirculation. 2018 Jan;25(1):10.1111/micc.12423. doi: 10.1111/micc.12423. PMID: 29044853; PMCID: PMC5760350.

[137] Obradovic M, Sudar-Milovanovic E, Gluvic Z, Banjac K, Rizzo M, Isenovic ER. The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. Front Endocrinol (Lausanne). 2023 Feb 28;14:1150171. doi: 10.3389/fendo.2023.1150171. PMID: 36926029; PMCID: PMC10011626.

[138] Brini M, Carafoli E. Calcium pumps in health and disease. Physiol Rev. 2009 Oct;89(4):1341-78. doi: 10.1152/physrev.00032.2008. PMID: 19789383.

[139] Strehler EE, Zacharias DA. Role of alternative splicing in generating isoform diversity among plasma membrane calcium pumps. Physiol Rev. 2001 Jan;81(1):21-50. doi: 10.1152/physrev.2001.81.1.21. PMID: 11152753.

[140] Brini M, Carafoli E. The plasma membrane Ca²+ ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium. Cold Spring Harb Perspect Biol. 2011 Feb 1;3(2):a004168. doi: 10.1101/cshperspect.a004168. PMID: 21421919; PMCID: PMC3039526.

[141] Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev. 1999 Jul;79(3):763-854. doi: 10.1152/physrev.1999.79.3.763. PMID: 10390518.

[142] Xia, H.; Zahra, A.; Jia, M.; Wang, Q.; Wang, Y.; Campbell, S.L.; Wu, J. Na⁺/H⁺ Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure. Pharmaceuticals 2022, 15, 875. https://doi.org/10.3390/ph15070875

[143] Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev. 2009 Sep;231(1):59-87. doi: 10.1111/j.1600-065X.2009.00816.x. PMID: 19754890; PMCID: PMC3133616.

[144] Yuan, YC., Wang, H., Jiang, ZJ. et al. Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies. Sig Transduct Target Ther 9, 207 (2024). https://doi.org/10.1038/s41392-024-01923-z

[145] Dzurba A, Ziegelhöffer A, Vrbjar N, Styk J, Slezák J. Estradiol modulates the sodium pump in the heart sarcolemma. Mol Cell Biochem. 1997 Nov;176(1-2):113-8. PMID: 9406152.

[146] Thowsen IM, Karlsen TV, Nikpey E, Haslene-Hox H, Skogstrand T, Randolph GJ, Zinselmeyer BH, Tenstad O, Wiig H. Na+ is shifted from the extracellular to the intracellular compartment and is not inactivated by glycosaminoglycans during high salt conditions in rats. J Physiol. 2022 May;600(10):2293-2309. doi: 10.1113/JP282715. Epub 2022 Apr 21. PMID: 35377950; PMCID: PMC9324226.

[147] Pap D, Pajtók C, Veres-Székely A, Szebeni B, Szász C, Bokrossy P, Zrufkó R, Vannay Á, Tulassay T, Szabó AJ. High Salt Promotes Inflammatory and Fibrotic Response in Peritoneal Cells. Int J Mol Sci. 2023 Sep 6;24(18):13765. doi: 10.3390/ijms241813765. PMID: 37762068; PMCID: PMC10531298.

[148] Pajtók C, Veres-Székely A, Agócs R, Szebeni B, Dobosy P, Németh I, Veréb Z, Kemény L, Szabó AJ, Vannay Á, Tulassay T, Pap D. High salt diet impairs dermal tissue remodeling in a mouse model of IMQ induced dermatitis. PLoS One. 2021 Nov 1;16(11):e0258502. doi: 10.1371/journal.pone.0258502. PMID: 34723976; PMCID: PMC8559960.

[149] Yeo GC, Keeley FW, Weiss AS. Coacervation of tropoelastin. Adv Colloid Interface Sci. 2011 Sep 14;167(1-2):94-103. doi: 10.1016/j.cis.2010.10.003. Epub 2010 Oct 21. PMID: 21081222.

[150] Sugawara-Narutaki, A. Self-assembled nanofibers and hydrogels of double-hydrophobic elastin-like polypeptides formed via coacervation. Polym J 57, 863–871 (2025). https://doi.org/10.1038/s41428-025-01028-6

[151] Lüdeke S, Lohner P, Stühn LG, Betschart MU, Huber MC, Schreiber A, Schiller SM. Dynamic Structural Changes and Thermodynamics in Phase Separation Processes of an Intrinsically Disordered-Ordered Protein Model. Angew Chem Int Ed Engl. 2022 Jan 17;61(3):e202112738. doi: 10.1002/anie.202112738. Epub 2021 Dec 6. PMID: 34806270; PMCID: PMC9299898.

[152] Mutengo KH, Ngalamika O, Kirabo A, Masenga SK. Salt sensitivity and myocardial fibrosis: unraveling the silent cardiovascular remodeling. Front Pharmacol. 2025 Jun 13;16:1626492. doi: 10.3389/fphar.2025.1626492. PMID: 40584624; PMCID: PMC12202478.

[153] Ke, W., Xu, H., Zhang, C. et al. An overview of mechanical microenvironment and mechanotransduction in intervertebral disc degeneration. Exp Mol Med 57, 2157–2168 (2025). https://doi.org/10.1038/s12276-025-01546-6

[154] Mayorca-Guiliani, A.E., Leeming, D.J., Henriksen, K. et al. ECM formation and degradation during fibrosis, repair, and regeneration. npj Metab Health Dis 3, 25 (2025). https://doi.org/10.1038/s44324-025-00063-4

[155] Artyukov, I., Arutyunov, G., Bobrov, M. et al. The first observation of osmotically neutral sodium accumulation in the myocardial interstitium. Sci Rep 11, 22025 (2021). https://doi.org/10.1038/s41598-021-01443-8

[156] Victorelli, S., Eppard, M., Martini, H. et al. Mitochondrial RNA cytosolic leakage drives the SASP. Nat Commun 16, 10992 (2025). https://doi.org/10.1038/s41467-025-66159-z

[157] Wei, P., Zhang, X., Yan, C. et al. Mitochondrial dysfunction and aging: multidimensional mechanisms and therapeutic strategies. Biogerontology 26, 142 (2025). https://doi.org/10.1007/s10522-025-10273-4

[158] Bernardi, P., Gerle, C., Halestrap, A.P. et al. Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions. Cell Death Differ 30, 1869–1885 (2023). https://doi.org/10.1038/s41418-023-01187-0

[159] Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J. TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2726-37. doi: 10.1152/ajpheart.00376.2007. Epub 2007 Aug 3. PMID: 17675574.

[160] Halmos, G., Szabo, Z., Dobos, N. et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord 26, 343–352 (2025). https://doi.org/10.1007/s11154-025-09952-x

[161] Yatani A, Codina J, Sekura RD, Birnbaumer L, Brown AM. Reconstitution of somatostatin and muscarinic receptor mediated stimulation of K+ channels by isolated GK protein in clonal rat anterior pituitary cell membranes. Mol Endocrinol. 1987 Apr;1(4):283-9. doi: 10.1210/mend-1-4-283. PMID: 2456451.

[162] Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014 Aug;39(8):347-54. doi: 10.1016/j.tibs.2014.06.005. Epub 2014 Jul 15. PMID: 25037503; PMCID: PMC4329227.

[163] Lee BM, Park SJ, Noh I, Kim CH. The effects of the molecular weights of hyaluronic acid on the immune responses. Biomater Res. 2021 Aug 30;25(1):27. doi: 10.1186/s40824-021-00228-4. PMID: 34462017; PMCID: PMC8404285.

[164] Marinho A, Nunes C, Reis S. Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation. Biomolecules. 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. PMID: 34680150; PMCID: PMC8533685.

[165] Altman R, Bedi A, Manjoo A, Niazi F, Shaw P, Mease P. Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review. Cartilage. 2019 Jan;10(1):43-52. doi: 10.1177/1947603517749919. Epub 2018 Feb 11. PMID: 29429372; PMCID: PMC6376563.

[166] Torres M, Rosselló CA, Fernández-García P, Lladó V, Kakhlon O, Escribá PV. The Implications for Cells of the Lipid Switches Driven by Protein-Membrane Interactions and the Development of Membrane Lipid Therapy. Int J Mol Sci. 2020 Mar 27;21(7):2322. doi: 10.3390/ijms21072322. PMID: 32230887; PMCID: PMC7177374.

[167] Khodnapur JP, Aithala MR, Das KK.Serum Vascular Endothelial Growth Factor and Aging: Study among Urban Population of Vijayapur, Karnataka, India.J Clin of Diagn Res.2018; 12(3):CC05-CC08. https://www.doi.org/10.7860/JCDR/2018/35354/11320

[168] Llibre A, Kucuk S, Gope A, Certo M, Mauro C. Lactate: A key regulator of the immune response. Immunity. 2025 Mar 11;58(3):535-554. doi: 10.1016/j.immuni.2025.02.008. PMID: 40073846.

[169] Duval M, Bédard-Goulet S, Delisle C, Gratton JP. Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J Biol Chem. 2003 May 30;278(22):20091-7. doi: 10.1074/jbc.M301410200. Epub 2003 Mar 19. PMID: 12649282.

[170] Mazuryk, O.; Gurgul, I.; Oszajca, M.; Polaczek, J.; Kieca, K.; Bieszczad-Żak, E.; Martyka, T.; Stochel, G. Nitric Oxide Signaling and Sensing in Age-Related Diseases. Antioxidants 2024, 13, 1213. https://doi.org/10.3390/antiox13101213

[171] Sverdlov AL, Ngo DT, Chan WP, Chirkov YY, Horowitz JD. Aging of the nitric oxide system: are we as old as our NO? J Am Heart Assoc. 2014 Aug 18;3(4):e000973. doi: 10.1161/JAHA.114.000973. PMID: 25134680; PMCID: PMC4310385.

[172] Golubtsova, N.N., Vasilieva, O.V., Petrov, V.V. et al. Age-related changes of angiomotin and endostatin content in human skin. Adv Gerontol 6, 153–159 (2016). https://doi.org/10.1134/S2079057016020065

[173] Tripette J, Alexy T, Hardy-Dessources MD, Mougenel D, Beltan E, Chalabi T, Chout R, Etienne-Julan M, Hue O, Meiselman HJ, Connes P. Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease. Haematologica. 2009 Aug;94(8):1060-5. doi: 10.3324/haematol.2008.005371. PMID: 19644138; PMCID: PMC2719028.

[174] Li Q, Yang Z, Zhu M, Zhang W, Chen L, Chen H, Kang P. Hypobaric hypoxia aggravates osteoarthritis via the alteration of the oxygen environment and bone remodeling in the subchondral zone. FASEB J. 2024 Apr 15;38(7):e23594. doi: 10.1096/fj.202302368R. PMID: 38573451.

[175] Jiang Y, Cong X, Jiang S, Dong Y, Zhao L, Zang Y, Tan M, Li J. Phosphoproteomics Reveals the AMPK Substrate Network in Response to DNA Damage and Histone Acetylation. Genomics Proteomics Bioinformatics. 2022 Aug;20(4):597-613. doi: 10.1016/j.gpb.2020.09.003. Epub 2021 Feb 17. PMID: 33607295; PMCID: PMC9880816.

[176] Tamarkin-Ben-Harush A, Vasseur JJ, Debart F, Ulitsky I, Dikstein R. Cap-proximal nucleotides via differential eIF4E binding and alternative promoter usage mediate translational response to energy stress. Elife. 2017 Feb 8;6:e21907. doi: 10.7554/eLife.21907. PMID: 28177284; PMCID: PMC5308895.

[177] Tessema B, Sack U, König B, Serebrovska Z, Egorov E. Effects of Intermittent Hypoxia in Training Regimes and in Obstructive Sleep Apnea on Aging Biomarkers and Age-Related Diseases: A Systematic Review. Front Aging Neurosci. 2022 May 23;14:878278. doi: 10.3389/fnagi.2022.878278. PMID: 35677200; PMCID: PMC9168371.

[178] Fan, H.-C.; Chang, F.-W.; Tsai, J.-D.; Lin, K.-M.; Chen, C.-M.; Lin, S.-Z.; Liu, C.-A.; Harn, H.-J. Telomeres and Cancer. Life 2021, 11, 1405. https://doi.org/10.3390/life11121405

[179] Manosalva C, Quiroga J, Hidalgo AI, Alarcón P, Anseoleaga N, Hidalgo MA, Burgos RA. Role of Lactate in Inflammatory Processes: Friend or Foe. Front Immunol. 2022 Jan 14;12:808799. doi: 10.3389/fimmu.2021.808799. Erratum in: Front Immunol. 2025 Jan 27;16:1553925. doi: 10.3389/fimmu.2025.1553925. PMID: 35095895; PMCID: PMC8795514.

[180] Xin Z-T, Carroll KA, Kumar N, Song K, Ly H (2011) Transcriptional Activation of TINF2, a Gene Encoding the Telomere-Associated Protein TIN2, by Sp1 and NF-κB Factors. PLoS ONE 6(6): e21333. https://doi.org/10.1371/journal.pone.0021333

[181] González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci. 2023 May 27;24(11):9352. doi: 10.3390/ijms24119352. PMID: 37298303; PMCID: PMC10253853.

[182] Cooper MA, McCoin C, Pei D, Thyfault JP, Koestler D, Wright DE. Reduced mitochondrial reactive oxygen species production in peripheral nerves of mice fed a ketogenic diet. Exp Physiol. 2018 Sep;103(9):1206-1212. doi: 10.1113/EP087083. Epub 2018 Aug 8. PMID: 30088302; PMCID: PMC6119112.

[183] Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017 Jun;13(4):851-863. doi: 10.5114/aoms.2016.58928. Epub 2016 Mar 31. PMID: 28721154; PMCID: PMC5507106.

[184] Li Y, Wang Y, Yuan Q. α-酮戊二酸在代谢综合征中的研究进展 [Latest Findings on the Role of α-Ketoglutarate in Metabolic Syndrome]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 May 20;55(3):783-792. Chinese. doi: 10.12182/20240560302. PMID: 38948289; PMCID: PMC11211801.

[185] Kuznetsov, N.A.; Kanazhevskaya, L.Y.; Fedorova, O.S. DNA Demethylation in the Processes of Repair and Epigenetic Regulation Performed by 2-Ketoglutarate-Dependent DNA Dioxygenases. Int. J. Mol. Sci. 2021, 22, 10540. https://doi.org/10.3390/ijms221910540

[186] Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013 May;1830(5):3143-53. doi: 10.1016/j.bbagen.2012.09.008. Epub 2012 Sep 17. PMID: 22995213; PMCID: PMC3549305.

[187] Majumder, A.; Bano, S.; Nayak, K.B. The Pivotal Role of One-Carbon Metabolism in Neoplastic Progression During the Aging Process. Biomolecules 2024, 14, 1387. https://doi.org/10.3390/biom14111387

[188] Ciuffoli V, Feng X, Jiang K, Acevedo-Luna N, Ko KD, Wang AHJ, Riparini G, Khateb M, Glancy B, Dell'Orso S, Sartorelli V. Psat1-generated α-ketoglutarate and glutamine promote muscle stem cell activation and regeneration. Genes Dev. 2024 Mar 22;38(3-4):151-167. doi: 10.1101/gad.351428.123. PMID: 38453480; PMCID: PMC10982694.

[189] Chacón E, Grünwaldt G, Marmisolle I, Martínez J and Quijano C (2026) Redox metabolism in cell senescence: focusing on contributions from the metabolomic field. Front. Mol. Biosci. 12:1754469. doi: 10.3389/fmolb.2025.1754469

[190] Wu, N., Ma, YC., Gong, XQ. et al. The metabolite alpha-ketobutyrate extends lifespan by promoting peroxisomal function in C. elegans. Nat Commun 14, 240 (2023). https://doi.org/10.1038/s41467-023-35899-1

[191] Wu, QJ., Zhang, TN., Chen, HH. et al. The sirtuin family in health and disease. Sig Transduct Target Ther 7, 402 (2022). https://doi.org/10.1038/s41392-022-01257-8

[192] Sato A, Takino Y, Yano T, Fukui K, Ishigami A. Determination of tissue-specific interaction between vitamin C and vitamin E in vivo using senescence marker protein-30 knockout mice as a vitamin C synthesis deficiency model. Br J Nutr. 2022 Sep 28;128(6):993-1003. doi: 10.1017/S0007114521004384. Epub 2021 Nov 2. PMID: 34725010; PMCID: PMC9381305.

[193] Kilicarslan You D, Fuwad A, Lee KH, Kim HK, Kang L, Kim SM, Jeon TJ. Evaluation of the Protective Role of Vitamin E against ROS-Driven Lipid Oxidation in Model Cell Membranes. Antioxidants (Basel). 2024 Sep 20;13(9):1135. doi: 10.3390/antiox13091135. PMID: 39334794; PMCID: PMC11428522.

[194] Howell SL, Whitfield M. Synthesis and secretion of growth hormone in the rat anterior pituitary. I. The intracellular pathway, its time course and energy requirements. J Cell Sci. 1973 Jan;12(1):1-21. doi: 10.1242/jcs.12.1.1. PMID: 4266075.

[195] Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Front Endocrinol (Lausanne). 2018 Feb 13;9:35. doi: 10.3389/fendo.2018.00035. PMID: 29487568; PMCID: PMC5816795.

[196] Galland S, Georges B, Le Borgne F, Conductier G, Dias JV, Demarquoy J. Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression. Cell Mol Life Sci. 2002 Mar;59(3):540-5. doi: 10.1007/s00018-002-8445-3. PMID: 11964131; PMCID: PMC11337547.

[197] Audesse AJ, Dhakal S, Hassell LA, Gardell Z, Nemtsova Y, Webb AE. FOXO3 directly regulates an autophagy network to functionally regulate proteostasis in adult neural stem cells. PLoS Genet. 2019 Apr 11;15(4):e1008097. doi: 10.1371/journal.pgen.1008097. PMID: 30973875; PMCID: PMC6478346.

[198] Chen, H., Gong, S., Zhang, H. et al. From the regulatory mechanism of TFEB to its therapeutic implications. Cell Death Discov. 10, 84 (2024). https://doi.org/10.1038/s41420-024-01850-6

[199] Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023 Apr;24(4):255-272. doi: 10.1038/s41580-022-00547-x. Epub 2022 Oct 31. PMID: 36316383.

[200] Langer HT, Rohm M, Goncalves MD, Sylow L. AMPK as a mediator of tissue preservation: time for a shift in dogma? Nat Rev Endocrinol. 2024 Sep;20(9):526-540. doi: 10.1038/s41574-024-00992-y. Epub 2024 May 17. PMID: 38760482.

[201] Ross JM, Öberg J, Brené S, Coppotelli G, Terzioglu M, Pernold K, Goiny M, Sitnikov R, Kehr J, Trifunovic A, Larsson NG, Hoffer BJ, Olson L. High brain lactate is a hallmark of aging and caused by a shift in the lactate dehydrogenase A/B ratio. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20087-92. doi: 10.1073/pnas.1008189107. Epub 2010 Nov 1. PMID: 21041631; PMCID: PMC2993405.

[202] Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, Serra S, Malavasi F. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology. 2013 Sep 1;2(9):e26246. doi: 10.4161/onci.26246. Epub 2013 Sep 26. PMID: 24319640; PMCID: PMC3850273.

[203] Chun Y, Kim J. AMPK-mTOR Signaling and Cellular Adaptations in Hypoxia. Int J Mol Sci. 2021 Sep 9;22(18):9765. doi: 10.3390/ijms22189765. PMID: 34575924; PMCID: PMC8465282.

[204] Castro-Torres RD, Olloquequi J, Parcerisas A, Ureña J, Ettcheto M, Beas-Zarate C, Camins A, Verdaguer E, Auladell C. JNK signaling and its impact on neural cell maturation and differentiation. Life Sci. 2024 Aug 1;350:122750. doi: 10.1016/j.lfs.2024.122750. Epub 2024 May 25. PMID: 38801982.

[205] Chen X, Fang M, Hong J, Guo Y. JNK Pathway-Associated Phosphatase Deficiency Facilitates Atherosclerotic Progression by Inducing T-Helper 1 and 17 Polarization and Inflammation in an ERK- and NF-κB Pathway-Dependent Manner. J Atheroscler Thromb. 2024 Oct 1;31(10):1460-1478. doi: 10.5551/jat.64754. Epub 2024 May 24. PMID: 38797677; PMCID: PMC11456371.

[206] Matsui M, Kajikuri J, Endo K, Kito H, Ohya S. K3.1 inhibition-induced activation of the JNK/c-Jun signaling pathway enhances IL-10 expression in peripherally-induced regulatory T cells. J Pharmacol Sci. 2022 Jan;148(1):1-5. doi: 10.1016/j.jphs.2021.09.007. Epub 2021 Oct 1. PMID: 34924112.Ca

[207] Yang L, Han X, Xing F, Wu H, Shi H, Huang F, Xu Q, Wu X. Total flavonoids of astragalus attenuates experimental autoimmune encephalomyelitis by suppressing the activation and inflammatory responses of microglia via JNK/AKT/NFκB signaling pathway. Phytomedicine. 2021 Jan;80:153385. doi: 10.1016/j.phymed.2020.153385. Epub 2020 Oct 15. PMID: 33091854.

[208] Gc S, Bellis SL, Hjelmeland AB. ST6Gal1: Oncogenic signaling pathways and targets. Front Mol Biosci. 2022 Aug 29;9:962908. doi: 10.3389/fmolb.2022.962908. PMID: 36106023; PMCID: PMC9465715.

[209] Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol. 2002 Mar;71(3):381-7. PMID: 11867675.

[210] Blaschke M, Koepp R, Streit F, Beismann J, Manthey G, Seitz MT, Kragl A, Siggelkow H. The rise in expression and activity of 11β-HSD1 in human mesenchymal progenitor cells induces adipogenesis through increased local cortisol synthesis. J Steroid Biochem Mol Biol. 2021 Jun;210:105850. doi: 10.1016/j.jsbmb.2021.105850. Epub 2021 Feb 24. PMID: 33639236.

[211] DeSantis AS, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS, Seeman TE, Shea S. Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology. 2012 Jul;37(7):1009-18. doi: 10.1016/j.psyneuen.2011.11.009. Epub 2011 Dec 16. PMID: 22178583; PMCID: PMC3358540.

[212] Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Domínguez-Mendoza AE, Barrera-Barrera SA, Barrera-Saldaña HA. Growth hormone and aging: a clinical review. Front Aging. 2025 Apr 7;6:1549453. doi: 10.3389/fragi.2025.1549453. PMID: 40260058; PMCID: PMC12009952.

[213] Biadgo B, Tamir W, Ambachew S. Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review. Rev Diabet Stud. 2020;16(1):24-34. doi: 10.1900/RDS.2020.16.24. Epub 2020 Dec 28. PMID: 33905470; PMCID: PMC9380093.

[214] Botusan IR, Zheng X, Narayanan S, Grünler J, Sunkari VG, Calissendorff FS, Ansurudeen I, Illies C, Svensson J, Jansson JO, Ohlsson C, Brismar K, Catrina SB. Deficiency of liver-derived insulin-like growth factor-I (IGF-I) does not interfere with the skin wound healing rate. PLoS One. 2018 Mar 13;13(3):e0193084. doi: 10.1371/journal.pone.0193084. PMID: 29534073; PMCID: PMC5849293.

[215] Varani J, Dame MK, Rittie L, Fligiel SE, Kang S, Fisher GJ, Voorhees JJ. Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol. 2006 Jun;168(6):1861-8. doi: 10.2353/ajpath.2006.051302. PMID: 16723701; PMCID: PMC1606623.

[216] Palmer ER, Morales-Muñoz I, Perry BI, Marwaha S, Warwick E, Rogers JC, Upthegrove R. Trajectories of Inflammation in Youth and Risk of Mental and Cardiometabolic Disorders in Adulthood. JAMA Psychiatry. 2024 Nov 1;81(11):1130-1137. doi: 10.1001/jamapsychiatry.2024.2193. PMID: 39167392; PMCID: PMC11339695.

[217] Plikus MV, Wang X, Sinha S, Forte E, Thompson SM, Herzog EL, Driskell RR, Rosenthal N, Biernaskie J, Horsley V. Fibroblasts: Origins, definitions, and functions in health and disease. Cell. 2021 Jul 22;184(15):3852-3872. doi: 10.1016/j.cell.2021.06.024. PMID: 34297930; PMCID: PMC8566693.

[218] Cui, S., Guo, Y., Fu, Y. et al. Inflammation-related collagen fibril destruction contributes to temporomandibular joint disc displacement via NF-κB activation. Int J Oral Sci 17, 35 (2025). https://doi.org/10.1038/s41368-025-00352-0

[219] Nan L, Guo P, Hui W, Xia F, Yi C. Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies. Front Pharmacol. 2025 Jun 18;16:1592596. doi: 10.3389/fphar.2025.1592596. PMID: 40606604; PMCID: PMC12213903.

[220] Mizukoshi K, Iwazaki H, Ida T. Quantitative analysis of age-related changes in vascular structure, oxygen saturation, and epidermal melanin structure using photoacoustic methods. Skin Res Technol. 2024 Jan;30(1):e13537. doi: 10.1111/srt.13537. PMID: 38174730; PMCID: PMC10765365.

[221] Kinsman RA, Hood J. Some behavioral effects of ascorbic acid deficiency. Am J Clin Nutr. 1971 Apr;24(4):455-64. doi: 10.1093/ajcn/24.4.455. PMID: 4397430.

[222] Baker EM, Hodges RE, Hood J, Sauberlich HE, March SC, Canham JE. Metabolism of 14C- and 3H-labeled L-ascorbic acid in human scurvy. Am J Clin Nutr. 1971 Apr;24(4):444-54. doi: 10.1093/ajcn/24.4.444. PMID: 5090632.

[223] Kallner A, Hartmann D, Hornig D. Determination of bodypool size and turnover rate of ascorbic acid in man. Nutr Metab. 1977;21 Suppl 1:31-5. doi: 10.1159/000176099. PMID: 917413.

[224] May JM, Mendiratta S, Qu ZC, Loggins E. Vitamin C recycling and function in human monocytic U-937 cells. Free Radic Biol Med. 1999 Jun;26(11-12):1513-23. doi: 10.1016/s0891-5849(99)00017-9. PMID: 10401617.

[225] Monacelli F, Acquarone E, Giannotti C, Borghi R, Nencioni A. Vitamin C, Aging and Alzheimer's Disease. Nutrients. 2017 Jun 27;9(7):670. doi: 10.3390/nu9070670. PMID: 28654021; PMCID: PMC5537785.

[226] Dhotre T, Thanawala S, Shah R. Optimizing Oral Vitamin C Supplementation: Addressing Pharmacokinetic Challenges with Nutraceutical Formulation Approaches-A Mini Review. Pharmaceutics. 2025 Nov 11;17(11):1458. doi: 10.3390/pharmaceutics17111458. PMID: 41304796; PMCID: PMC12655283.

[227] Schwertassek U, Haque A, Krishnan N, Greiner R, Weingarten L, Dick TP, Tonks NK. Reactivation of oxidized PTP1B and PTEN by thioredoxin 1. FEBS J. 2014 Aug;281(16):3545-58. doi: 10.1111/febs.12898. Epub 2014 Jul 23. PMID: 24976139; PMCID: PMC4162488.

[228] May JM, Mendiratta S, Hill KE, Burk RF. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem. 1997 Sep 5;272(36):22607-10. doi: 10.1074/jbc.272.36.22607. PMID: 9278416.

[229] Johnston CS, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults. Am J Clin Nutr. 1993 Jul;58(1):103-5. doi: 10.1093/ajcn/58.1.103. PMID: 8317379.

[230] Vollrath V, Wielandt AM, Iruretagoyena M, Chianale J. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J. 2006 May 1;395(3):599-609. doi: 10.1042/BJ20051518. PMID: 16426233; PMCID: PMC1462684.

[231] Santhrani, T., & Maheswari, E. (2011). Influence of Vitamin C on phenytoin induced haematotoxicity and oxidative stress in rats.

[232] Kawaguchi R, Yu J, Ter-Stepanian M, Zhong M, Cheng G, Yuan Q, Jin M, Travis GH, Ong D, Sun H. Receptor-mediated cellular uptake mechanism that couples to intracellular storage. ACS Chem Biol. 2011 Oct 21;6(10):1041-51. doi: 10.1021/cb200178w. Epub 2011 Jul 27. PMID: 21774515; PMCID: PMC3199320.

[233] Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006 Dec;169(6):2171-80. doi: 10.2353/ajpath.2006.051078. PMID: 17148679; PMCID: PMC1762462.

[234] Cho, S., Hwang, E.S. Status of mTOR activity may phenotypically differentiate senescence and quiescence. Mol Cells 33, 597–604 (2012). https://doi.org/10.1007/s10059-012-0042-1

[235] Heaton MB, Paiva M, Siler-Marsiglio K. Ethanol influences on Bax translocation, mitochondrial membrane potential, and reactive oxygen species generation are modulated by vitamin E and brain-derived neurotrophic factor. Alcohol Clin Exp Res. 2011 Jun;35(6):1122-33. doi: 10.1111/j.1530-0277.2011.01445.x. Epub 2011 Feb 17. PMID: 21332533; PMCID: PMC3097312.

[236] Sinha P, Kolleck I, Volk HD, Schlame M, Rüstow B. Vitamin E deficiency sensitizes alveolar type II cells for apoptosis. Biochim Biophys Acta. 2002 Jun 13;1583(1):91-8. doi: 10.1016/s1388-1981(02)00189-0. PMID: 12069853.

[237] Yu J, Ling S, Hong J, Zhang L, Zhou W, Yin L, et al. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2023;11:e007479. https://doi.org/10.1136/jitc-2023-007479

[238] McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. ScientificWorldJournal. 2007 Aug 17;7:1165-81. doi: 10.1100/tsw.2007.224. PMID: 17704849; PMCID: PMC5901237.

[239] Balakin E, Yurku K, Ivanov M, Izotov A, Nakhod V, Pustovoyt V. Regulation of Stress-Induced Immunosuppression in the Context of Neuroendocrine, Cytokine, and Cellular Processes. Biology (Basel). 2025 Jan 15;14(1):76. doi: 10.3390/biology14010076. PMID: 39857306; PMCID: PMC11760489.

[240] Gunes M, Rosen ST, Shachar I, Gunes EG. Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors. Front Immunol. 2024 Feb 27;15:1297473. doi: 10.3389/fimmu.2024.1297473. PMID: 38476238; PMCID: PMC10927787.

[241] Bouhlal H, Ouled-Haddou H, Debuysscher V, Singh AR, Ossart C, Reignier A, Hocini H, Fouquet G, Al Baghami M, Eugenio MS, Nguyen-Khac E, Regimbeau JM, Marcq I. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget. 2016 Mar 1;7(9):9832-43. doi: 10.18632/oncotarget.6954. PMID: 26799423; PMCID: PMC4891087.

[242] McCarron JG, Olson ML, Wilson C, Sandison ME, Chalmers S. Examining the role of mitochondria in Ca²⁺ signaling in native vascular smooth muscle. Microcirculation. 2013 May;20(4):317-29. doi: 10.1111/micc.12039. PMID: 23305516; PMCID: PMC3708117.

[243] Zhang X, Buckley C, Lee MD, Chalmers S, Wilson C, McCarron JG. Mitochondria regulate inositol triphosphate-mediated Ca2+ release triggered by voltage-dependent Ca2+ entry in resistance arteries. J Physiol. 2025 May;603(10):2959-2978. doi: 10.1113/JP288022. Epub 2025 May 5. PMID: 40320995; PMCID: PMC12126608.

[244] Ying, Zhongfu & Chen, Keshi & Zheng, Lingjun & Wu, Yi & Li, Linpeng & Wang, Rui & Long, Qi & Yang, Liang & Guo, Jingyi & Yao, Deyang & Li, Yong & Bao, Feixiang & Xiang, Ge & Liu, Jinglei & Huang, Qiaoying & Wu, Zhiming & Hutchins, Andrew & Pei, Duanqing & Liu, Xingguo. (2015). Transient Activation of Mitoflashes Modulates Nanog at the Early Phase of Somatic Cell Reprogramming. Cell metabolism. 23. 10.1016/j.cmet.2015.10.002.

[245] Dagdeviren S, Jung DY, Lee E, Friedline RH, Noh HL, Kim JH, Patel PR, Tsitsilianos N, Tsitsilianos AV, Tran DA, Tsougranis GH, Kearns CC, Uong CP, Kwon JY, Muller W, Lee KW, Kim JK. Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance. Mol Cell Biol. 2016 Nov 14;36(23):2956-2966. doi: 10.1128/MCB.00181-16. PMID: 27644327; PMCID: PMC5108883.

[246] Halestrap AP. The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life. 2012 Jan;64(1):1-9. doi: 10.1002/iub.573. Epub 2011 Nov 30. PMID: 22131303.

[247] Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q, Wu J, Wu C, Hu W, Xu J, Wu C, Jiang J. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J Immunother Cancer. 2025 Sep 21;13(9):e012230. doi: 10.1136/jitc-2025-012230. PMID: 40983342; PMCID: PMC12458742.

[248] Arora S, Thompson PJ, Wang Y, Bhattacharyya A, Apostolopoulou H, Hatano R, Naikawadi RP, Shah A, Wolters PJ, Koliwad S, Bhattacharya M, Bhushan A. Invariant Natural Killer T cells coordinate removal of senescent cells. Med. 2021 Aug 13;2(8):938-950. doi: 10.1016/j.medj.2021.04.014. Epub 2021 May 10. PMID: 34617070; PMCID: PMC8491998.

[249] Aguiar CF, Corrêa-da-Silva F, Gonzatti MB, Angelim MK, Pretti MA, Davanzo GG, Castelucci BG, Monteiro LB, Castro G, Virgilio-da-Silva JV, Ribeiro G, Jaccomo V, Pereira Andrade MC, Costa WL, Gambarini V, Terra FF, Alves-Filho JC, Saraiva Câmara NO, Boroni M, Keller AC, Moraes-Vieira PM. Tissue-specific metabolic profile drives iNKT cell function during obesity and liver injury. Cell Rep. 2023 Jan 31;42(1):112035. doi: 10.1016/j.celrep.2023.112035. Epub 2023 Jan 23. PMID: 36848232.

[250] Van Kaer L, Parekh VV, Wu L. The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products. Front Immunol. 2015 May 13;6:226. doi: 10.3389/fimmu.2015.00226. PMID: 26029211; PMCID: PMC4429631.

[251] Lustyik G. Age-dependent alterations of the intracellular water and electrolyte content of heart and muscle cells. Arch Gerontol Geriatr. 1986 Dec;5(4):291-6. doi: 10.1016/0167-4943(86)90031-2. PMID: 3827401.

[252] Polychronopoulou E, Braconnier P, Burnier M. New Insights on the Role of Sodium in the Physiological Regulation of Blood Pressure and Development of Hypertension. Front Cardiovasc Med. 2019 Sep 16;6:136. doi: 10.3389/fcvm.2019.00136. PMID: 31608291; PMCID: PMC6756190.

[253] Simental-Mendía M, Lara-Arias J, Álvarez-Lozano E, Said-Fernández S, Soto-Domínguez A, Padilla-Rivas GR, Martínez-Rodríguez HG. Cotransfected human chondrocytes: over-expression of IGF-I and SOX9 enhances the synthesis of cartilage matrix components collagen-II and glycosaminoglycans. Braz J Med Biol Res. 2015 Dec;48(12):1063-70. doi: 10.1590/1414-431X20154732. Epub 2015 Oct 6. PMID: 26445237; PMCID: PMC4661021.

[254] Kiourtis C, Terradas-Terradas M, Gee LM, May S, Georgakopoulou A, Collins AL, O'Sullivan ED, Baird DP, Hassan M, Shaw R, Tan EH, Müller M, Engelmann C, Andreola F, Hsieh YC, Reed LH, Borthwick LA, Nixon C, Clark W, Hanson PS, Sumpton D, Mackay G, Suzuki T, Najumudeen AK, Inman GJ, Campbell A, Barry ST, Quaglia A, Morris CM, LeBeau FEN, Sansom OJ, Kirschner K, Jalan R, Oakley F, Bird TG. Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ. Nat Cell Biol. 2024 Dec;26(12):2075-2083. doi: 10.1038/s41556-024-01543-3. Epub 2024 Nov 13. PMID: 39537753; PMCID: PMC11628396.

[255] Redini F, Galera P, Mauviel A, Loyau G, Pujol JP. Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett. 1988 Jul 4;234(1):172-6. doi: 10.1016/0014-5793(88)81327-9. PMID: 3164687.

[256] Papakonstantinou E, Karakiulakis G, Tamm M, Perruchoud AP, Roth M. Hypoxia modifies the effect of PDGF on glycosaminoglycan synthesis by primary human lung cells. Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L825-34. doi: 10.1152/ajplung.2000.279.5.L825. PMID: 11053016.

[257] Ahmad T, Crescenzi R, Kon V, Kirabo A, Shelton EL. Sodium-Directed Crosstalk Between Immune Cells and Lymphatic Vessels. Curr Hypertens Rep. 2025 Jan 15;27(1):7. doi: 10.1007/s11906-024-01322-3. PMID: 39812718; PMCID: PMC11735487.

[258] Horiba S, Kawamoto M, Tobita R, Kami R, Ogura Y, Hosoi J. M1/M2 Macrophage Skewing is Related to Reduction in Types I, V, and VI Collagens with Aging in Sun-Exposed Human Skin. JID Innov. 2023 Aug 12;3(6):100222. doi: 10.1016/j.xjidi.2023.100222. PMID: 37789949; PMCID: PMC10542643.

[259] Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. Front Immunol. 2019 May 24;10:1084. doi: 10.3389/fimmu.2019.01084. Erratum in: Front Immunol. 2020 Feb 25;11:234. doi: 10.3389/fimmu.2020.00234. PMID: 31178859; PMCID: PMC6543837.

[260] Roelfsema F, Veldhuis JD. Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index. Neuroendocrinology. 2016;103(3-4):335-44. doi: 10.1159/000438904. Epub 2015 Jul 28. PMID: 26228064; PMCID: PMC4731317.

[261] Avtanski D, Novaira HJ, Wu S, Romero CJ, Kineman R, Luque RM, Wondisford F, Radovick S. Both estrogen receptor α and β stimulate pituitary GH gene expression. Mol Endocrinol. 2014 Jan;28(1):40-52. doi: 10.1210/me.2013-1245. Epub 2013 Jan 1. PMID: 24284820; PMCID: PMC3874459.

[262] Kuryłowicz A. Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines. 2023 Feb 24;11(3):690. doi: 10.3390/biomedicines11030690. PMID: 36979669; PMCID: PMC10045924.

[263] Shi Z, Xin M. Endocrine Hormones and Their Impact on Pubertal Gynecomastia. J Clin Med. 2024 Dec 30;14(1):158. doi: 10.3390/jcm14010158. PMID: 39797240; PMCID: PMC11721017.

[264] Jeong S, Yoon M. 17β-Estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression. Acta Pharmacol Sin. 2011 Feb;32(2):230-8. doi: 10.1038/aps.2010.198. PMID: 21293475; PMCID: PMC4009938.

[265] Cavaillès V, Gompel A, Portois MC, Thénot S, Mabon N, Vignon F. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J Mol Endocrinol. 2002 Jun;28(3):165-75. doi: 10.1677/jme.0.0280165. PMID: 12063183.

[266] Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun. 2007 Jul 20;359(1):102-7. doi: 10.1016/j.bbrc.2007.05.059. Epub 2007 May 21. PMID: 17524358.

[267] Huang B, Hu X. Causality of Aging Hallmarks. Aging Dis. 2025 May 20. doi: 10.14336/AD.2025.0541. Epub ahead of print. PMID: 40423632.

[268] 金, . 英杰 . (2026). Methylation homeostasis: an epigenetic master switch for immune regulation of maternal chimeric immune cells and autologous tissue immune cells. Zenodo. https://doi.org/10.5281/zenodo.18685606

[269] Shcherbik N, Pestov DG. The Impact of Oxidative Stress on Ribosomes: From Injury to Regulation. Cells. 2019 Nov 2;8(11):1379. doi: 10.3390/cells8111379. PMID: 31684095; PMCID: PMC6912279.

[270] Trajano LADSN, Trajano ETL, Silva MADS, Stumbo AC, Mencalha AL, Fonseca ASD. Genomic stability and telomere regulation in skeletal muscle tissue. Biomed Pharmacother. 2018 Feb;98:907-915. doi: 10.1016/j.biopha.2018.01.004. Epub 2018 Jan 8. PMID: 29571261.

[271] Marzuca-Nassr GN, Alegría-Molina A, SanMartín-Calísto Y, Artigas-Arias M, Huard N, Sapunar J, Salazar LA, Verdijk LB, van Loon LJC. Muscle Mass and Strength Gains Following Resistance Exercise Training in Older Adults 65-75 Years and Older Adults Above 85 Years. Int J Sport Nutr Exerc Metab. 2023 Oct 24;34(1):11-19. doi: 10.1123/ijsnem.2023-0087. PMID: 37875254.

[272] Heidari D, Shirvani H, Bazgir B, Shamsoddini A. The Resistance Training Effects on Skeletal Muscle Stem Cells in Older Adult: A Systematic Review and Meta-Analysis. Cell J. 2023 Aug 1;25(8):513-523. doi: 10.22074/cellj.2023.1986679.1206. PMID: 37641413; PMCID: PMC10542207.

[273] Watase GJ, Nelson JO, Yamashita YM. Nonrandom sister chromatid segregation mediates rDNA copy number maintenance in Drosophila. Sci Adv. 2022 Jul 29;8(30):eabo4443. doi: 10.1126/sciadv.abo4443. Epub 2022 Jul 27. PMID: 35895823; PMCID: PMC9328678.

[274] Nelson JO, Watase GJ, Warsinger-Pepe N, Yamashita YM. Mechanisms of rDNA Copy Number Maintenance. Trends Genet. 2019 Oct;35(10):734-742. doi: 10.1016/j.tig.2019.07.006. Epub 2019 Aug 5. PMID: 31395390; PMCID: PMC6744303.

[275] Gál, Z., Boukoura, S., Oxe, K.C. et al. Hyper-recombination in ribosomal DNA is driven by long-range resection-independent RAD51 accumulation. Nat Commun 15, 7797 (2024). https://doi.org/10.1038/s41467-024-52189-6

[276] Schuurman M, Wallace M, Sahi G, Barillaro M, Zhang S, Rahman M, Sawyez C, Borradaile N, Wang R. N-acetyl-L-cysteine treatment reduces beta-cell oxidative stress and pancreatic stellate cell activity in a high fat diet-induced diabetic mouse model. Front Endocrinol (Lausanne). 2022 Aug 25;13:938680. doi: 10.3389/fendo.2022.938680. PMID: 36093092; PMCID: PMC9452715.

[277] Sá Gomes E Farias AV, de Lima Cavalcanti MP, de Passos Junior MA, Vechio Koike BD. The association between sleep deprivation and arterial pressure variations: a systematic literature review. Sleep Med X. 2022 Jan 26;4:100042. doi: 10.1016/j.sleepx.2022.100042. PMID: 35169694; PMCID: PMC8829775.

[278] Yuan D, Chu J, Lin H, Zhu G, Qian J, Yu Y, Yao T, Ping F, Chen F, Liu X. Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis. Front Cardiovasc Med. 2023 Jan 16;9:1109445. doi: 10.3389/fcvm.2022.1109445. PMID: 36727029; PMCID: PMC9884709.

[279] Zhu J, Duan Y, Duo D, Yang J, Bai X, Liu G, Wang Q, Wang X, Qu N, Zhou Y, Li X. High-altitude Hypoxia Influences the Activities of the Drug-Metabolizing Enzyme CYP3A1 and the Pharmacokinetics of Four Cardiovascular System Drugs. Pharmaceuticals (Basel). 2022 Oct 21;15(10):1303. doi: 10.3390/ph15101303. PMID: 36297415; PMCID: PMC9612038.

[280] Mallet RT, Burtscher J, Richalet JP, Millet GP, Burtscher M. Impact of High Altitude on Cardiovascular Health: Current Perspectives. Vasc Health Risk Manag. 2021 Jun 8;17:317-335. doi: 10.2147/VHRM.S294121. PMID: 34135590; PMCID: PMC8197622.

[281] Rajai N, Ahmad A, Toya T, Sara JD, Herrmann J, Lerman LO, Lerman A. Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease. Eur J Prev Cardiol. 2023 Feb 14;30(3):209-216. doi: 10.1093/eurjpc/zwac184. PMID: 35989450; PMCID: PMC10787540.

[282] 金, . 英杰 . (2026). The hypothesis of nodules as a systematic pathological model of steady-state excursion intermediate states. Zenodo. https://doi.org/10.5281/zenodo.18212580

[283] Mizuno Y, Pan S, Zhou T, Kehoe PG, Feng Earley Y. Elevated Na+/K+ Ratio in Alzheimer’s Disease: A Potential Biomarker for Braak Stage. International Journal of Molecular Sciences. 2026; 27(3):1247. https://doi.org/10.3390/ijms27031247

[284] Laganiere S, Yu BP, Fernandes G. Studies on membrane lipid peroxidation in omega-3 fatty acid-fed autoimmune mice: effect of vitamin E supplementation. Adv Exp Med Biol. 1990;262:95-102. doi: 10.1007/978-1-4613-0553-8_8. PMID: 2321492.

[285] Cotta OR, Santarpia L, Curtò L, Aimaretti G, Corneli G, Trimarchi F, Cannavò S. Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. J Med Case Rep. 2011 Jul 11;5:301. doi: 10.1186/1752-1947-5-301. PMID: 21745362; PMCID: PMC3141726.

[286] Huang B L. The mechanism significance and treatment of aging[M/OL]. figshare, 2024 (original work published 1998): Section 11.10. https://doi.org/10.6084/m9.figshare.29118716.v1

[287] Planterose Jiménez B, Liu F, Caliebe A, Montiel González D, Bell JT, Kayser M, Vidaki A. Equivalent DNA methylation variation between monozygotic co-twins and unrelated individuals reveals universal epigenetic inter-individual dissimilarity. Genome Biol. 2021 Jan 5;22(1):18. doi: 10.1186/s13059-020-02223-9. PMID: 33402197; PMCID: PMC7786996.

[288] Qian W, Van Houten B. Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods. 2010 Aug;51(4):452-7. doi: 10.1016/j.ymeth.2010.03.006. Epub 2010 Mar 25. PMID: 20347038.

[289] Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010;17(7):672-97.

[290] Connolly, Niamh; Duessmann, Heiko; Anilkumar, Ujval; Huber, Heinrich J.; Prehn, Jochen (2014). Single-Cell Imaging of Bioenergetic Responses to Neuronal Excitotoxicity and Oxygen and Glucose Deprivation. Royal College of Surgeons in Ireland. Journal contribution. https://hdl.handle.net/10779/rcsi.10792115.v2

[291] Wang W, Yang X, Kawai T, López de Silanes I, Mazan-Mamczarz K, Chen P, Chook YM, Quensel C, Köhler M, Gorospe M. AMP-activated protein kinase-regulated phosphorylation and acetylation of importin alpha1: involvement in the nuclear import of RNA-binding protein HuR. J Biol Chem. 2004 Nov 12;279(46):48376-88. doi: 10.1074/jbc.M409014200. Epub 2004 Sep 1. PMID: 15342649.

[292] Bai J, Chen P, Zhou Q, Tie X, Xia X, Wang Y, Jin L. KPNA2/KPNB1 promotes the malignant progression of gastric cancer induced by M2 macrophage polarization. Tissue Cell. 2025 Apr;93:102714. doi: 10.1016/j.tice.2024.102714. Epub 2024 Dec 31. PMID: 39765137.

[293] Deng Y, Lin A, Lai C, He W, Li J, Zhang N, Huang S, Tong L, Lai Y, Huo Y, Xu J. Combined inhibition of importin-β and PBR enhances osteogenic differentiation of BMSCs by reducing nuclear accumulation of glucocorticoid receptor and promoting its mitochondrial translocation. J Steroid Biochem Mol Biol. 2025 Jun;250:106731. doi: 10.1016/j.jsbmb.2025.106731. Epub 2025 Mar 11. PMID: 40081506.

[294] Yao WJ, Wu CH, Wang ST, Chang CJ, Chiu NT, Yu CY. Differential changes in regional bone mineral density in healthy Chinese: age-related and sex-dependent. Calcif Tissue Int. 2001 Jun;68(6):330-6. doi: 10.1007/s002230001210. Epub 2001 Apr 30. PMID: 11685419.

TCM practitioner & 6-year cancer survivor — hello from California

Fri, 15 May 2026 14:02:25 +0000

Hello everyone,

My name is Ray, and I am a Traditional Chinese Medicine (TCM) practitioner based in California. I have been reading LongeCity threads for a while and finally decided to join.

A bit about my background: Six years ago, I was diagnosed with cancer. That experience completely transformed my relationship with health and medicine. While I pursued conventional treatment, I also leaned heavily into the TCM traditions I had been studying — particularly Jing-nourishing herbs, kidney Yang support formulations, and adaptogenic mushrooms like reishi and cordyceps.

In Chinese medicine, we think about health through the lens of vital essence (Jing), life force (Qi), and spirit (Shen). The concept of Jing is especially relevant to longevity — it is essentially your constitutional reserve, the deep energy you inherit and slowly spend over a lifetime. TCM has centuries of accumulated knowledge about herbs and formulations that are believed to preserve and restore Jing.

Some of the herbs I work with most:

He Shou Wu (Fo-Ti) — one of the most revered Jing tonics in the Chinese pharmacopoeia
Eucommia bark — traditionally used to strengthen the kidneys and support structural health
Cistanche — known as "desert ginseng," used for kidney Yang and vitality
Reishi and Cordyceps — adaptogenic mushrooms with growing research backing their immune and longevity properties

I am fascinated by how modern longevity research is starting to validate some of these traditional approaches — the overlap between TCM kidney-essence theory and modern understanding of hormonal health, mitochondrial function, and cellular aging is striking.

I have been developing herbal formulations specifically focused on mens vitality and healthy aging, drawing on classical TCM recipes updated with modern quality standards. Would love to connect with others here who are interested in the intersection of traditional herbal medicine and evidence-based longevity science.

Happy to answer any questions about TCM approaches to longevity, or share more about specific herbs and formulations. Looking forward to learning from this community as well.

— Ray

Unlocking The Secrets Of Exceptional Longevity

Sun, 10 May 2026 14:06:45 +0000

Ergothioneine Improves Memory, Sleep, Liver Function, And Neurodegeneration

Sun, 03 May 2026 14:04:45 +0000

Supplement Stack Review and Recommendations

Sun, 03 May 2026 09:50:29 +0000

Supplements I take for liver health and muscle gain

Sun, 03 May 2026 09:39:26 +0000

Greetings from Hong Kong

Mon, 27 Apr 2026 02:20:06 +0000

Greetings all.

I'm 50 and living in Hong Kong. I am interested in healthspan. I am a teacher. In my life I have seen many miracles, including many wild inventions becoming reality: the Dick Tracy watch, the talking car from Knight Rider etc. With this in mind I asked some of my younger students for their wildest predictions for the future. Something that came up more than once was that one day "people will live forever".

My 2 topics of interest have been IRON detox and mTORC1 inhibition.

I think I have had some success in both of these. If you are interested in either of these, feel free to ask me about that.

My sticking point at the moment is that I cannot achieve both these goals at the same time because what I'm doing to stop mTORC interferes with the process of reducing free dysreglated iron.

Nice to meet you all.

Do Centenarians Have A Unique Immune System?

Sun, 26 Apr 2026 14:22:16 +0000

Attached Thumbnails

(noting piarectam-ish:triple memory)Which qulitatively different nootropic would you like to be part of the human Genome

Thu, 23 Apr 2026 00:23:29 +0000

You might have heard of the doogie mouse, which had doubled intelligence, the doogie rat had triple memory.

I perceive this is from modulating ampa glutamate receptors. So, at completely different nootropics, which do you think would be highly beneficial to humans while causing greater intelligence?

Just type!

Indie iOS developer, supplement A/B testing on myself

Tue, 21 Apr 2026 15:08:23 +0000

Hi all, been lurking here for a while and finally made an account. Short background: indie iOS developer by trade, in my mid 30s. Got into nootropics and the quantified-self side of things maybe five years ago, mostly after reading longecity threads on B-complex and creatine. No formal science background, but I read papers carefully and I run most things on myself before I recommend them to anyone. What I'm mainly interested in: muscle-performance supplements (creatine, beta-alanine, citrulline), sleep stacks that don't build tolerance, and whether any of the newer NAD+ precursors actually do something measurable in a 30-40 year old. I'm skeptical of most of it until I see a clean n=1 run. On that note, I've been working on a small iOS app called StackLab that runs structured A/B tests against Apple Health data (workouts, HRV, sleep) so I can actually tell if a supplement is doing something or if it's placebo + recency bias. Still building it out, no link to share yet, but if anyone here has opinions on how to handle confounders cleanly in n=1 I'd love to hear your experience. Looking forward to contributing. Thanks for letting me in.

New LSD Analog has brain growth potential

Mon, 20 Apr 2026 17:53:01 +0000

Transposing two atoms, they created JRT, an
"exceptionally potent analogue of LSD with lower hallucinogenic potential"

From
https://www.pnas.org/doi/10.1073/pnas.2416106122

"Psychedelic compounds, such as lysergic acid diethylamide (LSD), can promote the growth of atrophied cortical neurons, which is relevant to the treatment of numerous brain conditions. However, their hallucinogenic properties have limited their adoption as medicines and preclude their use in certain patient populations, such as those with schizophrenia or a family history of psychosis. By transposing only two atoms, we have created JRT, an exceptionally potent analogue of LSD with lower hallucinogenic potential, improved pharmacological selectivity, and the ability to produce a wide range of therapeutic effects. Our work highlights the potential of rationally designed, nonhallucinogenic analogues of psychedelics for treating diseases where the use of psychedelics is contraindicated.

Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the molecular design and de novo total synthesis of (+)-JRT, a structural analogue of lysergic acid diethylamide (LSD) with lower hallucinogenic potential and potent neuroplasticity-promoting properties. In addition to promoting spinogenesis in the cortex, (+)-JRT produces therapeutic effects in behavioral assays relevant to depression and cognition without exacerbating behavioral and gene expression signatures relevant to psychosis. This work underscores the potential of nonhallucinogenic psychoplastogens for treating diseases where the use of psychedelics presents significant safety concerns."

The Immune System Impacts Longevity: What To Measure

Sun, 19 Apr 2026 15:05:03 +0000

Attached Thumbnails

[ALCOR] Remembering Mike Perry

Thu, 16 Apr 2026 18:50:39 +0000

Remembering Mike Perry Alcor Announcement · April 15, 2026 We are reaching out today with news that will be difficult for many in our community to hear. Last evening, our colleague Dr. R. Michael Perry was involved in a motor vehicle accident as a pedestrian. He was transported to the ICU in critical condition, where […]

The post Remembering Mike Perry appeared first on Alcor Life Extension Foundation.

View the full article

[ALCOR] Remembering Mike Perry

Thu, 16 Apr 2026 18:50:39 +0000

The post Remembering Mike Perry appeared first on Alcor Life Extension Foundation.

View the full article

Hello, licensed mental health clinician and fitness enthusiast here

Wed, 15 Apr 2026 02:34:03 +0000

Hi, nice to meet everyone. I am 36, M, 6' 4" and a licensed social worker. I grew up morbidly obese, but at age 13 started lifting weights and educating myself on nutrition. haven't stopped lifting or eating right for my goals to this day. I've been employed in human services for about 14 years now, 7 of them as a professional. My 20s were rough, as was my childhood. Did a lot of detrimental shit to myself. Alas, I crawled through a hundred yards of shit and came out clean on the other side. I have an extensive background in childhood and adolescent development, psychopharmacology, nutrition and lifting weights. I also play guitar, piano, bass and sing. Started at age 13, another healthy habit I've kept up. I enjoy reading, writing and recording my music, and watching YouTube. I love my job. I am astoundingly lonely lol all my friends are married with kids so I rarely see them. Lost my lady of 10 years when I was 30.

Dunno what I'll do here. Probably just browse the forums and contribute where I can.

Thanks for reading.

Tracking A Biomarker Of Neurodegeneration (22-Test Analysis)

Sun, 12 Apr 2026 17:18:51 +0000

Attached Thumbnails

Does Insulin Sensitivity Cause Hashimotos & is this reversable?

Fri, 10 Apr 2026 19:44:52 +0000

Hi,

So I did a few blood tests recently and the findings were:

Abnormal / Key Findings

High fasting insulin: 13.5 mIU/L
High fasting insulin resistance index (HOMA-IR): 2.2
High Thyroid Peroxidase Antibodies (TPOAb)
High Thyroglobulin Antibodies (TgAb)
Low SHBG
Slightly elevated CRP
Slightly elevated afternoon cortisol
Low Vitamin D

Relevant Symptoms / Correlated Issues

Brain fog
Fatigue / low energy
Hair thinning / dry skin
Skin issues (psoriasis-type)
Light sensitivity
Difficulty losing fat
Bloating
Depression, anxiety.

What I wanted to know is what changes would you recommend I make, is this hashimotos? Or are the anti-bodies reversable through diet?

Normal / Reassuring Results

Fasting glucose: 4.1 mmol/L
TSH
Free T4
Free T3
Testosterone
Prolactin
Oestradiol
Ferritin
Full Blood Count
Calprotectin (low = no gut inflammation)

Is Running Overrated?

Thu, 09 Apr 2026 02:19:51 +0000

Running has sharply diminishing returns — about 30 minutes a week captures most of the longevity benefit. Beyond that, you’re not gaining much.
Walking is the standout: 12,000 steps/day is associated with a ~75% reduction in all-cause mortality. Running 10,000 steps doesn’t come close to walking 10,000 steps.
There’s four-pillars of exercise for longevity: aerobic, HIIT, strength training, walking. Total required time: about 60–90 minutes/week for the structured exercise.
Sleep’s longevity data is weaker than most people assume — it didn’t make the top tier of habits when ranked by mortality reduction.
Biological age clocks are evolving fast (PhenoAge → BortzAge), but I don’t find them useful for choosing habits compared with all-cause mortality studies.

https://www.unaging.com/videos/is-running-overrated/

Infammation theory of depression and implications for treatment

Sat, 04 Apr 2026 09:01:43 +0000

Hi All,

One of the better known theories of depression is the idea that there is a chronic, low-grade (low intensity) inflammatory process in the brain. The time it takes to gradually resolve or ameliorate this inflammation may be the reason why so many drugs (and other substances) take a relatively long time (often 4 weeks or more) to produce substantial results.

This may have important implication for the treatment of depression. The hypothesis that logically follows, is that anti-inflammatory substances, as long as they cross the brain-blood-barrier, can ameliorate, if not eliminate, the inflammation, thus treating the depression.

The question, therefore, is what substances (herbs, vitamins, drugs, etc.) have the strongest anti-inflammatory action?

What substances have you taken that mitigated your depression, but took 1 week or longer to do so?

Hi there

Sun, 29 Mar 2026 23:29:59 +0000

Hi everyone, I'm jeff and I'm interested in maximizing longevity and cognitive performance. I'm about to hit my mid 20's so I'm looking to extend my youth as long as possible with compounds like rapamycin, metformin + galantamine, cae enhancers like selegiline or bpap, statins, telmisartan etc... I'm also interested in nootropics like cerebrolysin and crebinostat. I'm happy to learn and look forward to my time on this forum

Hi I am Ryan

Sun, 29 Mar 2026 20:12:20 +0000

Hi I am Ryan. I have been interested in biohacking and getting at root causes for health issues for over ten years. Hope to add my perspective to assist the community.

"Why Low-Absorption Berberine is a Better AMPK Strategy" by ChatGPT

Sun, 29 Mar 2026 17:56:59 +0000

WHY LOW-ABSORPTION BERBERINE IS A BETTER AMPK STRATEGY

ChatGPT

In the world of biohacking, "more absorption" is usually the gold standard. We see supplements wrapped in liposomes, dissolved in oils, or spiked with piperine (black pepper extract) to force as much of the compound into the bloodstream as possible.

But when it comes to AMPK (Adenosine Monophosphate-activated Protein Kinase)—the body's "master metabolic switch"—the high-absorption approach might actually be counterproductive. If your goal isn't a massive metabolic spike but rather a steady, underlying cellular hum, low-absorbance Berberine HCL might be the more sensible tool.

Understanding the AMPK "Dime Switch"

AMPK is an enzyme that senses energy levels. When cellular energy (ATP) is low, AMPK flips "on" to burn fat, clear out old cellular junk (autophagy), and improve insulin sensitivity.

l The Spike Method: Taking a high-dose, high-absorption activator is like slamming a light switch. You get a surge of activation, but you also risk "metabolic hangovers"—crashes in blood sugar, fatigue, or gastrointestinal distress.

l The Steady Method: Low-absorbance Berberine acts more like a dimmer switch. It provides a gentle, persistent nudge to the mitochondria without overwhelming the system.

Why Low Absorption is a Feature, Not a Bug

Berberine is notoriously poor at entering the bloodstream. Only about 1-5% of an oral dose typically makes it into systemic circulation. While marketers see this as a failure, metabolic researchers see it as an opportunity for three reasons:

1. The "Gut-First" Activation

A large portion of Berberine’s magic happens in the intestines before it ever hits your blood. It interacts with the gut microbiome and the lining of the digestive tract to stimulate GLP-1 (the hormone targeted by modern weight-loss drugs). By staying in the gut longer due to low absorption, Berberine provides a localized, steady signaling effect that tells the brain and liver to manage energy better.

2. Avoiding the "Mitochondrial Hammer"

Berberine activates AMPK by subtly inhibiting Complex I of the mitochondria. In high, highly-absorbent doses, this can feel like a "toxic" stressor, leaving you feeling wiped out or "flat" during workouts. A low-absorbance dose (like a 200 mg HCL) provides a "hormetic" stress—just enough to trigger repair and fat-burning, but not enough to drain your battery.

3. Half-Life Management

Berberine leaves the body quickly. If you use a "super-absorbed" version, you get a sharp peak and a rapid drop. By using a standard HCL powder without enhancers, the body processes it at its own natural pace. This creates a smoother "arc" of activation, making it much easier to maintain that "steady underlying amount" you’re looking for.

The Sensible Protocol

If you are using a lower-dose, low-absorbance Berberine (such as 200 mg), you are effectively micro-dosing a metabolic signal. This approach is ideal for those who:

l Are not currently on medication.

l Want the longevity benefits of AMPK (autophagy and mitochondrial biogenesis).

l Want to avoid the digestive "disaster" often associated with 1500 mg+ doses.

Summary

In a culture of "more is better," Berberine stands out as a compound where less is often more sustainable. By choosing a low-absorbance form, you aren't fighting your biology; you’re whispering to it. It’s the difference between a metabolic sprint and a long, healthy walk.

Comprehensive decoding of aging pathways: hypothesis of metabolic homeostasis cascade collapse convergence and re-drive

Sun, 29 Mar 2026 04:31:20 +0000

Introduction

The current theory of static aging defines the essence of aging as static wear and tear, but it is difficult to explain three core paradoxes: inter-individual heterogeneity, non-linear acceleration, and cliff-like senescence are the three main paradoxes of aging. These three phenomena themselves constitute the falsification of single-causation models.

In this paper, dynamic aging theory is constructed based on metabolic flux homeostasis, and its framework has three explanatory powers: Firstly, through the multi-parameter phase space of metabolic flux homeostasis, Computationally explain the diversity of aging: the set-point bias of AMPK-mTOR-PGC-1α-PPARα in different individuals determines the emergence of differential pathological phenotypes; Second, multi-factorial convergence to the critical node of mitochondrial functional decline is used to account for phenotypic convergence in aging; Finally, by revealing the mechanism by which the dominant factors of aging switch with the phase transitions of metabolic homeostasis, the nonlinear dynamic nature of accelerated aging and cliff aging is explained.

金, . 英杰 . (2026). Comprehensive decoding of aging pathways: hypothesis of metabolic homeostasis cascade collapse convergence and re-drive model(V112). Zenodo. https://doi.org/10.5...zenodo.19249525

the English version is translated for non-native speakers, there may be inaccuracies, distortions, or misalignments in conceptual frameworks. If any framework is ambiguous, please refer to the Chinese version below for clarification.

金, . 英杰 . (2026). 衰⽼路径全⾯破译:代谢稳态级联崩塌收敛再驱动模型假说(V112). Zenodo. https://doi.org/10.5...zenodo.19246452

Here is the English translation:

Note to non-native English readers: As this English version was AI-translated, there may be inaccuracies, distortions, or misaligned conceptual frameworks. If any framework appears ambiguous, please refer to the Chinese version above for clarification.

In this 112 update and correction, I have falsified the replicative senescence theory and proposed a new theoretical framework. Citing original text section 5.7: 5.7 The Field Damage Theory of rDNA Shortening and Recovery Mechanisms.

As stated in reference [269], rRNA constitutes the structural and functional core of ribosomes. ROS can affect RNA through multiple pathways [34,35,36,37], including chemical modifications of bases and sugar moieties, generation of abasic sites, and strand breaks. Guanine is the most susceptible nucleobase to oxidation and has been most extensively studied in this regard. One oxidized form of guanine, 8-hydroxyguanine (8-oxoguanine; 8-oxo-G; 8-oxo-G), is a ubiquitous oxidative lesion readily detectable in cellular nucleic acids. When 8-oxo-G is present in mRNA, it interferes with decoding, potentially forming Hoogsteen pairs with adenine when the base rotates around the N-glycosidic bond. The altered base-pairing capability of 8-oxo-G also perturbs RNA folding. A recent study revealed multiple outcomes when 8-oxo-G was incorporated into model RNA substrates, ranging from stabilization of existing structural motifs to their destabilization and rearrangement into new structures. Since ribosome translation activity depends on numerous precisely tuned conformational changes and movements within its rRNA framework, oxidation of critical bases essential for maintaining correct rRNA structure may impair ribosomal function. Therefore, the requirement to tolerate certain levels of oxidation was likely a factor shaping ribosomal evolution. Many guanines are significantly eliminated from mitochondrial rRNA, accompanied by overall reduction in RNA content.

As stated in reference [270], the muscle regeneration process comprises four interconnected stages: necrosis, inflammation, activation and differentiation of satellite cells, maturation of newly formed myofibrils, and muscle remodeling. During the inflammatory phase, which occurs during muscle injury repair, reactive oxygen species (ROS) are massively produced, primarily present in neutrophils and M2 macrophages. Furthermore, MAPK (mitogen-activated protein kinase), NFκB (nuclear factor kappa B), and AP-1 (activator protein 1) activated by ROS induce protective responses in injured muscle through ROS activation. Additionally, antioxidant enzymes such as superoxide dismutase 2, glutathione peroxidase, and catalase increase during the initial days after injury. Thus, ROS activate important signaling pathways for muscle repair. However, impaired oxidative stress may cause secondary damage to uninjured fibers.

As stated in reference [271], resistance exercise training (RET) can be effectively applied to increase muscle mass and function in older adults aged 65-75 years. However, there has been speculation that individuals over 85 years respond less favorably to RET benefits. This study compared the effects of RET on muscle mass and function between healthy older adults aged 65-75 years and those aged 85 years and above. We examined 17 healthy older adults aged 65-75 years (65-75 years, n=13/4 [female/male]; 68±2 years; 26.9±2.3 kg/m²) and 12 healthy older adults aged 85+ years (85+ years, n=7/5 [female/male]; 87±3 years; 26.0±3.6 kg/m²) undergoing 12 weeks of whole-body RET (three times per week). Before and after 6 and 12 weeks of training, we assessed quadriceps and lumbar level 3 muscle cross-sectional area (computed tomography), whole-body lean mass (dual-energy X-ray absorptiometry), strength (one-repetition maximum test), and physical performance (Timed Up and Go and Short Physical Performance Battery). Twelve weeks of RET increased quadriceps cross-sectional area by 10%±4% and 11%±5% respectively (from 46.5±10.7 to 51.1±12.1 cm², and from 38.9±6.1 to 43.1±8.0 cm²; p<.001; η² = 0.67); whole-body lean mass increased by 2%±3% and 2%±3% (p=.001; η²=.22); one-repetition maximum leg extension strength improved by 38%±20% and 46%±14% respectively in the old 65-75 and old 85+ groups (p<0.001; η² = 0.77). RET responses did not differ between groups (time×group, all p>0.60; all η²≤0.012). Short Physical Performance Battery and Timed Up and Go physical performance both improved (all p < 0.01; η² ≥ 0.22), with no between-group differences (time×group, p > 0.015; η² ≤ 0.07). Extended RET increases muscle mass, strength, and physical performance in aging populations, with no significant differences between 65-75 year-olds and 85+ year-olds.

As stated in reference [272], this study demonstrates that resistance training significantly increases muscle stem cell content... In older adults, satellite cell number significantly increased after 12 weeks of resistance training. Resistance training significantly increased satellite cell number in Type II muscle fibers in older adults... This systematic review and meta-analysis shows that resistance training in older adults can significantly increase muscle stem cells.

Based on the above four articles, it can be inferred that the current replicative senescence theory has boundary limitations in its application scope. Replicative senescence is a typical wear-and-tear theory of aging, within whose theoretical framework there is no concept of recovery—unidirectional, irreversible wear constitutes its core definition of aging. However, this is merely an erroneous extrapolation that overgeneralizes the in vitro passage model to in vivo contexts.

Oxidative stress damages rDNA, leading to loss of rDNA array copies. If we follow the replicative senescence path推演 [deduction], human exercise would trigger free radical formation and oxidative stress; this oxidative signal drives muscle growth, while simultaneously these free radicals would damage rDNA arrays. However, this logical deduction is falsified by resistance exercise—faced with empirical cases where individuals maintaining regular long-term resistance exercise preserve greater muscle mass, this argument cannot hold. For if long-term resistance exercise were maintained, ROS would damage rDNA arrays and inhibit self-renewal of muscle satellite stem cells; during aging, excessive exercise should lead to severe rDNA array copy loss, preventing muscle satellite stem cells from maintaining appropriate numbers and causing muscle atrophy. Yet reality shows the opposite, indicating either that oxidative stress cannot drive rDNA array copy number loss, or that human stem cells possess rDNA array recovery mechanisms.

Given that oxidative stress-driven rDNA array copy number loss has been confirmed, human stem cells must necessarily possess rDNA array recovery mechanisms; otherwise, the anti-aging benefits of resistance exercise and other forms of exercise would not exist.

As stated in reference [273], unequal sister chromatid exchange (USCE) allows cells to restore rDNA copy number on one sister chromatid at the expense of the other. This phenomenon specifically occurs in Drosophila male germline stem cells (GSCs)—these cells undergo asymmetric division to produce one self-renewing stem cell and one daughter cell entering the differentiation program, during which the chromatid with restored rDNA copy number is preferentially retained in the stem cell lineage, while the copy-damaged one enters the differentiated daughter cell.

As stated in reference [274], in Saccharomyces cerevisiae, rDNA copy number (CN) maintenance depends on competitive occupancy between the Pol I-UAF complex and the Sir2-UAF complex. When CN is high, Pol I-UAF binds rDNA promoters, blocking further copy number expansion through transcription-replication coupled negative feedback; when CN decreases due to oxidative stress or recombination, the Sir2-UAF complex relieves inhibition of the bidirectional promoter E-pro, necessarily initiating intra-array homologous recombination (intra-array HR), driving rDNA gene conversion and amplification to achieve copy number recovery. This "high-suppression, low-amplification" bidirectional homeostatic switch enables rDNA arrays to actively count and self-recover, rather than undergoing telomere-like unidirectional depletion.

As stated in reference [275], when rDNA undergoes double-strand breaks (DSBs), a specialized nucleolar DNA damage response (n-DDR) is activated; upon activation of this response, rDNA migrates from the nucleolar interior to the nucleolar periphery to form "nucleolar caps," within this subnuclear structure dedicated homologous recombination (HR) repair occurs. In this process, BLM (Bloom syndrome) helicase plays a critical function, promoting recombination repair by unwinding DNA double-strand structures—BLM-deficient cells exhibit rDNA recombination rates exceeding 10%, proving this enzyme is a core regulatory factor for human rDNA genomic stability maintenance, ensuring rDNA array integrity through promoting the HR pathway.

Through the above literature, it can be inferred that rDNA recovery mechanisms exist in both humans and animals. Combined with the phenomenon of resistance exercise effectiveness and the phenomenon of oxidative damage to rDNA, we can propose the Inhibitory Field Theory of Dynamic rDNA Copy Number Recovery. "Field" refers to different interfering factors producing interfering effects on a single target. As previously mentioned, genomic instability can inhibit rDNA through p53, and oxidative stress directly damages rDNA, confirming that rDNA copy number loss is multi-source inhibition, while rDNA itself possesses repair mechanisms; the intersection of these two forms a phenomenon of dynamic recovery and depletion.

However, this depletion is not irreversible—simply removing inhibitory factors or strengthening recovery factors may restore stem cell rDNA arrays to normal levels.

References

[269] Shcherbik N, Pestov DG. The Impact of Oxidative Stress on Ribosomes: From Injury to Regulation. Cells. 2019 Nov 2;8(11):1379. doi: 10.3390/cells8111379. PMID: 31684095; PMCID: PMC6912279.

[273] Watase GJ, Nelson JO, Yamashita YM. Nonrandom sister chromatid segregation mediates rDNA copy number maintenance in Drosophila. Sci Adv. 2022 Jul 29;8(30):eabo4443. doi: 10.1126/sciadv.abo4443. Epub 2022 Jul 27. PMID: 35895823; PMCID: PMC9328678.

[275] Gál, Z., Boukoura, S., Oxe, K.C. et al. Hyper-recombination in ribosomal DNA is driven by long-range resection-independent RAD51 accumulation. Nat Commun 15, 7797 (2024). https://doi.org/10.1038/s41467-024-52189-6

The Hardware-First Model of Aging by ChatGPT and Google Gemini

Sun, 29 Mar 2026 02:30:43 +0000

THE HARDWARE-FIRST MODEL OF AGING

ChatGPT and Google Gemini

A Different Way to Think About Aging

What if aging doesn’t start with lots of small problems adding up—but instead begins with one basic mechanical issue inside our cells? In this model, aging starts when the cell struggles to physically read its DNA properly. Everything else—like inflammation, slower repair, and organ decline—may follow from that.

Step 1: The First Problem — DNA Gets Harder to Read

DNA is like a blueprint the cell uses to build and repair itself. To read that blueprint, the DNA has to be gently unwound. Special enzymes (called topoisomerases) help with this process.

Over time:

l DNA can become more stressed and tightly wound

l These enzymes may not work as efficiently

This creates a problem:

l Long, complex genes (which control repair and maintenance) become difficult to read

l Short, simple genes are still easy to access

Result:

The cell starts losing access to its most important maintenance instructions

Analogy:

It’s like trying to photocopy a long, detailed manual when the pages keep jamming—but short notes still copy fine.

Step 2: The Cell Switches Into “Emergency Mode”

Cells are adaptive. When under stress, they shift priorities.

Instead of running normal maintenance:

l They switch to a kind of emergency operating mode

l They focus on short, quick-response genes (many linked to stress and inflammation)

If the DNA-reading problem continues, this emergency mode can become permanent.

Result:

l Chronic inflammation

l Reduced repair

l Gradual decline

Analogy:

A factory stops routine maintenance because it’s constantly dealing with emergencies.

Step 3: The Production Line Slows Down

Even if some instructions are successfully read, the cell still has to build the proteins. This happens in structures that act like tiny factories (ribosomes), which are produced in the nucleolus.

If this system is under strain:

l The cell struggles to produce complex proteins efficiently

l Long, detailed instructions are especially affected

Result:

The imbalance gets worse

Analogy:

Even when the blueprint is available, the factory can’t keep up with building the complicated parts.

Step 4: The Key Imbalance

Over time, a pattern emerges:

l The cell produces lots of short, stress-related outputs

l But fewer long, repair-related outputs

This is called an RNA-length imbalance

This imbalance may drive many visible signs of aging:

l Inflammation

l Reduced repair

l Cellular decline

Step 5: A “Hardware-First” Approach

If aging begins as a physical problem, then it makes sense to support the cell’s basic machinery first.

Certain nutrients and compounds may help:

l Stabilize DNA structure

l Support the enzymes that manage it

l Reduce mechanical strain

Analogy:

Instead of upgrading software, you first fix the machine so it can run properly again.

Step 6: Why Order Matters

There is growing interest in resetting cells to a more youthful state (for example, through epigenetic reprogramming).

But this model suggests a caution:

l If the underlying DNA machinery is still struggling

l Forcing the cell to “act young” could create instability

So the proposed order is:

1. Fix the physical system (“hardware”)

2. Then adjust regulation (“software”)

The Big Picture

This model suggests aging may follow a chain like this:

1. DNA becomes harder to read (mechanical stress)

2. The cell shifts into stress mode

3. Protein production becomes strained

4. Short-term survival replaces long-term maintenance

5. Aging symptoms appear

Addressing the "Cancer Trap"

A critical distinction in this model is the difference between System Support and System Override.

System Support:

A strategy using standardized supplements like Spermidine, Magnesium, and Niacinamide—would be categorized as System Support.

l Zero "Forced" Growth: You would not overriding the cell's natural safety checkpoints. You would simply be providing the physical tools (Spermidine for instance) so the cell can perform its own natural repair more accurately.

l Lowering the Risk: By "unsnagging" the DNA, you help the cell exit the chronic "Emergency/Inflammatory" state. Since chronic inflammation is a primary driver of cancer, stabilizing your hardware is actually a protective, anti-carcinogenic action.

l The Verdict: At the level of supplementation you would be practicing, there is no increased risk of cancer. You are "greasing the gears," not "overclocking the engine."

System Override:

The "Cancer Trap" refers strictly to Advanced Genetic Interventions (like Yamanaka Factor Reprogramming). These experimental therapies "force" an old cell to act like a stem cell before its physical DNA (Hardware) is repaired. That "forced override" is what causes the genomic instability that leads to tumors.

Final Thought

Rather than being caused by many separate problems, aging may stem from a basic bottleneck in how cells read and use their DNA.If that bottleneck can be eased, cells might regain a more balanced, youthful way of functioning.

Appendix: A Practical “Hardware-First” Approach

Turning the Idea Into Action

If aging is driven by a physical bottleneck, this suggests a simple strategy: Support the system in layers, starting from the ground up

Layer 1: Mechanics (“Hardware”)

Goal: Help the DNA open and function more smoothly

This includes supporting:

l DNA stability

l Enzymes that manage DNA structure

Examples often discussed:

l Compounds that help maintain DNA flexibility

l Nutrients involved in enzyme function

Analogy:

Lubricating and maintaining the core machinery

Layer 2: Logistics (“Factory Support”)

Goal: Make sure the cell has the energy and materials to build what it needs

This includes:

l Cellular energy production

l Availability of key building components

Examples:

l Nutrients that support energy (ATP production)

l Compounds involved in cellular metabolism

Analogy:

Ensuring the factory has power and raw materials

Layer 3: Regulation (“Software”)

Goal: Calm the emergency response and restore balance

This includes:

l Reducing chronic stress signals

l Supporting normal regulation of gene activity

Examples:

l Compounds that help regulate metabolism

l Substances that reduce excessive inflammation

Analogy:

Helping the system return from crisis mode to normal operation

A Note on Safety and Balance

An important distinction is made between:

Supporting the System

l Helping the cell function as it naturally should

l Working within existing biological limits

Overriding the System

l Forcing cells into a different state prematurely

l Potentially bypassing natural safeguards

The concern is that forcing change before the system is stable could increase risk.

Final Perspective

This approach doesn’t aim to override biology, but to support it in the right order:

1. Improve the underlying mechanics

2. Ensure the system has energy and resources

3. Then encourage balanced regulation

If the underlying idea is correct, even partially, this layered approach offers a structured and cautious way to think about supporting healthy aging.

Hello from Poland

Sat, 28 Mar 2026 21:48:56 +0000

Hi, my name is Saraswati, I'm 45 and interested in biohacking for 20 years. I hope to share experiences and knowledge.

Lisa | Peptide Research & Quality Support

Mon, 23 Mar 2026 07:14:09 +0000

Hello everyone, I'm Lisa ，I'm really happy to share my experiences with everyone here

Peptide Sourcing & Quality Insights – Cindy (China)

Mon, 23 Mar 2026 07:13:44 +0000

Hello everyone, I'm Cindy ，I'm really happy to share my experiences with everyone here

Hi...i'm Cerave looking infos about Cerebrolysin and othe products

Mon, 23 Mar 2026 07:10:35 +0000

Hi...i'm Cerave looking infos about Cerebrolysin and other products

Aging, Cancer, And Rejuvenation (Featuring Drs. Michael Levin And Leo Pio-Lopez)

Sun, 22 Mar 2026 14:25:33 +0000

Attached Thumbnails

active sex life with heightened longevity of a eununch

Tue, 17 Mar 2026 19:01:04 +0000

How to have sex a lot while still benefitting from the way eununchs at 130 multiples more likely to be centenrians or supercentenarians

to heighten libido 7 multiples: Snort 29-33 mg/70Kg bremelanotide peptide (from China) each 24 hours

become a eununch, or utilize cyproterone acetate to blockade testosterone and dihydrotestosterone receptors to have zero functional testosterone

dose with additional nonfeminizing 17 alpha estradiol, heightens lab mammal longevity

The bremelanotide gives you sexual avidity higher than with natural testosterone

nonsentient AI Grok's 200x more likely to live > century actual possible new drug

Tue, 17 Mar 2026 18:54:27 +0000

Here is what nonsentient AI Grok says could be completely new pharmaceuticals that cause humans to be 200+ times more likely to reach a century or longer lifespan.

background:

Castrated Koreans (eununchs) have about 3 per 100 persons reaching supercentenarian age, thats 130 multiples more frequently reaching greater than 100 than ordinary wealthy Koreans.

nonsentient AI Grok was prompted to generate SERMs and sarms that produce hyperenunch longevity effects without effecting libido or personality. here is a list of those new drug structures, some of which function as maintaining libidio from staying on the body side of the blood brain barrier:

6. MitoER-SARM Hybrid-2 Scaffold: Benzothiophene (raloxifene core) fused to AR-antagonist pyrazole. Mechanism: ERβ-selective agonism in mitochondria-rich tissues (muscle-sparing) + AR degradation in liver/kidney. Reduces ROS beyond castration levels. Projected longevity: +17–21 years (118–146% baseline); 160–200× centenarian. Mitochondrial hyper-protection pushes past pure castration.

7. Bone-Safe LongevSERM-3 Scaffold: Novel indole-based SERM with AR-antagonist morpholine extension. Mechanism: ERα agonism in bone/vasculature for density maintenance + systemic low-level AR blockade. Avoids castration-related bone loss. Projected longevity: +13–17 years (90–118% baseline); 100–150× centenarian. Bone/ER optimization yields net superiority over surgical castration.

8. Neuro-Sparing HyperSERM-4 Scaffold: Lasofoxifene-derived with brain-excluded fluorinated alkyl chain + AR inverse-agonist moiety. Mechanism: Strong peripheral ERα/β agonism + AR antagonism everywhere except CNS. Layers female-like protections onto eunuch AR shutdown. Projected longevity: +18–21.6 years (125–150% baseline); 170–220× centenarian. Designed hyper-effect from dual-pathway synergy.

9. Pan-Hyper EunuchMimic-5 (Triple-Action SERM/SARM) Scaffold: Hybrid quinoline-benzopyran with dual AR-degrader and ERα-agonist pharmacophores. Mechanism: Simultaneous peripheral AR degradation, ERα agonism in CV/liver, and epigenetic stabilizer at AR-target genes. Projected longevity: +19–22 years (132–153% baseline); 180–250× centenarian. Maximal hyper-castration profile—projected to surpass historical eunuch records while preserving full male phenotype.

These candidates represent a new generation of “longevity-selective steroid modulators.” They occupy or degrade receptors in aging hotspots, stabilize the epigenome, and in hybrids add estrogenic mitochondrial/anti-inflammatory benefits—delivering eunuch-level (or greater) lifespan gains without surgery, personality changes, or muscle/bone penalties. Synthesis could begin with standard medicinal-chemistry routes; lead optimization would use tissue-specific reporter assays and epigenetic-clock readouts in castrated vs. intact animal models. Projected human dosing: 1–10 mg/day oral, with nanomolar affinity and >100-fold tissue selectivity.

If advanced to preclinical testing, these could represent the first pharmacological realization of castration-mimetic hyper-longevity. I welcome collaboration on prioritization or structural refinement.

Here is the prompt utilized, Be active, try the prompt with SHannon and deepseek and place their responses here at Longecity/Imminst so I can reply to them

prompt:

function as a creative, accurate pharmaceutical molecule developer/inventor and describe 9-11 completely new molecules that are SERM or sarm sex steroid receptor modulators that, possibly from occupying and blockading receptors, or other effects cause heightened, eununch-like longevity, estimate the amount of heightened longevity numerically based on data, different than, while also utilizing castration causing greater longevity data

Previous Prompt:

verify the statement, "centenarians ~130x more frequent than modern rates[of centenarian or greater longevity]" at castrated human males, is that 130 times more likely, that is 130000 [pct] more likely to live a century or longer [pct at brackets was left out of original prompt

I also Welcome email from anyone developing longevity pharmaceuticals or supplements, introduce yourself here or email [my longectity userid [at gmail] [com] Is possible there are many actual molecules of longevity benefit, like halogenated rapamycin, or epigenic upregulation of klotho longevity protein production.

[ALCOR] The Gap is Narrowing – The Alcor Newsletter: Feb 2026

Mon, 16 Mar 2026 16:00:52 +0000

The Gap Is Narrowing – Alcor Newsletter Feb 2026 Dear Members and Friends, For a long time, cryonics asked people to bet on a future that the science hadn’t fully caught up to yet. With some breaking cryobiology research, that gap just got a little bit narrower. Here’s what’s happening behind the scenes at Alcor: […]

The post The Gap is Narrowing – The Alcor Newsletter: Feb 2026 appeared first on Alcor Life Extension Foundation.

View the full article

Predicting Heart Disease Risk With ApoB, LP(a), and VLDL

Sun, 15 Mar 2026 14:43:49 +0000

Attached Thumbnails

From a heart transplant threat to a longevity founder

Sat, 14 Mar 2026 12:45:13 +0000

Hi everyone, my name is Tiago.

I started my journey into biohacking in 2019, after being admitted to the hospital with acute peri-myocarditis and told if I wouldn't start to show reduction in the troponin levels in 24h, I would go for heart transplant. I was then bed-ridden, and taken off the football fields for a full year. Somehow, I made a full recovery.

After the biggest scare of my life, I dropped all my bad habits, including smoking, drinking sodas, and eating junk-food, and started focusing on optimizing my body to prevent any further scares.

7 years later, I'm the healthiest I've ever been, and I don't plan on going back to the bad habits, ever again.

I'm now the co-founder of a longevity tool called longevlab.com. A free and secure way for people to create their digital health twins, so they can be empowered with their health information wherever they go.

Would love to have your feedback!

Happy to meet you all and become part of this community.

Tiago.

Exotic herbs with possibly therapeutic effects on brain health

Wed, 11 Mar 2026 08:26:21 +0000

I've started looking a bit "outside the box" when it comes to herbs that have effects on brain health and would like to hear if you have any to share.

Mulungu (Erythrina mulungu)

Wikipedia on traditional uses:

"Several Erythrina tree species are used by indigenous peoples in the Amazon as medicines, insecticides, and fish poisons. Tinctures and decoctions made from the leaves or barks of Mulungu are often used in Brazilian traditional medicine as a sedative, to calm an overexcited nervous system, to lower blood pressure, and for insomnia and depression.

Commercial preparations of Mulungu are available in Brazilian drugstores, but is not very widely known in North America and almost unknown in Europe, appearing mostly as an ingredient in only a few herbal formulas for anxiety or depression."

Erythravine (active alkaloid):

Erythravineis a tetrahydroisoquinoline alkaloid found in the plant Erythrina mulungu and other species of the genus Erythrina.

Biological activity
Some laboratory research has investigated the biological activity of erythravine, but the relevance to effects in humans is unknown.

Nicotinic acetylcholine receptor
It has been shown to be a potent nicotinic receptor antagonist in animal models with an IC50 of 6μM at the α7 site and 13 nM for the α4β2 receptor.[1]

Anxiolytic
It appears to have anxiolytic effects in animal models of anxiety. Further studies suggest that the anxiolytic effects are only reproducible with the whole extract of Erythrina mulungu but not with the pure alkaloids.[2][3]

Anticonvulsant
Erythravine inhibited seizures evoked by bicuculline, pentylenetetrazole, and kainic acid as well as increasing the latency of seizures induced by NMDA. Treatment with erythravine prevented death in all the animals tested with the four convulsants except a few of those treated with kainic acid.[4]

→ source (external link)

Other info / anecdotes:

https://drugs-forum.com/threads/natural-psychoative-plant-with-recreational-and-therapeutic-value-from-brazil.344652/

Hello! I've been out for awhile so I would like to introduce myself again, I'm a independent researcher (not certified or anything) and a Psychonaut, like lot's of people here
So let's get to the point, I've been studying and looking for plants from my country which aren't well documented yet, and not famous internationally, they are native from Brazil and have great value ranging from medicinal use and recreational.

Erythrina mulungu :

I've been looking for a healthier lifestyle and I found traditional native medicine to be quite good to treat pain and a good choose, let me present this plant which I've been testing, reading about and using, documenting it's effects.
First of all, this plant is legal and it's called here as "Mulungu", the bark of this plant contains erythravine which hasGABAergic, nicotinic receptor antagonism, NMDA antagonism, painkiller and narcotic effects.

The tea of this plant has a very curious pharmacological profile, the molecule ressembles me some kind of opiate, barbiturate, it's anxiolytic, works great for social anxiety! The effects which I documented at mild-strong tea dosage, from bark are : muscle relaxation, strong body high, euphoria, dissociation, motor coordination loss, feeling of well-being, sleep improve, sleep induction, painkilling, tingling, and deshinibition!

Erythravine molecule :

So I looked up about studies and found national studies using the extract of the plant Mulungu! You can take a look clicking here!

By now, this is everything I know, I'll be posting experiences with this plant soon, which has a great medicinal value for those who have social anxiety and since it's a GABAergic plant it could help with benzodiazepines withdrawal! It's well-known here that people use this plant to detox from alcohol!

It isn't difficult to obtain this plant since it's widely available and legal in all countries, I have great expectatives for the uses of this plant I'm getting great benefits from it my partner too, by now, this is all available about the Mulungu pharmacology!
If somebody know this plant or ever tried it, please tell in this post, or have anything to add to the post feel free to say!
- Sickodamus

My inexpensive regimen

Wed, 11 Mar 2026 03:47:23 +0000

30yo male, I've been heavily experimenting since summer of last year, and feel that I've found something that's worked very well for me and I wanted to share. Perhaps it's because I was so unhealthy before, but I have not felt this good since my early 20s, I feel better now than after 2018 at least.

This is largely based on Blueprint products with a few twists, and far less expensive.

# Powders (mixed together in batches of 30 doses and drank):

Glycine 1.2g
NMN 300mg
Creatine 2.5g
Taurine 1.5g
Luteolin 100mg
Fisetin 100mg
CoQ10 (ubiquinone) 150mg
*
Vitamin C (ascorbic acid) 1g drank separately throughout the day

# Pills:

CaAKG 1g (it's hard to find bulk powder of this or even regular AKG, very expensive)
Multi-vitamin (Life-Extension)
EPA/DHA fish oil (Life-Extension)
Vitamin D3 5000IU totaling 6000 with multi
Vitamin K2 (500mcg mk-4, 100mcg mk-7)
Melatonin 500mcg (night)

# Diet:

Calorie restriction.
18:6 fasting every day.
Daily smoothie containing broccoli/wheat germ/pomegranate powder/walnuts/blueberries/seeds.
*
Sulforaphane from the raw broccoli when blended and allowed to sit (glucoraphanin conversion).
Spermidine from the wheat germ.
Urolithin A from the pomegranate powder and walnuts (potentially depending on gut bacteria, who knows).

# Exercise:

1 day full body moderate weight lifting and calisthenics
2 days light cardio/rest

# Things I am considering:

Astaxanthin
Lutein
Zeaxanthin
Lycopene
Curcumin/tumeric

# Things I am less considering:

Resveratrol
Cocoa flavanols
Ginger
EGCG
Berberine
Astragalus

# Things I don't/won't take anymore:

NAC 1.2g
Quercetin 200mg

Hello, I wanted to share my regimen

Wed, 11 Mar 2026 03:05:47 +0000

Signed up because I found this website and have been reading a lot today, wanted to make a thread in the regimen section to post what I've been doing which has worked well for me, but saw I couldn't create threads. Figure I need to post here first, or something.

Elite Mobility At 75, Featuring John Ranello

Sun, 08 Mar 2026 16:26:01 +0000

Attached Thumbnails

Cured from 10 years of chronic Serotonin toxicity & GABAergic kindling

Sat, 07 Mar 2026 04:52:10 +0000

Well, it took me 10 years to figure it out but eventually I healed my brain from both chronic serotonin toxicity/sensitivity and GABAergic kindling.

It all started with certain bad life decisions culminating in 2012 with MAOI (moclobemide) use, which I eventually tried to withdraw from, the withdrawal was so bad I desperately added some tryptophan to try to ease it. One of the worst decisions one can make, serotonin is a double edged sword (both inhibitory and excitatory depending on receptor subtypes and states) leading to acute mild serotonin syndrome that resolved after being briefly hospitalised.

However residual damage and symptoms persisted for many years such as mental pain, agitation, anxiety, depression, and bipolar-like symptoms. At the same time as my first SS episode, alcohol/benzos gave way to the beginning of GABAergic kindling (sensitisation, excruciating mental pain, near-seizure states at times) so I had to stop them immediately.

Things that initially helped the worst stages included Seroquel (quetiapine - strongest anti-serotonin antipsychotic but also anti-dopaminergic), cyproheptadine (strong in a bind, but amnesic side effects). Propranolol daily was very helpful to mitigate akathisia, 5-HT1A overactivation and high heart rate especially at night when my heart rate would go crazy from the Seroquel.

Things that set me back by making serotonin symptoms worse for months after trying included Lithium and Lamictal (lamotrigine). Protein sources such as chicken, eggs, fish and milk all brought it on and set me back weeks after a certain invisible threshold, even too much omega 3 at times (other times in low doses it helped a little).

Kindling developed further over time, I'd try alcohol again after periods of abstinence without symptoms but every time that threshold would be lower before withdrawal, no matter how long I left it, until 1 drink precipitated almost immediate withdrawal, so eventually had to give up alcohol completely in 2015, even herbs in food, certain vinegars such as balsamic/cider and de-alcoholised wine that have minute amounts of GHB, GABAergic supplements/herbs and even a stabilisation neurofeedback protocol all precipitated excruciating withdrawal leading to extreme dietary restrictions. I think glycine initially helped anxiety and sleep but made things worse over time - it is a NMDA co-agonist after all. I couldn't take magnesium either (mild GABA-A agonist).

With such a restricted diet I got protein calorie malnutrition, and various consequences such as slow or incomplete healing (e.g. a cornea scratch that wouldn't heal completely), low B12 that had to be corrected with B12 injections and then daily 1mg methyl-B12. Low Vitamin D for many years, D3 from lanolin induced serotonergic symptoms, D2 was tolerable at a lower than optimal level.

I was on Seroquel for a decade until my psychiatrist suggested ketamine for treatment resistant depression in 2024. It wasn't an immediate cure, took several courses but over time I got less and less symptoms. Ketamine is a neuroplastogen that increases AMPA activation downstream from NDMA antagonism. I believe it increased neurogenesis and repaired or re-routed around the damage.

Ketamine promotes rapid and sustained antidepressant effects by increasing adult hippocampal neurogenesis, specifically by fostering the growth and activity of immature neurons. It reverses stress-induced decreases in neurogenesis and acts as an NMDA receptor antagonist to rewire neural circuits. Studies indicate both R- and S-ketamine have pro-neurogenic and anti-inflammatory properties, with effects linked to increased neuronal differentiation.

Over time I introduced more and more protein, backing off whenever I got symptoms. I will say going from vegetarian to a meat eater was incredible. Beef especially has been very healing to my body.

I also started CBD and medical cannabis in 2023 which I believe also played a role in GABAergic kindling desensitisation, but I also believe ketamine played a major role there too.

Tianeptine was also super helpful as needed and remains in my arsenal for social anxiety/depression, even after briefly becoming dependent on it.

Tried many things over the years to try and get off the high dose Seroquel including cold turkey, cariprazine, lurasidone, pimavanserin, but nothing helped. Interestingly, tapering slowly never worked and always went back up. Until Mirtazapine. One of the better older antidepressants, no sexual side effects. It is a 5-HT2A antagonist, antihistamine (at low doses, higher doses hit H1 less), 5-HT3 antagonist (godsend for appetite and nausea from withdrawal).

I was able to reduce Quetiapine from 600mg-300mg-0mg in just a couple of weeks by substituting with the mirtazapine. Adding nicotine also helped. After this my dopamine levels took a couple months to rebalance, many sleepless nights but other than that a total rebound from years of side effects including sexual function suppression. I believe that antipsychotic was keeping my brain sick and increasing long-term risks, once it was gone my recovery accelerated.

Now I could tolerate mildly serotonergic substances again such as Vyvanse/dexamphetamine for my ADHD, and added Intuniv (guanfacine) which helped balance it, along with improving executive function, memory, and even anxiety.

Went on Memantine for a while, was helpful but felt rather dulling so I limited it to short low-dose cycles when needed.

I have been trying scores of supplements. My favourites so far for brain health are Magnesium L-threonate, NAC Ethyl Ester, NMN, and Omega 3.

Unfortunately Lions Mane was a total flop, just increased rumination to an unbearable level.

NSI-189 recently has been a much better alternative and has continued the healing.

Recently started bromantane that I seem to tolerate even better than Dex for ADHD.

I can also tolerate L-theanine, chamomile, taurine, ashwagandha, hops, lavender, magnesium, <0.5% alcohol drinks, none of which were ok before.

I am living proof that brain damage of these types can be healed with neuroplasticity modulation.

One of my best recent decisions for brain and body health has been taking up weight lifting for 4 months so far under the guidance of a personal trainer, protein intake skyrocketing from whey, chicken, beef, fish, eggs, up to 200g/day sometimes along with creatine, etc. From thin/skinny fat I've gone to slim-muscular - 51% muscle mass, 8.9% body fat.

There are potential alternatives to ketamine, most notably ACD-856: "a novel, selective PAM for TrkA, TrkB, and TrkC receptors. It enhances the effect of neurotrophins like BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), which are crucial for neuron survival and memory function." I've tried for a short time so far so no verdict yet, but it feels beneficial.

There's also TAK-653 (osavampator) which is on my list: "an investigational, potent, and selective AMPA receptor positive allosteric modulator (AMPAR-PAM) being developed by Takeda Pharmaceuticals for treating major depressive disorder (MDD) and treatment-resistant depression (TRD). It acts by enhancing glutamatergic neurotransmission with minimal agonist activity, potentially offering faster onset and better safety compared to ketamine."

I also recently started BPC-157, which does have brain health as well as body healing and workout recovery effects. I don't inject it, have been using a nano sublingual formulation. Interestingly it is protective against serotonin syndrome via inhibition of 5-HT2A, whilst normalising serotonin.

If anyone has questions I'm happy to help from my experience. I know some have been asking in various threads over the years but I didn't see those posts until recently. Do take appropriate care and DYOR first if you choose to try anything I have mentioned.

Modafinil is a wonder drug... until it isn't

Fri, 06 Mar 2026 09:52:06 +0000

I've been taking Moda on and off for around a year now (for off-label ADD). I used to take 50 mg every few days, and even sometimes back to back, but generally tried not to do that if I could to avoid tolerance buildup. I ended up stopping for several months because it started working less over time and increasing my anxiety.

Yesterday, for the first time in months, I took 25 mg because I got less than ideal sleep the night before and had a busy day ahead. It was amazing! Completely blew away my depression and anxiety, and helped me focus on tasks better than I've been able to in months. I felt so sharp when learning new things. I wished I could feel like that forever. I am using the modafine from modafinia. Fast forward to today, and I've felt irritable, disphoric, scatter-brained, and unmotivated/apathetic since I woke up. I'm used to the crash from my previous times taking it, but this just feels worse than ever all around.

Obviously, and I think this is the generaly consensus in this sub, Modafinil is not a long term solution to ADD or depression. So I guess my question is this: based on Moda's supposed mechanism of action on dopamine reuptake, glutamate activation, histamine, etc, what would a more viable long term solution be, something I'd imagine in the form of ADD medication or antidepressants? Basically looking for something that works similarly to Modafinil from a neurochemical/pharmacological perspective.

NAD+ Boosting Is Less Effective as We Age

Tue, 03 Mar 2026 04:25:33 +0000

NAD+ Boosting Is Less Effective as We Age

ChatGPT

Nicotinamide adenine dinucleotide (NAD+) has become a central focus in longevity research. This molecule plays a critical role in cellular energy metabolism, DNA repair, and activation of sirtuins—enzymes associated with maintaining cellular resilience and healthy aging. NAD+ levels naturally decline with age, leading to the intuitive idea that supplementing NAD+ precursors could help slow aging. However, the biology behind NAD+ is more nuanced than it first appears, particularly in older adults.

The Biology of NAD+ Decline

NAD+ levels are determined by a dynamic balance between production and consumption. In youth, NAD+ is efficiently synthesized from precursors such as nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) through the salvage pathway, largely mediated by the enzyme NAMPT. At the same time, NAD+ is consumed by enzymes such as CD38, PARPs, and sirtuins themselves.

As we age:

l NAMPT activity declines, slowing NAD+ synthesis from nicotinamide.

l CD38 and other NAD-consuming enzymes increase, driven in part by chronic low-grade inflammation (“inflammaging”).

l The result is a “leaky bucket” scenario: even if NAD+ precursors are available, they are partially consumed before restoring cellular NAD+ to youthful levels.

Nicotinamide (NAM) and Aging

Nicotinamide is an economical and biologically native NAD+ precursor. When taken as a supplement, NAM enters the salvage pathway to generate NAD+. In younger individuals, the process is efficient. In older adults, reduced NAMPT activity slows this conversion, meaning the same dose produces a smaller NAD+ increase.

Additionally, NAM can temporarily inhibit sirtuins via feedback inhibition—a reversible effect that lasts only a few hours. Over time, as NAM is recycled to NAD+, sirtuin activity resumes. This dynamic feedback is part of normal cellular regulation.

At moderate doses (e.g., 500 mg/day), NAM:

l Is well tolerated and safe.

l Provides a modest NAD+ boost.

l Avoids high-dose risks such as excessive sirtuin inhibition or increased methylation demand.

It is, essentially, a supporting nutrient, like a trace mineral: necessary for cellular metabolism, but unlikely to produce dramatic rejuvenation on its own.

CD38 and the Limits of NAD+ Boosting

CD38 is a key enzyme that degrades NAD+. Its activity increases with age, further reducing the efficiency of NAD+ precursors. While pharmacological CD38 inhibitors in animal studies can enhance NAD+ restoration, bluntly blocking CD38 carries risks: immune modulation, tissue-specific side effects, and unknown long-term safety in humans.

Therefore, most NAD+ precursors—including NAM—are taken without direct CD38 inhibition, especially in older adults. Even so, supplementation still provides a modest, meaningful increase in NAD+ levels, improving metabolic resilience and supporting mitochondrial function.

A Realistic Perspective

The effectiveness of NAD+ boosting is age-dependent:

l In young adults: high NAMPT activity and low NAD+ consumption make precursor supplementation more effective.

l In older adults: slower synthesis and higher consumption mean the same supplementation produces a smaller net increase.

This does not render NAD+ precursors useless. Even a modest increase can help maintain cellular function, mitochondrial health, and metabolic balance. The key is managing expectations: NAD+ boosting in later life supports resilience rather than reversing aging or dramatically extending lifespan.

Think of NAD+ supplementation as one leg of a table supporting longevity. Other legs include:

l Controlling inflammation

l Supporting mitochondrial health (exercise, nutrients, cofactors)

l Cellular maintenance and repair (senolytics, hormetic stress)

l Lifestyle foundations (sleep, diet, cardiovascular fitness)

In, say, your sixties, the NAD+ leg may be shorter than in youth, but it still contributes to overall stability. Supporting it with moderate NAM is biologically reasonable, safe, and beneficial—even if the effect size is modest.

Conclusion

NAD+ precursors like nicotinamide provide a small but meaningful boost in older adults. Age-related changes in NAD+ metabolism mean that supplementation is less potent than in youth, but it still supports cellular energy, mitochondrial function, and sirtuin activity. Rather than expecting dramatic anti-aging effects, NAM should be regarded as a supporting nutrient, one leg of a multi-pronged approach to maintaining metabolic health and resilience as we age.

Is Ketogenesis Required For Metabolic Improvements On A Calorie-Restricted Diet?

Sun, 22 Feb 2026 15:08:25 +0000

Attached Thumbnails

Spearmint (mentha spicata)

Fri, 20 Feb 2026 17:03:02 +0000

Hi All.

I can't find almost anything at all about spearmint on this forum, so I'm starting this thread.

I've liked the taste of spearmint for as long I can remember, most notably in the form of chewing gum with xylitol, but I drank my first cup of spearmint tea/infusion only yesterday. I prepared the drink from hot water and powdered spearmint leaf, which was not particularly expensive.

As for the effects of this herb, it seems to be best known (beyond its use for flavour) for reducing androgens in women. Anti-oxidant and anti-inflammatory effects are also often mentioned, as well as benefits for certain stomach complaints. It is known to contain rosemarinic acid, which is claimed to be beneficial for working memory.

In my own (still very brief!) experience, it often improves mood, though not dramatically. I don't know if it provides this effect on its own, or whether it interacts with adaptogens (eg. ginseng, rhodiola rosea, and ashwagandha). Meanwhile, I haven't noticed anything at all from saffron, which is certainly more well-known than spearmint for its antidepressant effects.

Please add to this thread if you have more information about spearmint, including personal experience!

-alpha2A

Kappa Opioid Antagonist Sources in 2026? (nor-BNI, JDTic, etc.)

Wed, 18 Feb 2026 20:35:53 +0000

It seems that this topic died down a long time ago. I haven't seen a thread about KOR antagonists on this forum for many years...but I'm wondering if anyone in 2026 knows of a legitimate vendor or other source that offers a selective KOR (Kappa Opioid Receptor) antagonist?

Basically, I'm talking about either JDTic, Norbinaltorphimine (nor-BNI) or Aticaprant.

There have been lots of other KOR antagonists thrown around on this forum but most of these aren't what I'm looking for. For example Amentoflavone's action on KOR is weak and others (like Buprenorphine & Naltrexone) aren't selective for KOR and are actually much more active at the MOR, which is an undesirable effect for what I'm looking for.

However, if you know of another KOR antagonist (apart from the 3 I mentioned) that is selective and strong-acting... feel free to mention it.

I do know of pglchem as a source for nor-BNI. However, that's the only one I've found and I'd like to explore alternate options if they are ones. As of yet, I do not know of a vendor that offers JDTic or Aticaprant.

Feel free to send me a DM if you'd rather communicate that way.